<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003505.pub5" GROUP_ID="INCONT" ID="755001100316070639" MERGED_FROM="" MODIFIED="2015-11-20 13:18:18 +0000" MODIFIED_BY="Muhammad Imran Omar" REVIEW_NO="001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2015-11-20 13:18:18 +0000" MODIFIED_BY="Muhammad Imran Omar">
<TITLE>Lifestyle interventions for the treatment of urinary incontinence in adults</TITLE>
<CONTACT MODIFIED="2015-11-20 13:18:18 +0000" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="65858575107888788713090924150112" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mari</FIRST_NAME><LAST_NAME>Imamura</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>m.imamura@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Academic Urology Unit</DEPARTMENT><ORGANISATION>University of Aberdeen</ORGANISATION><ADDRESS_1>Health Sciences Building</ADDRESS_1><ADDRESS_2>Foresterhill</ADDRESS_2><CITY>Aberdeen</CITY><ZIP>AB25 2ZD</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-11-20 13:18:18 +0000" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="65858575107888788713090924150112" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mari</FIRST_NAME><LAST_NAME>Imamura</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>m.imamura@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Academic Urology Unit</DEPARTMENT><ORGANISATION>University of Aberdeen</ORGANISATION><ADDRESS_1>Health Sciences Building</ADDRESS_1><ADDRESS_2>Foresterhill</ADDRESS_2><CITY>Aberdeen</CITY><ZIP>AB25 2ZD</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="8310" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kate</FIRST_NAME><LAST_NAME>Williams</LAST_NAME><POSITION>Senior Research Fellow in Nursing</POSITION><EMAIL_1>ksw6@le.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Health Sciences</DEPARTMENT><ORGANISATION>University of Leicester</ORGANISATION><ADDRESS_1>22-28 Princess Road West</ADDRESS_1><CITY>Leicester</CITY><ZIP>LE2 6GS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 116 252 5432</PHONE_1><FAX_1>+ 44 116 252 5423</FAX_1></ADDRESS></PERSON><PERSON ID="98538281604026055240100215150420" ROLE="AUTHOR"><FIRST_NAME>Mandy</FIRST_NAME><LAST_NAME>Wells</LAST_NAME><POSITION>Consultant Nurse/ Head of Dept</POSITION><EMAIL_1>mandy.wells310752@hotmail.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>Integrated Bladder and Bowel Care Services</DEPARTMENT><ORGANISATION>NHS Devon</ORGANISATION><ADDRESS_1>Franklyn House, Franklyn Drive</ADDRESS_1><ADDRESS_2>St Thomas</ADDRESS_2><CITY>Exeter</CITY><ZIP>EX2 9HS</ZIP><REGION>Devon</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1392 208467</PHONE_1></ADDRESS></PERSON><PERSON ID="93015930157146413782100215150556" ROLE="AUTHOR"><FIRST_NAME>Catherine</FIRST_NAME><LAST_NAME>McGrother</LAST_NAME><EMAIL_1>cm45@leicester.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Dept of Health Sciences</DEPARTMENT><ORGANISATION>University of Leicester</ORGANISATION><ADDRESS_1>University Road</ADDRESS_1><CITY>Leicester</CITY><ZIP>LE1 7RH</ZIP><REGION>Leicestershire</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-08-07 10:55:15 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="3" MONTH="7" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="7" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="11" YEAR="2015"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2013-07-30 11:21:08 +0100" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2013-07-30 11:21:08 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MINOR" MODIFIED="2013-07-30 11:21:08 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>new review authors</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-07-07 14:44:22 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>protocol amended</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-07-22 13:55:24 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-07-22 13:55:24 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-07-22 13:55:24 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure, Cochrane Programme Grant or Cochrane Incentive funding to the Incontinence Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-11-20 13:14:49 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-10-14 14:42:14 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-07-16 18:00:06 +0100" MODIFIED_BY="[Empty name]">Lifestyle interventions for the treatment of urinary incontinence in adults</TITLE>
<SUMMARY_BODY MODIFIED="2015-10-14 14:42:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Urinary incontinence imposes a considerable burden on individuals and on society. Although a range of treatments is available, alterations in lifestyle are frequently recommended for the treatment of urinary incontinence, as they are relatively low in cost and have few unwanted side-effects. Advice commonly given includes losing weight, changes in diet, adjusting volume of fluid intake, decreasing caffeine or alcohol consumption, avoiding constipation and straining (when passing faeces), stopping smoking, and being more physically active - though restricting excessive heavy activity.</P>
<P>
<B>What we wanted to find out</B>
</P>
<P>We (a team of Cochrane researchers) wanted to see whether lifestyle interventions have a beneficial effect on any type of urinary incontinence in adults</P>
<P>
<B>What we did</B>
</P>
<P>We searched the medical literature extensively up to July 2013 for studies that compared the effects of community-based lifestyle alterations with either no treatment, or other non-surgical treatments, or medical (medicine) treatment, on urinary incontinence in adults.</P>
<P>
<B>What we found</B>
</P>
<P>We identified 11 studies, with 5974 participants (nearly all women, only 20 were men), that investigated the effect of lifestyle alterations on urinary incontinence. Four investigated weight loss; one compared a soy-rich diet with a soy-free diet; three investigated changes in volume of fluid intake; and three investigated the effect of reducing caffeine intake. We identified no trials that investigated reducing alcohol intake, avoiding constipation and straining, stopping smoking or levels of physical activity. </P>
<P>Findings from four studies suggested that weight loss may reduce incontinence among overweight women and this merits further research. However, it should be noted that a large proportion of the participants contributing to this result were part of two diabetes studies that, while they recorded the effect of weight loss on urinary incontinence, did not record how many participants suffered from it at the start of the study. The duration of the weight loss programmes in these studies ranged from three to 12 months.</P>
<P>A small amount of very low quality evidence from the studies that investigated volume of fluid intake suggested that symptoms of urinary incontinence may reduce when fluid intake is reduced, although some participants in the studies reported headaches, constipation or thirst.</P>
<P>We could not combine the findings from other studies that investigated a similar treatment (e.g. caffeine reduction) because they measured their results in different ways, and/or were of poor quality, which means their results may be unreliable. Much more well-designed research is needed, so that lifestyle recommendations for the treatment of incontinence can be based on good evidence. At present there is not enough evidence to establish whether any lifestyle treatments work.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-11-20 12:42:53 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-09-02 16:42:00 +0100" MODIFIED_BY="[Empty name]">
<P>Low cost, non-invasive alterations in lifestyle are frequently recommended by healthcare professionals or those presenting with incontinence. However, such recommendations are rarely based on good evidence.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-11-20 12:42:27 +0000" MODIFIED_BY="[Empty name]">
<P>The objective of the review was to determine the effectiveness of specific lifestyle interventions (i.e. weight loss; dietary changes; fluid intake; reduction in caffeinated, carbonated and alcoholic drinks; avoidance of constipation; stopping smoking; and physical activity) in the management of adult urinary incontinence.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-09-09 10:22:16 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Incontinence Group Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and MEDLINE in process, and handsearching of journals and conference proceedings (searched 3 July 2013), and the reference lists of relevant articles. We incorporated the results of these searches fully in the review. We undertook an updated search of the Specialised Register, which now includes searches of ClinicalTrials.gov and WHO ICTRP, on 27 October 2014; potentially eligible studies from this search are currently awaiting classification.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-11-20 12:42:35 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised and quasi-randomised studies of community-based lifestyle interventions compared with no treatment, other conservative therapies, or pharmacological interventions for the treatment of urinary incontinence in adults.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-09-09 10:23:20 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed study quality and extracted data. We collected information on adverse effects from the trials. Data were combined in a meta-analysis when appropriate. We assessed the quality of the evidence using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-11-20 12:42:53 +0000" MODIFIED_BY="[Empty name]">
<P>We included 11 trials in the review, involving a total of 5974 participants.</P>
<P>Four trials involving 4701 women compared weight loss programmes with a control intervention. Low quality evidence from one trial suggested that more women following weight loss programmes reported improvement in symptoms of incontinence at six months (163/214 (76%) versus 49/90 (54%), risk ratio (RR) 1.40, 95% confidence interval (CI) 1.14 to 1.71), and this effect was sustained at 18 months (N = 291, 75% versus 62%, RR not estimable, reported P value 0.02). No data were available for self-reported cure and quality of life. One of the weight loss trials involving 1296 women reported very low quality evidence for a reduction in weekly urinary incontinence a mean of 2.8 years after following a lifestyle weight loss intervention that had been compared with a pharmacological weight loss intervention.</P>
<P>Three trials involving 181 women and 11 men compared change in fluid intake with no change. Limited, very low quality evidence suggested that symptom-specific quality of life scores improved when fluid intake was reduced, although some people reported headaches, constipation or thirst. A further three trials involving 160 women and nine men compared reduction in caffeinated drinks with no change, and one trial involving 42 women compared a soy-rich diet with soy-free diet. However, it was not possible to reach any conclusions about the effects of these changes, due to methodological limitations, that resulted in very low quality evidence.</P>
<P>Adverse effects appeared relatively uncommon for all interventions studied.</P>
<P>All included studies had a high or unclear risk of bias across all bias parameters, but most notably for allocation concealment. The main factors for our downgrading of the evidence were risk of bias, indirect evidence (less than 12 months of follow-up; and not all participants having confirmed urinary incontinence at baseline in some studies), and imprecise results with wide confidence intervals.</P>
<P>Other interventions such as reduction in consumption of sweetened fizzy or diet drinks; reduction in alcohol consumption; avoiding constipation; smoking cessation; restricting strenuous physical forces; or reducing high levels of, or increasing low levels of, physical activity, could not be assessed in this review, as no evidence from randomized controlled trials or quasi-randomised trials was available.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-09-09 10:26:25 +0100" MODIFIED_BY="[Empty name]">
<P>Evidence for the effect of weight loss on urinary incontinence is building and should be a research priority. Generally, there was insufficient evidence to inform practice reliably about whether lifestyle interventions are helpful in the treatment of urinary incontinence.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-11-20 12:48:53 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-11-20 12:44:11 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-11-20 12:43:16 +0000" MODIFIED_BY="[Empty name]">
<P>Urinary symptoms pose a considerable health care burden with 200 million people suffering from incontinence worldwide (<LINK REF="REF-Abrams-2005" TYPE="REFERENCE">Abrams 2005</LINK>). The Leicestershire Medical Research Council (MRC) incontinence study, which was the largest comprehensive study of urinary symptoms in a UK general population, reported that 29% of men and 34% of women aged 40 years or over experience clinically significant incontinence or voiding symptoms (<LINK REF="REF-McGrother-2004" TYPE="REFERENCE">McGrother 2004</LINK>), with substantial impact on quality of life. This represents a financial burden to the National Health Service (NHS) of 1% of its annual budget (<LINK REF="REF-Turner-2004" TYPE="REFERENCE">Turner 2004</LINK>). Overall prevalence and service needs will continue to grow as the population ages. </P>
<P>Lifestyle factors may play a role in either in the improvement, or maintenance, of continence. While published literature about lifestyle factors and incontinence is sparse (<LINK REF="REF-Hannestad-2004" TYPE="REFERENCE">Hannestad 2004</LINK>), alterations in lifestyle are frequently recommended by both healthcare professionals and lay people in the belief that they will decrease urine leakage. For example, advice is commonly given to lose weight, increase or decrease fluid intake, stop using caffeinated drinks, reduce alcohol consumption, or to be more physically active - but restrict excessive heavy activities that put pressure on the pelvic floor, such as aerobics or lifting - to stop smoking and avoid constipation and straining. Such recommendations are rarely based on evidence from clinical trials, but on the basis that there are plausible explanations for why these changes might work, and that they are unlikely to cause harm.
</P>
<P>Theoretically, the potential for diet and lifestyle to impact upon incontinence is wider than factors currently identified from a purely empirical viewpoint. It is generally recognised that nutritional and metabolic mechanisms impinge upon all systems of the body including the urinary tract. In practice, incontinence is more commonly observed in patients with specific morbidities such as cerebrovascular disease, dementia, depression and diabetes, and this is supported by scientific evidence (<LINK REF="REF-McGrother-2007" TYPE="REFERENCE">McGrother 2007</LINK>). In these chronic conditions, diet and lifestyle factors have been identified as probably causal: for example, high saturated fat, low fatty fish/omega-3 fat, low fibre, high glycaemic index, low vegetable and high salt intakes (<LINK REF="REF-Chowdhury-2012" TYPE="REFERENCE">Chowdhury 2012</LINK>; <LINK REF="REF-He-2006" TYPE="REFERENCE">He 2006</LINK>; <LINK REF="REF-Baumgart-2015" TYPE="REFERENCE">Baumgart 2015</LINK>; <LINK REF="REF-Ortega-2012" TYPE="REFERENCE">Ortega 2012</LINK>; <LINK REF="REF-Skerrett-2010" TYPE="REFERENCE">Skerrett 2010</LINK>). More generally, the WHO and statutory guidance in the UK and USA currently recognize the importance of poor diet, physical inactivity, excess alcohol and sugary drinks plus smoking in the prevention of such chronic conditions. On this basis, modifications to such diet and lifestyle factors may prevent or reduce bladder dysfunction.</P>
<P>A wide range of interventions and treatments has been used in the management of urinary incontinence, including conservative interventions such as physical therapies: a review by Dumoulin and colleagues broadly supported the recommendation for pelvic floor muscle training in women (<LINK REF="REF-Dumoulin-2010" TYPE="REFERENCE">Dumoulin 2010</LINK>); and Herbison and colleagues reported that the evidence tentatively supported the use of vaginal cones in women who find them acceptable (<LINK REF="REF-Herbison-2002" TYPE="REFERENCE">Herbison 2002</LINK>). In the area of behavioural training, Wallace and colleagues identified that there was limited evidence on the use of bladder training (<LINK REF="REF-Wallace-2004" TYPE="REFERENCE">Wallace 2004</LINK>), but it was unlikely to do harm. The <LINK REF="REF-Lipp-2011" TYPE="REFERENCE">Lipp 2011</LINK> review on anti-incontinence devices identified insufficient evidence for the use of devices and suggested further well designed trials in the area. The <LINK REF="REF-Nabi-2006" TYPE="REFERENCE">Nabi 2006</LINK> review on pharmaceutical interventions, e.g. anticholinergics, reported statistically significant improvements in symptoms, while for surgical interventions, the <LINK REF="REF-Ogah-2009" TYPE="REFERENCE">Ogah 2009</LINK> review reported that minimally invasive surgery was as effective as traditional surgery. For absorbent products, Fader and colleagues identified minimal evidence (<LINK REF="REF-Fader-2007" TYPE="REFERENCE">Fader 2007</LINK>; <LINK REF="REF-Fader-2008" TYPE="REFERENCE">Fader 2008</LINK>), although there was sufficient evidence to support the use of some pads over others. However, this review specifically focuses on the use of lifestyle interventions for the treatment of urinary incontinence.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-11-20 12:43:58 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1) Weight loss</HEADING>
<P>Both obesity and urinary incontinence are common problems in women and men. Obese women have higher intra-abdominal pressure than non-obese women, and it is thought that this chronically elevated pressure may predispose to incontinence by weakening pelvic floor support structures. In recent years, a number of trials (<LINK REF="REF-Hunskaar-2008" TYPE="REFERENCE">Hunskaar 2008</LINK>; <LINK REF="REF-Subak-2002" TYPE="REFERENCE">Subak 2002</LINK>; <LINK REF="REF-Subak-2009a" TYPE="REFERENCE">Subak 2009a</LINK>) including three which specifically reported on weight loss by obese or overweight adults compared to no treatment (<LINK REF="REF-Brown-2006a" TYPE="REFERENCE">Brown 2006a</LINK>; <LINK REF="REF-Subak-2005a" TYPE="REFERENCE">Subak 2005a</LINK>; <LINK REF="REF-Subak-2009b" TYPE="REFERENCE">Subak 2009b</LINK>) have reported an association between increased weight and urinary incontinence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2) Dietary factors</HEADING>
<P>Dietary factors are recognised as contributing to the maintenance of good health, which is strongly related to low levels of incontinence (<LINK REF="REF-McGrother-2007" TYPE="REFERENCE">McGrother 2007</LINK>). Indications from epidemiological data suggest that poor diet may play a specific role in urinary incontinence. The prospective Leicestershire MRC Incontinence Study, which examined food items and nutrients in relation to incidence of urinary incontinence, found associations between 1) stress urinary incontinence and low intake of bread plus high saturated fat, zinc and Vitamin B12, and 2) overactive bladder and low intakes of bread, vegetables, chicken, protein, vitamin D and potassium in women (<LINK REF="REF-Dallosso-2003" TYPE="REFERENCE">Dallosso 2003</LINK>; <LINK REF="REF-Dallosso-2004a" TYPE="REFERENCE">Dallosso 2004a</LINK>; <LINK REF="REF-Dallosso-2004b" TYPE="REFERENCE">Dallosso 2004b</LINK>). Overactive bladder was associated only with high potato intake in men (<LINK REF="REF-Dallosso-2004c" TYPE="REFERENCE">Dallosso 2004c</LINK>). The ratio of high saturated fat to polyunsaturated fat intake has also been related to the severity of incontinence in women (<LINK REF="REF-Maserejian-2010" TYPE="REFERENCE">Maserejian 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3) Fluids</HEADING>
<P>Worsening of urinary urgency, frequency and incontinence is often reported after consuming caffeine, alcohol, fizzy (carbonated) drinks, sweetened diet drinks (<LINK REF="REF-Cartwright-2007" TYPE="REFERENCE">Cartwright 2007</LINK>), or excessive fluids. In a large prospective cohort study, fizzy drinks was the only type of fluid intake independently associated with incontinence in women (<LINK REF="REF-Dallosso-2003" TYPE="REFERENCE">Dallosso 2003</LINK>), whereas in men, beer intake appeared to be protective (<LINK REF="REF-Dallosso-2004c" TYPE="REFERENCE">Dallosso 2004c</LINK>). In a study of urinary symptoms in younger men, caffeine, exercise and tobacco were all associated with worse symptoms in the lower urinary tract (<LINK REF="REF-Moon-1997" TYPE="REFERENCE">Moon 1997</LINK>). Caffeine may increase bladder muscle contractility (<LINK REF="REF-Creighton-1990" TYPE="REFERENCE">Creighton 1990</LINK>), whereas alcohol or excessive fluids may have a diuretic effect, while it has been hypothesised that some sweeteners lead to increased detrusor overactivity (<LINK REF="REF-Dasgupta-2006" TYPE="REFERENCE">Dasgupta 2006</LINK>). Sugary fizzy drinks have a high glycaemic index, which worsens control of diabetes and related neuro-muscular functions. These factors are also recognised as potential hazards to general health, which is predictive of urinary incontinence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4) Constipation and straining</HEADING>
<P>Some evidence suggests that the chronic straining associated with constipation may be a risk factor in the development of urinary incontinence (<LINK REF="REF-Moller-2000" TYPE="REFERENCE">Moller 2000</LINK>), and may increase the latency time of the pudendal nerve (<LINK REF="REF-Kiff-1984" TYPE="REFERENCE">Kiff 1984</LINK>). This nerve supplies the muscles responsible for pelvic support, which is why it has been suggested that constipation may result in, or worsen, urinary incontinence. Poor diet and lack of fibre in the diet can also lead to constipation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5) Smoking cessation</HEADING>
<P>Several trials have suggested that smokers are more likely than non-smokers to report urinary incontinence (<LINK REF="REF-Dallosso-2003" TYPE="REFERENCE">Dallosso 2003</LINK>; <LINK REF="REF-Tampakoudis-1995" TYPE="REFERENCE">Tampakoudis 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6) Physical activity</HEADING>
<P>Prospective cohort evidence suggests that moderate physical activity decreases the risk of onset of urinary incontinence in middle-aged and older women (<LINK REF="REF-Danforth-2007" TYPE="REFERENCE">Danforth 2007</LINK>; <LINK REF="REF-McGrother-2012" TYPE="REFERENCE">McGrother 2012</LINK>; <LINK REF="REF-Townsend-2008" TYPE="REFERENCE">Townsend 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7) Physical forces</HEADING>
<P>It is likely that weakened pelvic floor support structures and raised intra-abdominal pressure caused by heavy lifting and strenuous activity such as aerobics may affect incontinence. Strenuous activity alone may also lead to incontinence in the short term (<LINK REF="REF-Nygaard-2006" TYPE="REFERENCE">Nygaard 2006</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<IMPORTANCE MODIFIED="2015-11-20 12:44:11 +0000" MODIFIED_BY="[Empty name]">
<P>This review aimed to evaluate the effects of these types of lifestyle interventions on improving incontinence and related symptoms by assessing the evidence available from randomized controlled trials. Such interventions are cheap to deploy, have few side effects, are broadly acceptable and may improve the overall health of adults with and without urinary incontinence. This review will enable us to better understand the effect such interventions have on urinary incontinence.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-11-20 12:44:16 +0000" MODIFIED_BY="[Empty name]">
<P>The objective of the review was to determine the effectiveness of specific lifestyle interventions (i.e. weight loss; dietary changes; fluid intake; reduction in caffeinated, carbonated and alcoholic drinks; avoidance of constipation; stopping smoking; and physical activity) in the management of adult urinary incontinence (UI).</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-11-20 12:45:22 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-11-20 12:44:48 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-09-10 16:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trials or quasi-randomised trials (that use some assignment rule such as alternation, or hospital or clinic record number).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-11-20 12:44:48 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with urinary incontinence, diagnosed either by symptom classification (stress UIurinary incontinence (SUI); urgency urinary incontinence (UUI); mixed urinary incontinence (MUI)) or by urodynamic investigation (urodynamic stress incontinence (USI); idiopathic detrusor overactivity (IDO)). Due to the small number of studies available, we made a pragmatic decision after the review commenced, to include all studies if some of the participants had UI. An example would include studies primarily concerned with people with overactive bladder (OAB): OAB describes a clinical problem - that encompasses urgency and urgency UI (usually with frequency and nocturia) - from a symptomatic perspective (<LINK REF="REF-Abrams-2002" TYPE="REFERENCE">Abrams 2002</LINK>). The review excluded studies where all participants explicitly had overactive bladder without UI (so-called 'OAB-dry'). Otherwise we included studies with overactive bladder with the assumption that some participants (regardless of the proportion) had UI (so-called 'OAB-wet'). We also made the post hoc decision to include studies that reported prevalence of UI as an outcome. Here the identified studies were from diabetes trials where not all participants had UI at baseline. Given that obesity is amongst the most clearly established risk factors for UI in women (<LINK REF="REF-Abrams-2013" TYPE="REFERENCE">Abrams 2013</LINK>), we assumed that some study participants had UI at baseline. We excluded studies where all participants were continent at baseline.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-10-11 23:44:34 +0100" MODIFIED_BY="[Empty name]">
<P>One arm of the trial had to be allocated to a community-based lifestyle intervention following a standardised (within trial) protocol. Any of the following lifestyle interventions alone or in combination were included: advice given to lose weight, change diet, adapt the amount or type (e.g. caffeine) of fluid intake, and moderate alcohol consumption, as well as advice given to avoid constipation and straining, stop smoking, and be more physically active whilst restricting excessive heavy physical activity.</P>
<P>Comparison interventions included no (active) treatment, other conservative physical therapies such as pelvic floor muscle training (PFMT) or bladder training, or pharmacological therapies.</P>
<P>We did not consider interventions such as leaflet-only lifestyle advice, without a standardised (within trial) protocol, to be eligible active treatments.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-09-10 16:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>The International Continence Society recommends five outcome categories: the individual's observation (reported symptoms), quantification of symptoms (urine loss), the clinician's observation, and quality of life outcomes, namely, condition-specific, and generic and socioeconomic measures (<LINK REF="REF-Mattiasson-1998" TYPE="REFERENCE">Mattiasson 1998</LINK>).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-09-10 16:30:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Individual report of symptom cure/improvement.</LI>
<LI>Condition-specific quality of life, e.g. ICIQ-Urinary Incontinence Form (<LINK REF="REF-Avery-2004" TYPE="REFERENCE">Avery 2004</LINK>).</LI>
<LI>Adverse effects.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-09-10 16:31:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Quantification of symptoms (e.g. diary, bladder chart):</LI>
<UL>
<LI>cure and improvement rates on diary or pad test in the short term (less than 12 months) and longer term (more than 12 months);</LI>
<LI>number of incontinent episodes in 24 hours.</LI>
</UL>
<LI>Generic quality of life measures e.g. Short Form 36 (<LINK REF="REF-Ware-1993" TYPE="REFERENCE">Ware 1993</LINK>).</LI>
<LI>Socio-economic measures:</LI>
<UL>
<LI>costs of interventions;</LI>
<LI>cost-effectiveness of interventions;</LI>
<LI>resource implications.</LI>
</UL>
<LI>Non-specified outcomes judged important when performing the review. As the search identified trials in people with diabetes that reported prevalence of UI at follow-up, post hoc decisions were made to include prevalence as an outcome only for the assessment of weight loss interventions.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Main outcomes for 'Summary of findings' table</HEADING>
<P>Main outcomes for the 'Summary of findings' table were (in order of importance):</P>
<UL>
<LI>symptom cure based on individual report;</LI>
<LI>symptom improvement (including cure) based on individual report;</LI>
<LI>condition-specific quality of life;</LI>
<LI>adverse effects;</LI>
<LI>symptom cure based on quantification of symptoms;</LI>
<LI>symptom improvement (including cure) based on quantification of symptoms;</LI>
<LI>number of incontinent episodes in 24 hours.</LI>
</UL>
<P>For the assessment of weight loss interventions only, prevalence at follow-up was included in place of the number of incontinent episodes. Main outcomes for weight loss interventions thus were (in order of importance):</P>
<UL>
<LI>symptom cure based on individual report;</LI>
<LI>symptom improvement (including cure) based on individual report;</LI>
<LI>condition-specific quality of life;</LI>
<LI>adverse effects;</LI>
<LI>symptom cure based on quantification of symptoms;</LI>
<LI>symptom improvement (including cure) based on quantification of symptoms;</LI>
<LI>prevalence of UI at follow-up.</LI>
</UL>
<P>The timeframe chosen for these outcomes was at 12-month follow-up.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-11-20 12:45:05 +0000" MODIFIED_BY="[Empty name]">
<P> We did not impose any language or other restrictions on the searches.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-11-20 12:45:05 +0000" MODIFIED_BY="[Empty name]">
<P>This review drew on the search strategy developed for the Cochrane Incontinence Group. We identified relevant trials from the Cochrane Incontinence Group Specialised Trials Register. For more details of the search methods used to build the Specialised Register please see the Group's <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/INCONT/frame.html">module</A> in <I>The Cochrane Library</I>. The register contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and MEDLINE in process, and handsearching of journals and conference proceedings. Most of the trials in the Cochrane Incontinence Group Specialised Register are also contained in CENTRAL. The date of the search was 3 July 2013; the results of these searches are fully incorporated into the review.</P>
<P>We completed an additional search of <A HREF="http://www.clinicaltrials.gov">ClinicalTrials.gov</A> on 28 November 2013 - this search is detailed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. The results of this search have not been fully incorporated into the review - we have placed potentially eligible studies into <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>
.
</P>
<P>We undertook a further updated search of the Specialised Register on 27 October 2014 the results of which we assessed, and added potentially eligible studies to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> (the Specialised Register now includes searches of <A HREF="http://www.clinicaltrials.gov">ClinicalTrials.gov</A> and <A HREF="http://www.who.int/ictrp/en/">WHO ICTRP</A>).</P>
<P>The terms used to search the Incontinence Group Specialised Register were:</P>
<P>(({DESIGN.CCT*} OR {DESIGN.RCT*}) AND ({INTVENT.LIFESTYLE*}) AND {TOPIC.URINE.INCON*})</P>
<P>(All searches were of the keyword field of <LINK REF="REF-Reference-Manager-2012" TYPE="REFERENCE">Reference Manager 2012</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-06-06 13:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the references lists of relevant articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-11-20 12:45:22 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-09-10 16:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently screened eligible studies for inclusion. We resolved any disagreements by discussion. We listed excluded trials with reasons for their exclusion. </P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-11-20 12:45:22 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors extracted data from published reports independently,and resolved any disagreements by discussion. Where there was insufficient information in the published report, we planned to seek clarification from the trialists, but this was not required.</P>
<P>For studies where not all participants had UI at baseline, we preferred the data from a subgroup of people with UI, if these were reported separately. If such data were not available, we extracted data from the whole study but recorded the proportion of people with UI at baseline where possible.  </P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-09-10 16:32:44 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors evaluated all relevant studies independently for their potential risk of bias.</P>
<P>We undertook assessment of methodological quality using the Cochrane 'Risk of bias' tool to include assessment of: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other sources of bias. We resolved any differences of opinion related to the 'Risk of bias' assessment by discussion. We planned sensitivity analysis using only the data from studies having a low risk of bias, but this was not possible due to lack of data.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-09-10 16:33:15 +0100" MODIFIED_BY="[Empty name]">
<P>We undertook quantitative synthesis if we identified more than one eligible study. We used a fixed-effect model to calculate pooled estimates of treatment effect across similar trials with their 95% confidence intervals. We combined dichotomous outcome data using the relative risk (RR) method. We intended to combine continuous outcomes using the Mantel-Haenszel weighted mean difference (WMD) method, but this was not done because the continuous outcome data available were either not reported as means with standard deviations (SD), or were not reported by more than one study. We calculated a mean difference for individual trials where possible.</P>
<P>We grouped trial data according to the type of incontinence when data were available. We planned other subgroup analyses (e.g. age, gender, severity of symptoms, methodological quality), but could not perform these due to insufficient data. </P>
<P>We did not perform quantitative synthesis for adverse events, because the included studies reported adverse events narratively and very few numerical data were available; instead we report the findings by a qualitative summary.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-09-10 16:33:31 +0100" MODIFIED_BY="[Empty name]">
<P>We analyzed trials with a parallel group design on the basis of individuals randomized.</P>
<P>The recommended approach for including cross-over trials in a meta-analysis is to perform a paired analysis taking into account the within-person differences (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). However, the included cross-over trials tended to report all measurements after the active treatment period and all measurements after the control treatment period, and then compared these data as if they came from a parallel group trial. The trials also did not publish the mean and standard deviation values (for the within-person differences) required to perform paired analyses. We therefore presented data from these trials as reported, although this gives rise to a 'unit of analysis' error. These results should therefore be interpreted with caution.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-09-10 16:33:38 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible, we used data based on explicit intention-to-treat analysis. If this was unclear, we performed available case analysis. We collected data on dropout rates, and noted reasons for withdrawal and dropout reported by the trialists in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table when these appeared to be treatment-related.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-09-10 16:33:46 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity across studies by visual inspection of plots of the data, the Chi² test for heterogeneity, and the I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We also explored potential sources of heterogeneity.  </P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-09-10 16:33:54 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to create funnel plots of the intervention effect estimates against their standard errors using Review Manager (RevMan; <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), but the number of studies included in the review was not sufficient for us to perform this assessment.</P>
</BIAS_ASSESSMENT>
<SENSITIVITY_ANALYSIS MODIFIED="2015-09-10 16:35:13 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the potential impact of widening the inclusion criteria of the review to include studies where not all of the participants had UI at baseline, we considered conducting sensitivity analyses in which we would exclude studies with mixed populations (with and without incontinence) from the meta-analysis of each outcome, however, we could not do this due to the low number of studies available.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings table</HEADING>
<P>We summarised results in 'Summary of findings' tables, following the standard methods described in Chapters 11 and 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Sch_x00fc_nemann-2011a" TYPE="REFERENCE">Schünemann 2011a</LINK>; <LINK REF="REF-Sch_x00fc_nemann-2011b" TYPE="REFERENCE">Schünemann 2011b</LINK>). As the recommendation to generate 'Summary of findings' tables is relatively new and became prominent after the publication of the review protocol, we decided to undertake this exercise and determined main outcomes for these tables during the course of the review. We used no external information in the 'Assumed risk' column of the tables.</P>
<P>The overall quality of evidence for each outcome was assessed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). In GRADE, there are four levels of quality of evidence: high, moderate, low and very low. Randomised studies begin as &#8216;high&#8217; quality evidence, but may be rated downwards depending upon performance in one or more of five pre-defined categories: (i) limitation of study design (risk of bias), (ii) inconsistency (heterogeneity), (iii) indirectness, (iv) imprecision, and (v) other considerations (e.g. publication bias).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-11-20 12:48:02 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-11-20 12:45:54 +0000" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2015-09-11 17:05:56 +0100" MODIFIED_BY="[Empty name]">
<P>The electronic searches retrieved a total of 338 records, from which we obtained 60 full text articles we assessed for eligibility. We considered 32 reports of 11 trials eligible for inclusion in the review, and identified one report of an eligible ongoing trial (<LINK REF="STD-Moholdt-2011" TYPE="STUDY">Moholdt 2011</LINK>).</P>
<P>Additionally, we completed assessment of 1151 records retrieved from ClinicalTrials.gov (28 November 2013) after the main search was fully incorporated into the review - details of four potentially relevant records are given in the <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> table (<LINK REF="STD-Baker-2011" TYPE="STUDY">Baker 2011</LINK>; <LINK REF="STD-Heesakkers-2009" TYPE="STUDY">Heesakkers 2009</LINK>; <LINK REF="STD-Huang-2012" TYPE="STUDY">Huang 2012</LINK>; <LINK REF="STD-Markland-2013" TYPE="STUDY">Markland 2013</LINK>). A further updated search of the Specialised Register on 27 October 2014 retrieved 101 records; we screened these and added three extra studies to the <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> section (<LINK REF="STD-Gozukara-2014" TYPE="STUDY">Gozukara 2014</LINK>; <LINK REF="STD-Seckin-2011" TYPE="STUDY">Seckin 2011</LINK>; <LINK REF="STD-Wells-2014" TYPE="STUDY">Wells 2014</LINK>). The results of these latter two searches (ClinicalTrials.gov and the Specialised Register) have not been fully incorporated into the review. The flow of literature through the assessment process is shown in the PRISMA flowchart (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-11-20 12:45:54 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>The review included a total of 32 reports of 11 trials: five parallel-arm randomized controlled trials (RCTs; <LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>), four randomized cross-over trials (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>; <LINK REF="STD-Manonai-2006" TYPE="STUDY">Manonai 2006</LINK>; <LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>), and one quasi-randomised trial that used health record numbers as the basis for assigning people to interventions (<LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>). We also identified one unpublished RCT with limited information (<LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The included trials involved a total of 5974 participants, who were predominantly female (5954 women and 20 men). The average age (it was unclear if this was a mean or median) of the participants in the included trials ranged from 49 to 58 years, except for two trials with means of 62.7 years (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>), and 70.25 years (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>).</P>
<P>Sample size varied across trials. The majority of included trials had 60 or fewer participants (seven trials), however, two trials had more than 1000 participants and a further two trials had more than 100 participants <LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>; <LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>).</P>
<P>In four trials, all trial participants had UI at baseline:</P>
<UL>
<LI>
<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>: 58 women with UI;</LI>
<LI>
<LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>: 48 women with SUI (6%), stress predominant MUI (40%), UUI (11%) and urgency predominant MUI (43%);</LI>
<LI>
<LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>: 338 women with SUI (8%), stress predominant MUI (25%), UUI (18%) and urgency predominant MUI (48%);</LI>
<LI>
<LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>
: 110 women with USI (57%) and IDO (43%).</LI>
</UL>
<P>Four trials included adults with OAB, leading to UUI in some of the trial participants:</P>
<UL>
<LI>
<LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>: 9 men and 86 women with symptoms of urgency, frequency and/or UUI; 83% had UUI at baseline;</LI>
<LI>
<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>: 11 men and 13 women with OAB; 29% had UUI at baseline;</LI>
<LI>
<LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>: 60 women with OAB;</LI>
<LI>
<LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>: 14 women with OAB, with or without UI.</LI>
</UL>
<P>One trial included women with urogenital atrophy, leading to UI in some of the participants:</P>
<UL>
<LI>
<LINK REF="STD-Manonai-2006" TYPE="STUDY">Manonai 2006</LINK>: 42 women with urogenital atrophy; 61% had SUI and 19% had UUI at baseline.</LI>
</UL>
<P>The other trials that contributed the largest numbers of participants were sub-studies of large diabetes trials of intensive weight loss programmes, namely the DPP (Diabetes Prevention Program; <LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>), which focused on the prevention of diabetes, and Look AHEAD (Action For Health in Diabetes; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>), which evaluated cardiovascular morbidity and mortality among individuals with type 2 diabetes. Not all of the trial participants in these trials had UI at baseline, but reported prevalence of UI at follow-up:</P>
<UL>
<LI>
<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>: 2191 women in a diabetes trial; no baseline measures of UI;</LI>
<LI>
<LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>: 2994 women in a diabetes trial; 27% had weekly UI at baseline.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Weight loss</HEADING>
<P>Four trials assessed the effect of weight loss programmes on incontinence compared with a control intervention (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>). All weight loss interventions included components of diet and physical activity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Diet</HEADING>
<P>The review identified one trial that examined dietary factors by comparing a soy-rich diet with a control diet (<LINK REF="STD-Manonai-2006" TYPE="STUDY">Manonai 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Changing volume of fluid intake</HEADING>
<P>Three trials assessed the effect of changing the volume of fluid intake (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>; <LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>; <LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Type of fluid intake</HEADING>
<P>Three trials assessed the effect of reducing caffeinated drinks (<LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>; <LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>). No relevant trials were identified with respect to alcohol, sweetened fizzy drinks or diet drinks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Constipation and straining, smoking cessation, physical activity and physical forces</HEADING>
<P>The review identified no randomized trials addressing the effect of constipation and straining, smoking cessation, physical activity or physical forces on urinary incontinence.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome</HEADING>
<P>Quality of reporting of outcomes was generally poor. Not all specified outcomes were reported. Where reported, outcomes were reported using diverse measures, which made the results difficult to interpret. Meta-analysis was performed only for cure and improvement rates and UI prevalence from the weight loss interventions. All other outcomes were summarised narratively.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-09-11 17:07:17 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded 27 reports relating to 20 studies after full text screening; see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. For example, the review excluded studies where lifestyle change was implemented as part of a multi-faceted intervention, e.g. dietary change and constipation management with pelvic floor muscle training, because in such studies we could not separate the effects of lifestyle change from other factors.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-11-20 12:46:17 +0000" MODIFIED_BY="[Empty name]">
<P>The risk of bias of the included trials is summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2015-11-20 12:46:00 +0000" MODIFIED_BY="[Empty name]">
<P>Four of the 11 included trials described adequate methods of random sequence generation (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>), and of these, allocation was adequately concealed in two (<LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>), but was unclear in the other two (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>). One trial used quasi-randomisation based on health record numbers and was therefore at high risk of selection bias (<LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>). Other trials did not describe the methods used for random sequence generation and allocation concealment and so we judged them to be at unclear risk of bias for this domain.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-09-11 17:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>Blinding of participants and personnel was not feasible due to the nature of interventions; this may have biased self-reported outcomes such as cure, improvement and quality of life. Blinding of outcome assessment should be possible, but was done in only three trials (<LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>), and was unclear in the others.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-11-20 12:46:10 +0000" MODIFIED_BY="[Empty name]">
<P>The percentage of participants followed up and included in analysis varied across trials as shown below:</P>
<UL>
<LI>100% (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>);</LI>
<LI>90% or more (<LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>);</LI>
<LI>between 80% and 89% (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Manonai-2006" TYPE="STUDY">Manonai 2006</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>; <LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>);</LI>
<LI>between 70% and 79% (<LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>);</LI>
<LI>55% (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>); and</LI>
<LI>not reported (<LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>).</LI>
</UL>
<P>Of these, four trials were considered to be at low risk of attrition bias (incomplete outcome data) because the trial reports stated that either there were no missing outcome data (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>), or described use of imputation (<LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>), or confirmation that participants with missing data did not differ from participants with data in terms of demographic and clinical characteristics (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>). One trial (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>), in which 26 (45%) of the 58 participants did not complete diaries and were excluded from analysis, was assessed as having a high risk of attrition bias. Reasons for missing outcome data were not clearly described in the other trials, and it was difficult to determine whether the extent of missing data was likely to induce clinically important bias. We therefore judged them to be at unclear risk of bias for this domain.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-11-20 12:46:17 +0000" MODIFIED_BY="[Empty name]">
<P>All trials reported on the outcomes listed in their methods section but, as there was otherwise insufficient information to permit judgement of low or high risk of bias within published reports, we consider them to be at unclear risk of bias for this domain.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-09-11 17:08:06 +0100" MODIFIED_BY="[Empty name]">
<P>Two trials assessing fluid intake manipulation (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>; <LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>), and caffeine reduction (<LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>), noted that compliance to the trial protocol was relatively poor. Apart from this factor, it was difficult to assess whether any other important risk of bias existed in these and the other trials.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-11-20 12:48:02 +0000" MODIFIED_BY="[Empty name]">
<P>The results of the included studies, and the quality of the body of evidence for each outcome, are summarised in the 'Summary of findings' tables (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>; and <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">1) <I>Weight loss </I>by obese or overweight adults versus <I>no active intervention</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Description of studies</HEADING>
<P>We identified four trials involving a total of 4701 participants that compared intensive lifestyle weight loss interventions with control or no active interventions in relation to incontinence (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>). All participants in two of the included trials had UI (<LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>). The other two trials were sub-studies of large diabetes trials (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>), DPP and Look AHEAD, respectively, and contributed 4315 (92%) of the trial participants to the analysis. These trials did not recruit participants specifically with UI and therefore not all the participants had it. We extracted outcome data on cure and improvement (based on quantification of symptoms) from a subgroup of people with UI in the Look AHEAD trial (N = 738; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>), and data on prevalence of UI at follow-up from the whole (sub-)study (N = 2994). The trial authors reported the one-year results of a four-year intensive weight loss programme; the trialists planned that follow-up of this trial would run until 2014. The only relevant outcome from the DPP trial was prevalence at follow-up of UI from the whole (sub-)study (N = 1321; <LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>); the proportion of people with UI at baseline was unknown (not reported).</P>
<P>All participants in the included trials were female. The weight loss groups were given a reduced-calorie diet and increased physical activity according to a structured and supervised protocol. The comparison groups received:</P>
<UL>
<LI>no intervention (waiting list; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>);</LI>
<LI>a structured education programme on weight loss (<LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>);</LI>
<LI>diabetes support and education (<LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>); or</LI>
<LI>a placebo drug (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>).</LI>
</UL>
<P>Duration of the interventions varied across trials. The intensive intervention phase lasted for:</P>
<UL>
<LI>three months (<LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>);</LI>
<LI>six months followed by a further randomisation in the intervention group (not the control group) to motivation-based or skill-based maintenance programmes for an additional 12 months (<LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>);</LI>
<LI>six months with monthly follow-up thereafter for an average of 2.8 years (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>); or</LI>
<LI>12 months (<LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>).</LI>
</UL>
<P>All four trials reported that women allocated to the intervention group achieved a statistically significant decrease in body weight from baseline compared with those in the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>Improvement rates based on women's perception (self-report) were reported in one trial (<LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>). The results showed that at six months women in the intervention group were more likely to report improvement than those in the control group at six months (163/214 (76%) versus 49/90 (54%), risk ratio (RR) 1.4, 95% confidence interval (CI) 1.14 to 1.71; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), 12 months (298 women in analysis, 75% versus 68%, RR not estimable, reported P value 0.2) and 18 months (291 women in analysis, 75% versus 62%, RR not estimable, reported P value 0.02) after randomisation (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The reported P values suggest that the differences were statistically significant at six months and 18 months. No information was available on self-reported cure.</P>
<P>The intervention group also reported that incontinence had less adverse impact on their lives (median Incontinence Impact Questionnaire scores, 40 women in analysis, 37 versus 89, P value 0.01) and was less distressing (median Urogenital Distress Inventory scores, 40 women in analysis, 104 versus 195, P value &lt; 0.0001) compared with the control group in one trial that reported these outcomes (<LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>Adverse effects appeared to be relatively uncommon, with one trial reporting that the intervention had 'few side effects' (<LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Three trials reported cure and improvement rates based on quantification of symptoms (rather than women's perception; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). Depending on the trial, length of follow-up and type of incontinence, cure rates for the intervention group ranged from 7% to 35% and improvement rates ranged from 37% to 64%. In the control group cure rates ranged from0% to 32% of women, while improvement ranged from 0% to 62%.</P>
<P>In general the intervention group had higher rates in terms of both cure and improvement compared with the control group when stress and urgency UI symptoms were considered together ('all UI'). For improvement rates, the difference between the groups was statistically significant at three months (7/19 (37%) versus 0/21 (0%), RR 16.50, 95% CI 1.01 to 270.78; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), six months (88/214 (41%) versus 20/90 (22%), RR 1.85, 95% CI 1.22 to 2.81; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) and 12 months (234/583 (40%) versus 146/449 (32%), RR 1.21, 95% CI 1.02 to 1.44; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), although the effect was attenuated over time and was no longer statistically significant at 18 months (91/197 (46%) versus 36/90 (40%), RR 1.15, 95% CI 0.86 to 1.55; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). The difference for cure rates did not reach statistical significance (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>Looking at different types of UI at each outcome time point, the <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK> trial showed a similar pattern with a tendency towards greater improvement in the intervention group than in the control group among the subgroup of women who reported stress symptoms at six, 12 and 18 months (P values 0.01, 0.01 and 0.92 , respectively) or urgency symptoms at six, 12 and 18 months (P values 0.04, 0.07 and 0.03, respectively; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). In the same trial, cure rates by type of UI also favoured the intervention group for both SUI (P value 0.004) and UUI (P value 0.02) at six months, but no further follow-up was available (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>The prevalence of weekly (or more frequent) UI of any type (stress or urgency) was lower in the intervention group than in the control group in the two sub-studies of diabetes trials with a follow-up of between one and 2.8 years (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). According to adjusted odds ratios (ORs) reported by trial authors, the intervention was associated with a statistically significant reduction in the odds of having UI by around 20% to 24% compared with the control group (in <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>, adjusted OR 0.80, 95% CI 0.65 to 0.98; in <LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>, adjusted OR 0.76, 95% CI 0.61 to 0.95). The prevalence of weekly SUI was also lower in the intervention group compared with the control in both trials (in <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>, adjusted OR 0.73, 95% CI 0.55 to 0.96, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; in <LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>, adjusted OR 0.80, 95% CI 0.64 to 1.01) but no such difference was apparent for UUI (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). The trial authors suggest that the reduction in the prevalence of overall weekly incontinence may be due to differences in weekly SUI.</P>
<P>Compared with women in the control group, those in the intervention group had a greater percentage reduction from baseline in weekly incontinence episodes over the period of three to 18 months regardless of type of UI (all, stress or urgency; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). Differences between the groups for all UI and SUI episodes were reported to be statistically significant at three, six and 12 months but no longer significant at 18 months. The difference for UUI was not statistically significant at any point in time after three months.</P>
<P>General health-related quality of life was measured only in one small trial with 40 participants using SF-36 ( (<LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The median SF-36 Physical Component Score favoured the intervention group (55 versus 47, P value 0.003) but there was no significant difference between the groups in the Mental Component Score of the same instrument (48 versus 51, P value 0.09).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2) <I>Dietary changes versus no active intervention</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Description of study</HEADING>
<P>We identified only one small trial that assessed the effect of dietary factors on UI (<LINK REF="STD-Manonai-2006" TYPE="STUDY">Manonai 2006</LINK>). The trial used a randomized cross-over design and compared a soy-rich diet with a control (soy-free) diet in 42 women who experienced at least one of urinary or genital symptoms owing to urogenital atrophy. At baseline around 61% and 63% of women in the intervention and control groups, respectively, had SUI episodes and 19% and 11%, respectively, had UUI episodes. Partcipants underwent two two-week treatment periods in random order with two four-week washout periods before and between treatments. The trial authors found compliance to the diet to be satisfactory on the basis of the elevation of serum levels of daidzein and genistein during the soy-rich diet period. Outcome data were available for 36 women who completed the trial. As data subgrouped by incontinence status were not available, the extracted data were from the whole study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>The trial did not address self-reported cure and improvement rates, condition-specific quality of life and adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>The trial did not address cure and improvement rates based on quantification of symptoms, number of UI episodes and generic quality of life. The available data suggest that the percentage of women with UUI episodes in the control group increased from baseline during the control diet period (N = 36, from 11% to 22%, P value not reported; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Correspondingly, symptom scores (mean, SD) of UUI significantly increased during the control diet period (N = 36, from 0.14 (0.35) to 0.25 (0.50), P value &lt; 0.05; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), although the difference was small.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3) Change in fluid intake versus no treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Description of studies</HEADING>
<P>We identified three trials that examined altering the level of fluid intake (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>; <LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>; <LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>).</P>
<P>One RCT allocated 58 women with UI to one of three groups that increased fluid intake by 500 (
<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>
). The trial provided a five-week programme with randomisation in the second week. The trial reported that adherence to the fluid manipulation was poor, which made results difficult to interpret.</P>
<P>Another randomized cross-over trial with 84 women with UI reported outcome data for the 69 women (39 with USI and 30 with IDO) who completed the trial (<LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>). The trial lasted four weeks. In the first week participants drank normally (week 1, baseline) and in the second week drank normally, but only caffeine-free fluids (week 2, caffeine-free baseline). Participants were then randomized in the order in which they either increased fluids to 3 litres daily, or decreased fluids to 750 ml daily, in the third and fourth weeks while maintaining caffeine restriction (i.e. only drinking caffeine-free fluids). Adherence to fluid intake protocols seemed fair, with a mean fluid intake of 1639 ml for Week 1, 1630 ml for Week 2, 2673 ml for the week of increasing fluids and 872 ml for the week of decreasing fluids.</P>
<P>In another cross-over trial with 24 participants (11 men and 13 women) with OAB (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>), only seven (29%) participants had UUI at baseline. Participants were randomized into two groups and asked to either increase or decrease their fluid intake from baseline. As outcome data specific to a subgroup of people with UI were not reported separately, the extracted data applied to the whole study. Group I was asked to drink at &lt; 25% of baseline for four days, followed by two days' normal drinking, four days' at &lt; 50%, two days' normal drinking, four days at &gt; 25%, two days' normal drinking, and then four days at &gt; 50%. Group II did the reverse. The trial reported that participants had difficulty in either increasing or decreasing fluids by 50%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>One cross-over trial assessed quality of life using the Bristol Female Lower Urinary Tract Symptoms questionnaire (<LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>). Quality of life improved when fluid intake was decreased compared with baseline in women with USI (N = 39, P value &lt; 0.003) or IDO (N = 30, P value &lt; 0.003) but the women reported no significant difference in the impact of incontinence symptoms on their daily life before and after treatment (no further data were available).</P>
<P>Regarding adverse effects, the same cross-over trial reported that, with decreasing fluids, &#8216;side effects such as constipation and thirst were troublesome&#8217; (<LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>). Another cross-over trial with 24 participants reported that adverse events observed were mild and tolerable: four participants felt thirsty and two had headaches, constipation or concentrated urine when fluid intake was decreased by 50% from baseline; and one had headache when intake was reduced by 25% (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>). </P>
<P>No information was available regarding self-reported cure or improvement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>The number of daily incontinent episodes was reported by three trials that used different measures. A four-week cross-over trial stratified results by type of UI at baseline (<LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). Among 39 women with USI, the week of decreasing fluid intake (with caffeine restriction) was associated with a statistically significant reduction in the median number of daily incontinent episodes compared with the week of increasing fluid intake (with caffeine restriction; 0.5 versus 0.7, P value 0.006). Daily incontinent episodes after decreasing fluid intake (with caffeine restriction) were also statistically significantly fewer compared with the baseline week when participants drank normally (week 1, 0.5 versus 1.6, P value 0.006), but there was no significant difference when compared with the caffeine-free baseline week in which participants maintained a similar fluid intake from baseline, but substituted caffeine-free drinks for caffeine-containing drinks (week 2, 0.5 versus 0.8, P value 1.000). The week of increasing fluid intake (no caffeine) did not differ significantly from the caffeine-free baseline week (week 2, 0.7 versus 0.8, P value 0.426) in terms of daily incontinent episodes. For 30 women with IDO, drinking less fluid (no caffeine) had no statistically significant effect on daily incontinent episodes (0.5 versus 0.6, P value not significant) when compared with the caffeine-free baseline, but drinking more fluid (no caffeine) resulted in a significant worsening (increase) of the symptom (1.1 versus 0.6, P value &lt; 0.003).</P>
<P>In the other cross-over trial participants were asked to increase or decrease their fluid intake by 25% and 50% from baseline in random order (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>). There was no statistically significant difference in the mean number of daily incontinent episodes between the baseline period and each of the fluid manipulation periods, although it should be noted that only seven (29%) of the 24 participants had UUI at baseline (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>The <LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK> trial randomized participants to three groups (maintain, increase or decrease fluid), but the authors reported that adherence to the fluid manipulation protocol was poor and that results were inconclusive (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4) <I>Caffeine reduction versus continued caffeine intake</I>
</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Description of studies</HEADING>
<P>We identified three trials that assessed the effects of a reduction in caffeine intake on incontinence (<LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>; <LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>).</P>
<P>In <LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>, 95 participants (86 women, 9 men) with OAB (83% had UUI at baseline) were randomized by use of health record numbers (quasi-randomised) to caffeine reduction education or control (continued caffeine intake). In addition, both groups received bladder training and were followed up for four weeks. Caffeine intake in the intervention group was reduced significantly from baseline compared with the control group (58% versus 11%, P value &lt; 0 000.1)</P>
<P>
<LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK> was a randomized cross-over trial in which 14 women with OAB (with or without UI) underwent two two-week periods of caffeinated or caffeine-free fluids intake with a 14-day washout period between treatments. It was a feasibility trial and identified only in abstract form. Data were available for the 11 women who completed the trial. Two participants did not comply with caffeine substitution.</P>
<P>The third trial, <LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>, was an unpublished two-arm RCT that evaluated the effect of restricting 'irritating' beverages (caffeinated or non-caffeinated). In this trial around 60 women with OAB (it was unclear if some or all participants were incontinent) were asked to substitute 'irritating' beverages with milk or water, but to maintain a similar volume of fluid from baseline. The request to stop drinking irritating beverages was associated with an improvement in OAB symptoms, but the trial author noted that the findings were confounded by a significant reduction in overall fluid intake in the intervention group from baseline (email communication from the trial author to the Cochrane Incontinence Group). No further information was available regarding this trial. The remainder of this section therefore focuses on the first two trials.</P>
<P>In all three trials, outcome data were extracted from the whole study, as data specific to the UI subgroup of the trial population were not reported separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>The <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK> trial reported condition-specific quality of life using ICIQ Overactive Bladder (ICIQ-OAB) and ICIQ Overactive Bladder Symptoms Quality of Life (ICIQ-OABqol) questionnaires among 11 of the 14 women who completed the trial. Overall, women had lower (better) scores during the period of caffeine substitution (when drinking caffeine-free fluids) compared with the caffeine exposure period, but the difference in total scores for the ICIQ-OABqol was not statistically significant (mean 54 versus 68, P value 0.065; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). No information was available regarding self-reported cure and improvement, or adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>There was no evidence of a difference in incontinence episode frequency between the caffeine reduction and caffeine exposure groups. The <LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK> trial reported a mean difference of 0.2 episodes per day (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>: mean difference (MD) -0.20, CI -1.02 to 0.62), whereas the <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK> trial reported 'no difference' with no numerical data provided. No information was available for cure and improvement rates based on quantification of symptoms or generic quality of life.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5) Reduction in sweetened fizzy or diet drinks versus no treatment</HEADING>
<P>We found no trials that compared a reduction in sweetened fizzy or diet drinks with no treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6) Reduction in alcohol consumption versus no treatment</HEADING>
<P>We found no trials that compared a reduction in alcohol consumption with no treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7) Avoiding constipation versus no treatment</HEADING>
<P>We found no trials that compared avoidance of constipation with no treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">8) Smoking cessation versus no treatment</HEADING>
<P>We found no trials that compared stopping smoking with no treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">9) Restricting strenuous physical forces versus no treatment</HEADING>
<P>We found no trials that compared restricting strenuous physical forces with no treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">10) Reducing high levels of, or increasing low levels of, physical activity versus no treatment</HEADING>
<P>We found no trials that compared a reduction in high levels of physical activity, or increasing low levels of physical activity, with no treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">11) Any lifestyle interventions, either alone or in combination, versus other lifestyle interventions or pharmacological and other conservative therapies</HEADING>
<P>One trial was identified that compared a lifestyle weight loss intervention versus metformin. This trial was a sub-study of a large DPP trial for diabetes described above (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>), which compared different weight loss programmes: an intensive lifestyle intervention or a pharmacological intervention (metformin). This comparison included 1296 women.</P>
<P>The only relevant outcome for this review was the effect of weight loss on the prevalence of weekly or more frequent UI at a mean follow-up of 2.8 years. The results showed that women allocated to the lifestyle group (N = 659) had a significantly lower prevalence of UI (any UI) compared with those in the comparison group (252/659 (38%) versus 306/635 (48%), RR 0.79, 95% CI 0.70 to 0.90; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.1). The results hold for the prevalence of both weekly SUI symptoms (206/659 (31%) versus 252/635 (40%), RR 0.79, 95% CI 0.68 to 0.91; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.2), and UUI symptoms (156/659 (24%) versus 182/635 (29%), RR 0.83, 95% CI 0.69 to 0.99; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.3).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-11-20 12:48:53 +0000" MODIFIED_BY="[Empty name]">
<P>This is the first systematic review to consider the effectiveness of specific lifestyle interventions in the management of adults with urinary incontinence.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-11-20 12:48:37 +0000" MODIFIED_BY="[Empty name]">
<P>This review identified eleven trials that reported on the effect of weight loss (four trials), the intake of a soy-rich diet (one trial), change in fluid intake (three trials), reduction in caffeinated drinks (three trials), and lifestyle versus non-lifestyle interventions for weight loss (one trial).  No trials were identified that investigated alcohol, sweetened fizzy drinks or diet drinks, constipation and straining, smoking cessation, physical activity or physical forces.</P>
<P>Adverse effects appeared to be relatively uncommon for all interventions studied, although, with decreasing fluids, some participants experienced thirst, constipation, concentrated urine or headaches. </P>
<SUBSECTION>
<HEADING LEVEL="3">Is weight loss by obese or overweight adults more effective than no treatment?</HEADING>
<P>Four trials investigated whether weight loss by obese or overweight adults was more effective than no treatment and included a total of 4701 women (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>). It is important to note that two trials, which contributed over 90% of the women to this analysis, were primarily diabetes trials (N = 1321 and 2994, respectively; <LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>). </P>
<P>There is 'low' quality evidence that, compared with the control interventions, weight loss programmes were associated with higher improvement rates based on women&#8217;s self-report (primary outcome), and also higher cure and improvement rates based on quantifiable symptoms (secondary outcomes), although there was no information available on self-reported cure (primary outcome). The two diabetes trials also reported prevalence of urinary incontinence and identified a similar trend towards the weight loss groups having a greater reduction in the number of women with weekly incontinence episodes compared with the control groups ('very low' quality evidence). Only the smallest trial with 40 women measured disease-specific quality of life using the Incontinence Impact Questionnaire and the Urogenital Distress Inventory (<LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>), which showed statistically significant differences that favoured the weight loss group compared with the control group ('low' quality evidence).</P>
<P>This consistency of effect across a number of measured outcomes gives strength to the evidence. Overall, the differences in both cure and improvement when weight loss is compared to control suggest that weight loss interventions may be of interest to morbidly and moderately obese women and their clinicians. The degree of improvement in UI may be contingent upon the magnitude of the weight loss. A cohort analysis, <LINK REF="REF-Wing-2010" TYPE="REFERENCE">Wing 2010</LINK>, associated with one of the included trials (called the PRIDE study, N = 338 at baseline; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>) showed that women who lost 5% to 10% of their body weight (regardless of randomized treatment assignment) were two to four times more likely to achieve at least a 70% reduction in the number of total (i.e. stress or urgency) incontinence episodes per week compared with those who gained weight at follow-ups at six months (adjusted OR 3.7, 95% CI 1.6 to 8.2), at 12 months (adjusted OR 3.7, 95% CI 1.7 to 8.3) and at 18 months (adjusted OR 2.4, 95% CI 1.1 to 5.1). Weight losses greater than 10% did not result in greater improvements in incontinence outcomes (at 6 months, adjusted OR 3.8, 95% CI 1.5 to 9.6; at 12 months, adjusted OR 4.1, 95% CI 2.1 to 7.9; at 18 months, adjusted OR 3.3, 95% CI 1.7 to 6.4).</P>
<P>There is little evidence available concerning the potential mechanisms involved in the weight loss effect. There was inconsistency in the type of intervention provided that included various combinations of diet and physical activity. It was also unclear whether the dietary mechanism involved reduced calorie intake, or other change in the quality of the diet, or both. Some of the potential benefits of weight loss could also have been attributed to better glycaemic control rather than weight loss alone, in view of the substantial numbers of diabetics involved in the trials. Such results may not be entirely relevant to all people with obesity, although there was independent evidence for a weight loss effect in non-diabetics.</P>
<P>As might be expected, the benefit of the weight loss intervention diminished over time. This is clear from the forest plots for cure and improvement rates by quantification of symptoms and the number of incontinence episodes per week, which show that the point estimates move closer to the line of no effect from three months, through to 18 months. Maintenance of effect is rarely seen in long-term incontinence trials carried out years after intervention (<LINK REF="REF-Agur-2008" TYPE="REFERENCE">Agur 2008</LINK>; <LINK REF="REF-Glazener-2005" TYPE="REFERENCE">Glazener 2005</LINK>), and therefore sustainability of weight loss and its long-term effect on incontinence would require further research.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is dietary change more effective than no change?</HEADING>
<P>One small trial investigated whether dietary change is more effective than no change (<LINK REF="STD-Manonai-2006" TYPE="STUDY">Manonai 2006</LINK>); it included 42 women comparing a soy-rich diet with a soy-free diet. The only available outcome data for UI frequency found no evidence of a difference between the two diets ('very low' quality evidence). Other data were insufficient to draw any conclusions about the effect of the content of the diet on UI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is changing the volume of fluid intake more effective than no change in the volume of fluid intake?</HEADING>
<P>Three trials investigated whether changing the volume of fluid intake is more effective than no change in the volume of fluid intake; these included 181 women and 11 men (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>; <LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>; <LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>). Only one cross-over trial used disease-specific quality of life as the primary outcome and reported improvement in scores for the Bristol Female Lower Urinary Tract Symptoms questionnaire following decreased fluid intake (<LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>). One trial reported poor adherence to the intervention protocol, which led to inconclusive results (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>). Each trial used a different protocol detailing fluid manipulation and none of the trials reported improvement or cure. We ranked the quality of findings as 'very low'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is caffeine reduction more effective than no change in caffeine consumption?</HEADING>
<P>Three trials investigated whether caffeine reduction is more effective than no change in caffeine consumption and included a total of160 women and nine men (<LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>; <LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>). One trial was reported exclusively via an author email (<LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>), and was insufficiently detailed for us to draw firm conclusions. Across the trials, there was inconsistency in outcomes used, limited data and insufficient reporting to enable an analysis of whether caffeine reduction is better than no change in consumption. The limited and 'very low' quality data available on disease-specific quality of life (ICIQ-OABqol) and incontinence episode frequency found no evidence of a difference between the groups. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is any lifestyle intervention more effective than another intervention?</HEADING>
<P>One trial investigated whether one lifestyle intervention is more effective than any another intervention and included 1296 women (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>); this was a sub-study of a large diabetes trial that compared two weight loss programmes - an intensive lifestyle intervention or a pharmacological intervention (metformin). The only available outcome data were on the effect of weight loss on prevalence of weekly UI (a secondary outcome of 'very low' evidence quality). The results showed that women had a lower prevalence of weekly UI in the lifestyle group than in the metformin group at a mean of 2.8 years follow-up and this difference between the groups was statistically significant, favouring the lifestyle intervention. </P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-11-20 12:48:44 +0000" MODIFIED_BY="[Empty name]">
<P>The majority of included trials had small sample sizes, with 60 or fewer participants, and short follow-up (i.e. less than 12 months). Five of the included trials were parallel-arm RCTs (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>). The remainder included four randomized cross-over trials (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>; <LINK REF="STD-Manonai-2006" TYPE="STUDY">Manonai 2006</LINK>; <LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>), and one quasi-RCT (allocation made using health record numbers; <LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>). We also included one unpublished trial, with limited information, from an author email (<LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>).  </P>
<P>Participants in the trials included in this review were predominantly female, with the average age (unclear if this was mean or median) ranging from 49 to 58 years, except for two trials with means of 62.7 years, <LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>, and 70.25 years, <LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>. The trial participants were also those resident in the community. Therefore, the applicability of findings to men and older age groups, and particularly frail elderly people in care home settings, is uncertain.</P>
<P>Random sequence allocation was adequately generated and concealed in only two trials (<LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>); in other trials it was either inadequate or not described in sufficient detail. This may have introduced selection bias. </P>
<P>The percentage of participants followed up and included in analysis varied across the included trials. Only four trials had either no missing outcome data, imputed missing data, or stated that missing data were balanced across groups (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>; <LINK REF="STD-Subak-2005" TYPE="STUDY">Subak 2005</LINK>; <LINK REF="STD-Subak-2009" TYPE="STUDY">Subak 2009</LINK>), while in one trial nearly half of the participants were excluded from analysis due to missing data (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>). In the other trials, the numbers of and reasons for missing outcome data were not clearly described, which led to uncertainty about the degree of attrition bias present in these trials.</P>
<P>Reported outcome data were heterogenous in a number of ways and this limited our ability to make comparisons across trials. For example, within each category of lifestyle intervention (weight loss, diet quality, fluid restriction and caffeine restriction), the trials used no outcomes consistently. There was no single outcome common to all trials, and even outcomes that were conceptually similar were measured in different ways. No primary outcome data were available for six of the trials included in the review (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>; <LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>; <LINK REF="STD-Manonai-2006" TYPE="STUDY">Manonai 2006</LINK>; <LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>). In particular, quality-of-life outcomes were very poorly recorded. The importance of the inclusion of quality-of-life outcomes should not be underestimated, as they are likely to be the most keenly valued by patients themselves. More recent trials are likely to include quality-of-life measures, as they are increasingly identified as key outcomes, and use of recognised instruments for measuring them, such as the International Consultation on Incontinence Questionnaire (ICIQ), are becoming more widely used. </P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-09-14 12:58:58 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the levels of evidence for each outcome measured at 12 months after the commencement of the treatment using the GRADE approach (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>; and <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>). Overall, the GRADE level of evidence for all outcomes was either 'low' or 'very low' across the different interventions. The main factors for downgrading the evidence included risk of bias (lack of blinding and unclear allocation concealment), indirect evidence (less than 12 months of follow-up) and imprecise results due to a small sample size with wide confidence intervals, or a lack of information (e.g. standard deviation) required to estimate confidence intervals. Evidence from studies where only some of the participants were incontinent was also downgraded for indirectness as described below.</P>
<P>Quality of outcome reporting was generally poor. We judged methodological quality (risk of bias) from the trial reports, and so our judgements may reflect the quality of reporting, rather than the actual methodological quality of the trials.  </P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-11-20 12:48:53 +0000" MODIFIED_BY="[Empty name]">
<P>Due to the limited number of trials we identified that included only adults with UI, we made a post hoc decision to include data from trials where not all participants were incontinent when they entered the trial: the populations in these trials primarily had: overactive bladder (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>; <LINK REF="STD-Miller-2007" TYPE="STUDY">Miller 2007</LINK>; <LINK REF="STD-Wells-2011" TYPE="STUDY">Wells 2011</LINK>); urgency and frequency (<LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>); urogenital atrophy (<LINK REF="STD-Manonai-2006" TYPE="STUDY">Manonai 2006</LINK>), or diabetes (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>). Baseline incontinence ranged from 27% of the trial participants in <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK> to 83% in <LINK REF="STD-Bryant-2002" TYPE="STUDY">Bryant 2002</LINK>, or was not reported but assumed (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>). We extracted outcome data from the whole study for all trials except <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>, which provided subgrouped data specific to incontinence status.</P>
<P>We made another post hoc decision to include an outcome on the prevalence of UI at follow-up; this outcome was identified from the two weight loss trials in people with diabetes (<LINK REF="STD-Brown-2006b" TYPE="STUDY">Brown 2006b</LINK>; <LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>). Our literature search was systematic and designed to pick up any mention of UI, urinary leakage or overactive bladder in the title, abstract and controlled vocabulary. A more in-depth search required to identify studies for all clinical conditions was, however, not feasible within the limited resources available. This may have introduced reporting bias, as a large or beneficial intervention effect on UI may be more likely to be reported in abstracts of published reports than data showing little or no effect, and so be more likely to be identified by our search. If this is the case, including prevalence data could have exaggerated intervention effects. The applicability of evidence for managing people with urinary incontinence may also be limited, as the extent to which the weight loss programmes served as prevention, rather than treatment, of urinary incontinence is unclear.</P>
<P>Although every effort was made to adhere to the review protocol to minimise bias, these post hoc decisions resulted in changes to the inclusion criteria of the review. As data from those studies with mixed populations (with and without incontinence) often constituted the only information available for some of the interventions assessed in the review, we chose to include these data to provide relevant, albeit indirect, evidence. We exercised caution when interpreting these findings, by downgrading the quality of the body of evidence for the outcomes based on the studies with mixed populations (with and without incontinence) by one level on the ground of indirectness.</P>
<P>The review also encountered a problem associated with cross-over trials that did not report data in a standard way which would take into account the within-person differences (paired analysis). Instead, the included trials tended to report all measurements after completion of the treatment period and compared these data, as if they were a parallel group; some included trials also reported all measurements before and after intervention and compared these data within each treatment phase. The information required to perform paired analyses was not available from the published reports, which meant not only that the data from similar trials could not be incorporated into a meta-analysis, but also that the reported data presented a 'unit of analysis' error. These results should therefore be interpreted with caution.</P>
<P>The addition of the assessment of evidence quality using the GRADE approach and 'Summary of findings' tables was a relatively new development in the systematic review methods at the time of this review. While these methods were not specified in the protocol, we nevertheless attempted to incorporate them into the present review. Efforts were made to minimise bias in determining outcomes to be included in the tables and quality ratings for each outcome through careful discussion among the review authors. However, these steps may have been influenced by knowledge of the results of the research and may therefore carry some risk of bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-09-14 13:00:41 +0100" MODIFIED_BY="[Empty name]">
<P>We are unaware of other systematic reviews on this topic. However, a summary of the evidence in men and in women, including that from non-randomised studies, is provided in the 5th Edition of the International Consultation on Incontinence (<LINK REF="REF-Moore-2013" TYPE="REFERENCE">Moore 2013</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-09-14 13:00:57 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-09-14 13:00:49 +0100" MODIFIED_BY="[Empty name]">
<P>The available data show that evidence for weight loss as a treatment to reduce urinary incontinence (UI) among morbidly and moderately obese women is building, and might be worth considering as an initial treatment prior to other standard treatments such as pelvic floor muscle training and surgery. However, there is insufficient evidence to inform practice reliably about the effectiveness of lifestyle interventions in general.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-09-14 13:00:57 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence for lifestyle changes for UI is strongest for the effects of weight loss programmes, which should receive research priority. Weight loss interventions involving diet and fluid manipulation require more well designed trials that using representative samples of cases. Priority should also be given to investigating dietary mechanisms for weight loss effects, such as calorie reduction, specific food or drink items and nutrient content as well as the role of physical activity. Where specific evidence of effectiveness exists, as in weight loss, lifestyle interventions should be further evaluated as first-line treatments.</P>
<P>The review identified a complete lack of randomized trials for lifestyle factors that are generally supposed to increase incontinence, such as the intake of alcohol, sweetened fizzy or diet drinks, smoking, physical forces, or clinical constipation and straining. The widespread use of such lifestyle advice to moderate these factors in the hope of reducing UI, and the observational evidence we identified, suggest a need for further research in these areas.</P>
<P>There is a need for separate consideration of the components of multi-faceted lifestyle interventions in trials. Combining a number of individual interventions, whose efficacy has not been evaluated independently, in trials makes it impossible to determine which factors affect change. Ideally, the initial research focus should be on those areas where evidence is building (e.g. weight loss) or where healthcare advice often promotes lifestyle interventions in the absence of evidence (e.g. caffeine consumption). The results of such trials could then feed into a multi-faceted lifestyle intervention trial that would reflect common practice and be rooted in a sound evidence base.</P>
<P>It is expected that more recent trials are likely to have fewer methodological problems. Ongoing improvements in the quality of reporting, and incorporation of consistent use of CONSORT (Consolidated Standards of Reporting Trials, <A HREF="http://www.consort-statement.org/">http://www.consort-statement.org/</A>), should impact on the inclusion of trials in subsequent systematic reviews, ensuring that the most robust evidence contributes to clinical recommendations.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-08-23 11:51:20 +0100" MODIFIED_BY="[Empty name]"/>
<CONFLICT_OF_INTEREST MODIFIED="2015-11-20 12:49:09 +0000" MODIFIED_BY="[Empty name]">
<P>M Imamura: none known<BR/>K Williams: none known<BR/>M Wells: none known<BR/>C McGrother: none known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-08-18 16:18:20 +0100" MODIFIED_BY="[Empty name]">
<P>All authors contributed to the initial design and writing of the protocol. MI and KW led study selection, data abstraction and analysis, and wrote the first draft. CM and MW provided critical revisions of the draft for important intellectual content. All authors provided final approval of the version to publish.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-09-14 13:01:19 +0100" MODIFIED_BY="[Empty name]">
<P>Selection criteria for <LINK TAG="CRIT_PARTICIPANTS" TYPE="SECTION">Types of participants</LINK> has been amended after the review commenced. The protocol stated that only adults with urinary incontinence (UI) would be considered for inclusion. Due to the limited number of studies that met this criterion, we also included data from trials where some, but not all, participants had UI at baseline regardless of the proportion of people with UI or availability of data subgrouped by incontinence status.</P>
<P>As the recommendation to assess the quality of evidence using the GRADE approach and also to include 'Summary of findings' tables became prominent during the course of the review, we attempted to undertake the assessment, even though this was not mentioned in the protocol. The GRADE and 'Summary of findings' outcomes were thus defined after the review commenced.</P>
<P>Searches of MEDLINE, EMBASE, CINAHL included in the specialised register, and searches of the reference lists of relevant articles, had been planned originally but were not spelt out in the protocol. Descriptions of these searches have been added to the review for the sake of clarity.</P>
<P>ClinicalTrials.gov has been searched in response to a comment from an external referee.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-11-20 13:14:49 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-11-19 12:41:25 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-09-14 15:49:17 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-09-14 13:30:48 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2006b" MODIFIED="2014-11-18 10:28:05 +0000" MODIFIED_BY="[Empty name]" NAME="Brown 2006b" YEAR="2006">
<REFERENCE MODIFIED="2014-11-18 10:23:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, et al</AU>
<TI>Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program</TI>
<SO>Diabetes Care</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>2</NO>
<PG>385-90</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:23:29 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:23:29 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont21588"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 10:24:25 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20021127&lt;br&gt;IS - 0149-5992 (Print)&lt;br&gt;IS - 0149-5992 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;PT - Research Support, U.S. Gov't, P.H.S&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-11-18 10:24:25 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diabetes Prevention Program Research Group</AU>
<TI>The Diabetes Prevention Program (DPP): description of lifestyle intervention</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>12</NO>
<PG>2165-71</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:24:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:24:25 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont45301"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 10:25:23 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19990601&lt;br&gt;IS - 0149-5992 (Print)&lt;br&gt;IS - 0149-5992 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;PT - Research Support, U.S. Gov't, P.H.S&lt;br&gt;RN - 0 (Blood Glucose)&lt;br&gt;RN - 0 (Chromans)&lt;br&gt;RN - 0 (Hypoglycemic Agents)&lt;br&gt;RN - 0 (Thiazoles)&lt;br&gt;RN - 0 (Thiazolidinediones)&lt;br&gt;RN - 657-24-9 (Metformin)&lt;br&gt;RN - 97322-87-7 (troglitazone)&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-11-18 10:25:23 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diabetes Prevention Program Research Group</AU>
<TI>The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>4</NO>
<PG>623-34</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:25:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:25:23 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont45300"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 10:26:13 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20020208&lt;br&gt;IS - 1533-4406 (Electronic)&lt;br&gt;IS - 0028-4793 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;PT - Research Support, U.S. Gov't, P.H.S&lt;br&gt;RN - 0 (Blood Glucose)&lt;br&gt;RN - 0 (Hypoglycemic Agents)&lt;br&gt;RN - 657-24-9 (Metformin)&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-11-18 10:26:13 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al</AU>
<TI>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<NO>6</NO>
<PG>393-403</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:26:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:26:13 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont45299"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-18 10:28:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:28:05 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="TrialID.DPP"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bryant-2002" MODIFIED="2015-09-14 13:29:33 +0100" MODIFIED_BY="[Empty name]" NAME="Bryant 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-09-14 13:29:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bryant CM, Dowell CJ, Fairbrother G</AU>
<TI>A randomised trial of the effects of caffeine upon frequency, urgency and urge incontinence (Abstract number 96)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2000</YR>
<VL>19(4)</VL>
<NO>4</NO>
<PG>501-2</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:28:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:28:57 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont9985"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 10:29:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Bryant CM, Dowell CJ, Fairbrother G</AU>
<TI>Caffeine reduction education to improve urinary symptoms</TI>
<SO>British Journal of Nursing</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>8</NO>
<PG>560-5</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:29:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:29:16 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont14625"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-14 13:29:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bryant CM, Dowell CJ, Fairbrother G</AU>
<TI>Final results of a randomised trial of a caffeine reduction intervention and descriptive analysis of caffeine behaviours (Abstract number 303)</TI>
<SO>Proceedings of the International Continence Society (ICS), 31st Annual Meeting; 2001 Sept 18-21: Seoul, Korea</SO>
<YR>2001</YR>
<IDENTIFIERS MODIFIED="2014-11-18 10:30:02 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:30:02 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont14382"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dowd-1996" MODIFIED="2015-08-18 18:32:29 +0100" MODIFIED_BY="[Empty name]" NAME="Dowd 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-08-18 18:32:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;97074059&lt;/p&gt;" NOTES_MODIFIED="2015-08-18 18:32:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dowd TT, Campbell JM, Jones JA</AU>
<TI>Fluid intake and urinary incontinence in older community-dwelling women</TI>
<SO>Journal of Community Health Nursing</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>3</NO>
<PG>179-86</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:31:46 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:31:46 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont4875"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hashim-2008" MODIFIED="2015-09-14 13:29:47 +0100" MODIFIED_BY="[Empty name]" NAME="Hashim 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-09-14 13:29:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hashim H, Abrams P</AU>
<TI>How should OAB patients manipulate their fluid input? (Poster abstract 1187)</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>4 Suppl S</NO>
<PG>391-2</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:32:26 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:32:26 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont31881"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-14 13:29:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hashim H, Abrams P</AU>
<TI>How should patients with an overactive bladder manipulate their fluid intake?</TI>
<SO>BJU International</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>1</NO>
<PG>62-6</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:32:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:32:56 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont27614"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-03 17:04:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 18821925&lt;br&gt;CM - Comment on: BJU Int. 2008 Jul;102(1):62-6; PMID: 18284414&lt;br&gt;AS - BJU Int. 102(7):903; author reply 903-4, 2008 Sep&lt;br&gt;JC - dcu, 100886721&lt;br&gt;SB - IM&lt;br&gt;CP - England&lt;br&gt;PT - Comment&lt;br&gt;PT - Letter&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2015-09-03 17:04:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sivanandam A, Bhandari M</AU>
<TI>How should patients with an overactive bladder manipulate their fluid intake? [comment]</TI>
<SO>BJU International</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>7</NO>
<PG>903; author reply 903-4</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:34:03 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:34:03 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont27443"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manonai-2006" MODIFIED="2015-09-14 13:29:57 +0100" MODIFIED_BY="[Empty name]" NAME="Manonai 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-14 13:29:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manonai J, Songchitsomboon S, Chanda K, Hong JH, Komindr S</AU>
<TI>The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial</TI>
<SO>Maturitas</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>2</NO>
<PG>135-40</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:35:42 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:35:42 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont21878"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Miller-2007" MODIFIED="2015-09-14 13:30:05 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-09-14 13:30:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Miller JM</AU>
<TI>Overactive bladder and potentially "irritating" beverage intake: a randomized controlled trial</TI>
<SO>http://www.nursing.umich.edu/faculty/miller_janis.html (accessed 10 Dec 2007)</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2014-11-18 10:37:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:37:07 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont29636"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phelan-2012" MODIFIED="2014-11-18 10:40:19 +0000" MODIFIED_BY="[Empty name]" NAME="Phelan 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-11-18 10:37:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phelan S, Kanaya AM, Subak LL, Hogan PE, Espeland MA, Wing RR, et al</AU>
<TI>Prevalence and risk factors for urinary incontinence in overweight and obese diabetic women: action for health in diabetes (Look AHEAD) study</TI>
<SO>Diabetes Care</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>8</NO>
<PG>1391-7</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:37:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:37:51 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont32095"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 10:38:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Phelan S, Kanaya AM, Subak LL, Hogan PE, Espeland MA, Wing RR, et al</AU>
<TI>Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial</TI>
<SO>Journal of Urology</SO>
<YR>2012</YR>
<VL>187</VL>
<NO>3</NO>
<PG>939-44</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:38:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:38:14 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont44588"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 10:38:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20030922&lt;br&gt;IS - 0197-2456 (Print)&lt;br&gt;IS - 0197-2456 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, U.S. Gov't, P.H.S&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-11-18 10:38:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, et al</AU>
<TI>Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>5</NO>
<PG>610-28</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:38:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:38:55 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont45302"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-18 10:40:19 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:39:29 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00017953"/>
<IDENTIFIER MODIFIED="2014-11-18 10:40:19 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="TrialID.LOOK AHEAD"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subak-2005" MODIFIED="2014-11-18 10:41:27 +0000" MODIFIED_BY="[Empty name]" NAME="Subak 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-11-18 10:41:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS</AU>
<TI>Weight loss: a novel and effective treatment for urinary incontinence</TI>
<SO>Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>1</NO>
<PG>190-5</PG>
<IDENTIFIERS MODIFIED="2014-11-18 10:41:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:41:27 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont20655"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subak-2009" MODIFIED="2015-09-14 13:30:24 +0100" MODIFIED_BY="[Empty name]" NAME="Subak 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-09-14 13:30:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Grady D, Subak L, Kusek J, Nyberg L</AU>
<TI>PRIDE - program to reduce incontinence by diet and exercise</TI>
<SO>www.controlled-trials.com (accessed 17 January 2005) and http://clinicaltrials.gov/show/NCT00091988 (accessed 28 November 2013)</SO>
<YR>2004</YR>
<IDENTIFIERS MODIFIED="2014-11-18 10:49:36 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:47:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont19516"/>
<IDENTIFIER MODIFIED="2014-11-18 10:49:36 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont49826"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:09:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang AJ, Stewart AL, Hernandez AL, Shen H, Subak LL, for the Program to Reduce Incontinence by Diet and Exercise</AU>
<TI>Sexual function among overweight and obese women with urinary incontinence in a randomized controlled trial of an intensive behavioral weight loss intervention</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>181</VL>
<NO>5</NO>
<PG>2235-42</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:09:50 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:09:50 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont31149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:10:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang AJ, Subak LL, Wing R, West DS, Hernandez AL, Macer J, et al</AU>
<TI>An intensive behavioral weight loss intervention and hot flushes in women</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2010</YR>
<VL>170</VL>
<NO>13</NO>
<PG>1161-7</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:10:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:10:17 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont40225"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:11:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22453270&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - Female pelvic med. reconstr. surg.. 18(1):55-9, 2012 Jan-Feb&lt;br&gt;JC - 101528690&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, N.I.H., Extramural&lt;br&gt;SI - ClinicalTrials.gov&lt;br&gt;SA - ClinicalTrials.gov/NCT00091988&lt;br&gt;NO - U01DK067860 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01DK067861 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01DK067862 (United States NIDDK NIH HHS)&lt;br&gt;LG - English&lt;br&gt;DC - 20120328&lt;/p&gt;" NOTES_MODIFIED="2014-11-18 11:11:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myers DL, Sung VW, Richter HE, Creasman J, Subak LL</AU>
<TI>Prolapse symptoms in overweight and obese women before and after weight loss</TI>
<SO>Female Pelvic Medicine &amp; Reconstructive Surgery</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>1</NO>
<PG>55-9</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:11:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:11:20 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont44558"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:11:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21461953&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - Qual Life Res. 20(10):1655-62, 2011 Dec&lt;br&gt;JC - 9210257, bqm&lt;br&gt;CP - Netherlands&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Multicenter Study&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, N.I.H., Extramural&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;SI - ClinicalTrials.gov&lt;br&gt;SA - ClinicalTrials.gov/NCT00091988&lt;br&gt;NO - #U01 DK067860 (United States NIDDK NIH HHS)&lt;br&gt;NO - 5K23DK075645 (United States NIDDK NIH HHS)&lt;br&gt;NO - AU01 DK067862 (United States NIDDK NIH HHS)&lt;br&gt;NO - K24 DK080775-04 (United States NIDDK NIH HHS)&lt;br&gt;NO - U01DK067861 (United States NIDDK NIH HHS)&lt;br&gt;LG - English&lt;br&gt;DC - 20111121&lt;/p&gt;" NOTES_MODIFIED="2014-11-18 11:11:54 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto AM, Kuppermann M, Nakagawa S, Vittinghoff E, Wing RR, Kusek JW, et al</AU>
<TI>Comparison and correlates of three preference-based health-related quality-of-life measures among overweight and obese women with urinary incontinence</TI>
<SO>Quality of Life Research</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>10</NO>
<PG>1655-62</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:11:54 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:11:54 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont44597"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:12:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22161726&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Qual Life Res. 21(10):1685-94, 2012 Dec&lt;br&gt;JC - 9210257, bqm&lt;br&gt;CP - Netherlands&lt;br&gt;PT - Journal Article&lt;br&gt;NO - K24 DK080775 (United States NIDDK NIH HHS)&lt;br&gt;LG - English&lt;br&gt;DC - 20121115&lt;/p&gt;" NOTES_MODIFIED="2014-11-18 11:12:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pinto AM, Subak LL, Nakagawa S, Vittinghoff E, Wing RR, Kusek JW, et al</AU>
<TI>The effect of weight loss on changes in health-related quality of life among overweight and obese women with urinary incontinence</TI>
<SO>Quality of Life Research</SO>
<YR>2012</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1685-94</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:12:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:12:20 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont45862"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:12:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Subak L, Wing R, West D, Franklin F, Vittinghoff E, Creasman JM, et al</AU>
<TI>Weight loss to treat urinary incontinence in overweight and obese women</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>5</NO>
<PG>481-90</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:12:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:12:44 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont29651"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:13:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22825085&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Obstet Gynecol. 120(2 Pt 1):277-83, 2012 Aug&lt;br&gt;JC - oc2, 0401101&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20120724&lt;/p&gt;" NOTES_MODIFIED="2014-11-18 11:13:01 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subak LL, Marinilli Pinto A, Wing RR, Nakagawa S, Kusek JW, Herman WH, et al</AU>
<TI>Decrease in urinary incontinence management costs in women enrolled in a clinical trial of weight loss to treat urinary incontinence</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2012</YR>
<VL>120</VL>
<NO>2 Pt 1</NO>
<PG>277-83</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:13:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:13:01 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont45146"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-14 13:30:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subak LL, Wing R, Smith West D, Franklin F, Vittinghoff E, Creasman J, et al</AU>
<TI>A behavioral weight loss program significantly reduces urinary incontinence episodes in overweight and obese women (Abstract 1)</TI>
<SO>Journal of Pelvic Medicine &amp; Surgery</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>5</NO>
<PG>223-4</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:13:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:13:20 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont31081"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:13:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West DS, Gorin AA, Subak LL, Foster G, Bragg C, Hecht J, et al</AU>
<TI>A motivation-focused weight loss maintenance program is an effective alternative to a skill-based approach</TI>
<SO>International Journal of Obesity</SO>
<YR>2011</YR>
<VL>35</VL>
<NO>2</NO>
<PG>259-69</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:13:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:13:44 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont40994"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:14:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wing RR, Creasman JM, West DS, Richter HE, Myers D, Burgio KL, et al</AU>
<TI>Improving urinary incontinence in overweight and obese women through modest weight loss</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>2 Pt 1</NO>
<PG>284-92</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:14:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:14:09 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont39918"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-18 11:14:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wing RR, West DS, Grady D, Creasman JM, Richter HE, Myers D, et al</AU>
<TI>Effect of weight loss on urinary incontinence in overweight and obese women: results at 12 and 18 months</TI>
<SO>Journal of Urology</SO>
<YR>2010</YR>
<VL>184</VL>
<NO>3</NO>
<PG>1005-10</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:14:34 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:14:34 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont40041"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-18 10:48:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 10:48:03 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00091988"/>
<IDENTIFIER MODIFIED="2014-11-18 10:48:13 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="TrialID.PRIDE"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swithinbank-2005" MODIFIED="2015-09-14 13:30:32 +0100" MODIFIED_BY="[Empty name]" NAME="Swithinbank 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-11-18 11:23:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Swithinbank L, Hashim H, Abrams P</AU>
<TI>The effect of fluid intake on urinary symptoms in women</TI>
<SO>Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>1</NO>
<PG>187-9</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:23:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:23:47 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont20656"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-14 13:30:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Swithinbank LV, Rogers CA, Yang Q, Shepherd AM, Abrams P</AU>
<TI>Does the amount and type of fluid intake effect urinary symptoms in women? (Abstract number 104)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1999</YR>
<VL>18(4)</VL>
<NO>4</NO>
<PG>371-2</PG>
<IDENTIFIERS MODIFIED="2014-11-18 11:24:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:24:24 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont9946"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wells-2011" MODIFIED="2015-09-14 13:30:48 +0100" MODIFIED_BY="[Empty name]" NAME="Wells 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-09-14 13:30:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wells M, Green S, Jamieson K, Markham T, Rogers P, Getliffe K, et al</AU>
<TI>An investigation of the effect of drinking caffeinated versus decaffeinated fluids on symptoms of overactive bladder syndrome: a feasibility trial (Abstract 700)</TI>
<SO>Proceedings of the 41st Annual Meeting of the International Continence Society (ICS); 2011 Aug 29-Sept 2; Glasgow, Scotland</SO>
<YR>2011</YR>
<IDENTIFIERS MODIFIED="2014-11-18 11:25:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 11:25:06 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont42229"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-09-14 15:43:20 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-BE_x002d_DRI" MODIFIED="2015-09-14 15:35:46 +0100" MODIFIED_BY="[Empty name]" NAME="BE-DRI" YEAR="2007">
<REFERENCE MODIFIED="2015-09-14 15:33:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mueller ER, Litman H, Zimmern PE, Norton P, Goode P</AU>
<TI>Impact of fluid management on fluid intake and urge incontinence in the BE-DRI trial for OAB in women [Abstract 1530]</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>181</VL>
<NO>4 Suppl</NO>
<PG>547-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-03 13:41:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Urinary Incontinence Treatment Network (UITN)</AU>
<TI>Design of the Behavior Enhances Drug Reduction of Incontinence (BE-DRI) study</TI>
<SO>Contemporary Clinical Trials</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>1</NO>
<PG>48-58</PG>
<IDENTIFIERS MODIFIED="2012-09-03 13:41:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-03 13:41:01 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT22573"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-14 15:35:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimmern P, Litman H, Mueller E, Norton P, Goode P</AU>
<TI>Impact of fluid management on fluid intake and urge incontinence in the BE-DRI trial for OAB in women (Abstract: Podium #30)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>2</NO>
<PG>163</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-11 09:22:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zimmern P, Litman HJ, Mueller E, Norton P, Goode P, for the Urinary Incontinence Treatment Network</AU>
<TI>Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women</TI>
<SO>BJU International</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>12</NO>
<PG>1680-5</PG>
<IDENTIFIERS MODIFIED="2012-09-03 13:37:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-03 13:37:59 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT39953"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-18 12:05:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 12:05:51 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00090584"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bird-2005" MODIFIED="2015-08-18 18:42:53 +0100" MODIFIED_BY="[Empty name]" NAME="Bird 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-08-18 18:42:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bird ET, Parker BD, Kim HS, Coffield KS</AU>
<TI>Caffeine ingestion and lower urinary tract symptoms in healthy volunteers</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>7</NO>
<PG>611-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2007" MODIFIED="2015-08-18 18:43:22 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-09-03 13:45:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown CT, Emberton M</AU>
<TI>Self-management for men with lower urinary tract symptoms</TI>
<SO>Current Urology Reports</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>4</NO>
<PG>261-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-11 09:23:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K, et al</AU>
<TI>Self management for men with lower urinary tract symptoms: randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>2007</YR>
<VL>334</VL>
<NO>7583</NO>
<PG>25-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-18 18:43:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yap TL, Brown C, Cromwell DA, Van Der Meulen J, Emberton M</AU>
<TI>The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures</TI>
<SO>BJU International</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>8</NO>
<PG>1104-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dougherty-2002" MODIFIED="2012-09-03 13:50:50 +0100" MODIFIED_BY="[Empty name]" NAME="Dougherty 2002" YEAR="">
<REFERENCE MODIFIED="2012-09-03 13:50:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dougherty MC, Dwyer JW, Pendergast JF, Boyington AR, Tomlinson BU, Coward RT</AU>
<TI>A randomized trial of behavioral management for continence with older rural women</TI>
<SO>Research in Nursing &amp; Health</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>1</NO>
<PG>3-13</PG>
<IDENTIFIERS MODIFIED="2012-09-03 13:49:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-03 13:49:16 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT12933"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dumoulin-2011" MODIFIED="2015-09-14 13:31:28 +0100" MODIFIED_BY="[Empty name]" NAME="Dumoulin 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-09-14 13:31:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dumoulin C, Sran M, Lieblich P, Wilson P</AU>
<TI>Physiotherapy significantly reduces leakage in postmenopausal women with osteoporosis and urinary incontinence: result of a parallel randomised controlled trial (Abstract 130)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>6</NO>
<PG>985-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glazener-2001" MODIFIED="2013-06-11 09:24:51 +0100" MODIFIED_BY="[Empty name]" NAME="Glazener 2001" YEAR="2005">
<REFERENCE MODIFIED="2012-09-03 13:21:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazener CM, Herbison GP, MacArthur C, Grant A, Wilson PD</AU>
<TI>Randomised controlled trial of conservative management of postnatal urinary and faecal incontinence: six year follow up</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>330</VL>
<NO>7487</NO>
<PG>337-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-11 09:24:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Glazener CM, Herbison GP, Wilson PD, MacArthur C, Lang GD, Gee H, et al</AU>
<TI>Conservative management of persistent postnatal urinary and faecal incontinence: randomised controlled trial [Extended electronic version]</TI>
<SO>eBMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>1-5</PG>
<CY>England</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT12123"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-03 13:57:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Glazener CM, Herbison GP, Wilson PD, MacArthur C, Lang GD, Gee H, et al</AU>
<TI>Conservative management of persistent postnatal urinary and faecal incontinence: randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7313</NO>
<PG>593-6</PG>
<CY>England</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT 12122"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herschorn-2003" MODIFIED="2015-09-14 15:38:41 +0100" MODIFIED_BY="[Empty name]" NAME="Herschorn 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-09-14 15:38:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Herschorn S, Becker D, Miller B, Thompson M, Forte L</AU>
<TI>The impact of a simple health education intervention in overactive bladder patients (Abstract)</TI>
<SO>Proceedings of the International Continence Society (ICS), 33rd Annual Meeting; 2003 Oct 5-9; Florence Italy</SO>
<YR>2003</YR>
<PG>352-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herschorn-2004" MODIFIED="2012-09-03 13:31:06 +0100" MODIFIED_BY="[Empty name]" NAME="Herschorn 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-09-03 13:31:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herschorn S, Becker D, Miller E, Thompson M, Forte L</AU>
<TI>Impact of a health education intervention in overactive bladder patients</TI>
<SO>Canadian Journal of Urology</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>6</NO>
<PG>2430-7</PG>
<ED>Reference ID: 20194Canadian Journal of Urology 11 (6): 2430-2437.Herschorn,S., Becker,D., Miller,E., Thompson,M. and Forte,L. (2004). Impact of a health education intervention in overactive bladder patients.</ED>
<IDENTIFIERS MODIFIED="2012-09-03 13:31:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-03 13:31:06 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT20194"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofbauer-1990" MODIFIED="2015-09-14 15:43:20 +0100" MODIFIED_BY="[Empty name]" NAME="Hofbauer 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-09-14 15:43:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hofbauer J, Preisinger F, Nurnberger N</AU>
<TI>[The value of physical therapy in genuine female stress incontinence]. [German]</TI>
<TO>Der Stellenwert der Physikotherapie bei der weiblichen genuinen Stress-inkontinenz</TO>
<SO>Zeitschrift Fur Urologie Und Nephrologie</SO>
<YR>1990</YR>
<VL>83</VL>
<NO>5</NO>
<PG>249-54</PG>
<IDENTIFIERS MODIFIED="2012-09-03 14:01:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-03 14:01:31 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT350"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2011a" MODIFIED="2012-09-03 14:13:14 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2011a" YEAR="2011">
<REFERENCE MODIFIED="2012-09-03 14:13:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim H, Yoshida H, Suzuki T</AU>
<TI>The effects of multidimensional exercise treatment on community-dwelling elderly Japanese women with stress, urge, and mixed urinary incontinence: a randomized controlled trial</TI>
<SO>International Journal of Nursing Studies</SO>
<YR>2011</YR>
<VL>48</VL>
<NO>10</NO>
<PG>1165-72</PG>
<IDENTIFIERS MODIFIED="2012-09-03 14:13:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-03 14:13:14 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT42657"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2011b" MODIFIED="2012-09-03 14:14:30 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2011b" YEAR="2011">
<REFERENCE MODIFIED="2012-09-03 14:14:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim H, Yoshida H, Suzuki T</AU>
<TI>Effects of exercise treatment with or without heat and steam generating sheet on urine loss in community-dwelling Japanese elderly women with urinary incontinence</TI>
<SO>Geriatrics and Gerontology International</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>4</NO>
<PG>452-9</PG>
<IDENTIFIERS MODIFIED="2012-09-03 14:13:45 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-03 14:13:45 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT42661"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kincade-2007a" MODIFIED="2012-09-14 14:53:14 +0100" MODIFIED_BY="[Empty name]" NAME="Kincade 2007a" YEAR="2007">
<REFERENCE MODIFIED="2012-09-14 14:53:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kincade JE, Dougherty MC, Carlson JR, Wells EC, Hunter GS, Busby-Whitehead J</AU>
<TI>Factors related to urinary incontinence in community-dwelling women</TI>
<SO>Urologic Nursing</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>4</NO>
<PG>307-17</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT23858"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kincade-2007b" MODIFIED="2015-09-14 13:33:07 +0100" MODIFIED_BY="[Empty name]" NAME="Kincade 2007b" YEAR="2007">
<REFERENCE MODIFIED="2015-09-14 13:33:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kincade JE, Dougherty MC, Carlson JR, Hunter GS, Busby-Whitehead J</AU>
<TI>Randomized clinical trial of efficacy of self-monitoring techniques to treat urinary incontinence in women</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>4</NO>
<PG>507-11</PG>
<IDENTIFIERS MODIFIED="2012-09-03 14:39:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-03 14:39:43 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT23537"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2001" MODIFIED="2015-09-14 13:33:16 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-09-14 13:33:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li FZ, Harmer P, McAuley E, Duncan TE, Duncan SC, Chaumeton N, et al</AU>
<TI>An evaluation of the effects of Tai Chi exercise on physical function among older persons: a randomized controlled trial</TI>
<SO>Annals of Behavioral Medicine</SO>
<YR>2001</YR>
<VL>23</VL>
<NO>2</NO>
<PG>139-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parker-2005" MODIFIED="2015-09-14 13:33:23 +0100" MODIFIED_BY="[Empty name]" NAME="Parker 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-09-14 13:33:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parker B, Bird E, Coffield S</AU>
<TI>Randomized prospective study of caffeine's effect on lower urinary tract symptoms in healthy human subjects (Poster 7)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>2</NO>
<PG>167-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ree-2007" MODIFIED="2012-09-03 13:21:07 +0100" MODIFIED_BY="[Empty name]" NAME="Ree 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-09-03 13:21:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ree ML, Nygaard I, Bo K</AU>
<TI>Muscular fatigue in the pelvic floor muscles after strenuous physical activity</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>2007</YR>
<VL>86</VL>
<NO>7</NO>
<PG>870-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schauss-2006" MODIFIED="2015-09-14 13:33:31 +0100" MODIFIED_BY="[Empty name]" NAME="Schauss 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-09-14 13:33:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schauss DA, Spiller DG</AU>
<TI>Reducing the symptoms of overactive bladder and urinary incontinence: results of a two-month randomized, double-blind, placebo-controlled clinical trial (Abstract 300)</TI>
<SO>Proceedings of the International Continence Society (ICS), 36th Annual Meeting; 2006 Nov 27-Dec 1; Christchurch, New Zealand</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomlinson-1999" MODIFIED="2012-09-03 13:21:07 +0100" MODIFIED_BY="[Empty name]" NAME="Tomlinson 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-09-03 13:21:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomlinson BU, Dougherty MC, Pendergast JF, Boyington AR, Coffman MA, Pickens SM</AU>
<TI>Dietary caffeine, fluid intake and urinary incontinence in older rural women</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>1</NO>
<PG>22-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Hespen-2006" MODIFIED="2012-09-03 13:21:07 +0100" MODIFIED_BY="[Empty name]" NAME="Van Hespen 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-09-03 13:21:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Hespen ATH, Tak ECPM, Van Dommelen P, Hopman-Rock M</AU>
<TI>Evaluation of the urinary incontinence training programme, INCondition, for women living in homes for the elderly</TI>
<SO>Nederlands Tijdschrift voor Fysiotherapie</SO>
<YR>2006</YR>
<VL>116</VL>
<NO>6</NO>
<PG>136-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagg-2007" MODIFIED="2012-09-03 14:09:29 +0100" MODIFIED_BY="[Empty name]" NAME="Wagg 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-09-03 14:09:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wagg AR, Barron D, Kirby M, Stott D Corlett K</AU>
<TI>A randomised partially controlled trial to assess the impact of self-help vs. structured help from a continence nurse specialist in women with undiagnosed urinary problems in primary care</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2007</YR>
<VL>61</VL>
<NO>11</NO>
<PG>1863-73</PG>
<IDENTIFIERS MODIFIED="2012-09-03 14:08:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-09-03 14:08:50 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT23948"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-09-03 14:09:02 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-09-14 15:49:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-2011" MODIFIED="2015-08-18 18:50:23 +0100" MODIFIED_BY="[Empty name]" NAME="Baker 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-08-18 18:50:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Baker J</AU>
<TI>Mindfulness-Based Stress Reduction Techniques and Yoga for treatment of urinary urge incontinence (MBSR-Yoga) (Trials registry number: NCT01470560)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/show/NCT01470560)</SO>
<YR>2011</YR>
<IDENTIFIERS MODIFIED="2014-11-18 12:08:48 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 12:08:48 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont49230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gozukara-2014" MODIFIED="2014-11-25 09:17:06 +0000" MODIFIED_BY="[Empty name]" NAME="Gozukara 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-11-25 09:17:06 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 24711149&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Int Urogynecol J Pelvic Floor Dysfunct. 25(9):1219-25, 2014 Sep&lt;br&gt;JC - cl5, 9514583, 101567041&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20140821&lt;/p&gt;" NOTES_MODIFIED="2014-11-25 09:17:06 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gozukara YM, Akalan G, Tok EC, Aytan H, Ertunc D</AU>
<TI>The improvement in pelvic floor symptoms with weight loss in obese women does not correlate with the changes in pelvic anatomy</TI>
<SO>International Urogynecology Journal</SO>
<YR>2014</YR>
<VL>25</VL>
<NO>9</NO>
<PG>1219-25</PG>
<IDENTIFIERS MODIFIED="2014-11-25 09:17:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-25 09:17:06 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont62552"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heesakkers-2009" MODIFIED="2015-09-14 15:47:05 +0100" MODIFIED_BY="[Empty name]" NAME="Heesakkers 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-09-14 15:47:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Heesakkers J</AU>
<TI>Prospective intervention study of drink advice in overactive bladder syndrome (OAB) (Trials registry number: NCT00982241)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/show/NCT00982241)</SO>
<YR>2009 (accessed 2 December 2013)</YR>
<IDENTIFIERS MODIFIED="2014-11-18 12:10:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 12:10:05 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont49231"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2012" MODIFIED="2015-09-14 15:48:18 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-14 15:48:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Huang A</AU>
<TI>Lessening Incontinence by Learning Yoga (LILY) (Trials registry number: NCT01672190)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/show/NCT01672190)</SO>
<YR>2012 (accessed 28 November 2013)</YR>
<IDENTIFIERS MODIFIED="2014-11-25 09:19:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-25 09:19:00 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT01672190"/>
<IDENTIFIER MODIFIED="2014-11-25 09:19:13 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="TrialID.LILY."/>
<IDENTIFIER MODIFIED="2014-11-18 12:10:47 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont49228"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-11-25 09:18:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 24763156&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Female pelvic med. reconstr. surg.. 20(3):147-54, 2014 May-Jun&lt;br&gt;JC - 101528690&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20140425&lt;/p&gt;" NOTES_MODIFIED="2014-11-25 09:18:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang AJ, Jenny HE, Chesney MA, Schembri M, Subak LL</AU>
<TI>A group-based yoga therapy intervention for urinary incontinence in women: a pilot randomized trial</TI>
<SO>Female Pelvic Medicine &amp; Reconstructive Surgery</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>3</NO>
<PG>147-54</PG>
<IDENTIFIERS MODIFIED="2014-11-25 09:18:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-25 09:18:28 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT01672190"/>
<IDENTIFIER MODIFIED="2014-11-25 09:18:43 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="TrialID.LILY."/>
<IDENTIFIER MODIFIED="2014-11-25 09:18:00 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont60608"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markland-2013" MODIFIED="2015-09-14 15:49:17 +0100" MODIFIED_BY="[Empty name]" NAME="Markland 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-14 15:49:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Markland AD, Shanks JL</AU>
<TI>Vitamin D supplementation in older adults with urinary incontinence (Trial registry number: NCT01971801)</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/show/NCT01971801)</SO>
<YR>2013 (accessed 28 November 2013)</YR>
<IDENTIFIERS MODIFIED="2014-11-18 12:16:33 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 12:16:33 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont49229"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seckin-2011" MODIFIED="2015-09-14 13:33:46 +0100" MODIFIED_BY="[Empty name]" NAME="Seckin 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-09-14 13:33:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Journal: Conference Abstract&lt;br&gt;English; ABSTRACT LANGUAGE:English&lt;/p&gt;" NOTES_MODIFIED="2015-09-14 13:33:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seckin B, Kulaksizoglu H, Cakmakci E</AU>
<TI>The effects of pelvic floor muscle targeted Pilates versus regular aerobic exercise on urinary incontinence (Abstract UP-03.170)</TI>
<SO>Urology</SO>
<YR>2011</YR>
<VL>78</VL>
<NO>3 Suppl 1</NO>
<PG>S400-1</PG>
<IDENTIFIERS MODIFIED="2014-11-25 09:23:31 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-25 09:23:31 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont61934"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wells-2014" MODIFIED="2014-11-25 09:23:51 +0000" MODIFIED_BY="[Empty name]" NAME="Wells 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-11-25 09:23:51 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 24988515&lt;br&gt;ST - In-Process&lt;br&gt;AS - J Wound Ostomy Continence Nurs. 41(4):371-8, 2014 Jul-Aug&lt;br&gt;JC - bv2, 9435679&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20140703&lt;/p&gt;" NOTES_MODIFIED="2014-11-25 09:23:51 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wells MJ, Jamieson K, Markham TC, Green SM, Fader MJ</AU>
<TI>The effect of caffeinated versus decaffeinated drinks on overactive bladder: a double-blind, randomized, crossover study</TI>
<SO>Journal of Wound, Ostomy, &amp; Continence Nursing</SO>
<YR>2014</YR>
<VL>41</VL>
<NO>4</NO>
<PG>371-8</PG>
<IDENTIFIERS MODIFIED="2014-11-25 09:23:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-25 09:23:51 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont62569"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2014-11-18 12:17:58 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Moholdt-2011" MODIFIED="2014-11-18 12:17:58 +0000" MODIFIED_BY="[Empty name]" NAME="Moholdt 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-11-18 12:17:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moholdt TT, Salvesen K, Ingul CB, Vik T, Oken E, Morkved S</AU>
<TI>Exercise Training in Pregnancy for obese women (ETIP): study protocol for a randomised controlled trial</TI>
<SO>Trials [Electronic Resource]</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>154</PG>
<IDENTIFIERS MODIFIED="2014-11-18 12:17:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 12:17:23 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="sr-incont41703"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-11-18 12:17:58 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-18 12:17:58 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01243554"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-11-19 12:41:25 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-11-19 12:41:25 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abrams-2002" MODIFIED="2015-09-14 13:35:16 +0100" MODIFIED_BY="[Empty name]" NAME="Abrams 2002" TYPE="JOURNAL_ARTICLE">
<AU>Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al</AU>
<TI>The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</TI>
<SO>American Journal of Ostetrics and Gynecology</SO>
<YR>2002</YR>
<VL>187</VL>
<NO>1</NO>
<PG>116-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abrams-2005" MODIFIED="2015-09-14 13:35:24 +0100" MODIFIED_BY="[Empty name]" NAME="Abrams 2005" TYPE="BOOK">
<AU>Abrams P, Cardozo L, Khoury S, Wein A</AU>
<SO>Incontinence: 3rd International Consultation on Incontinence, 2004, Volume 1: Basics and Evaluation</SO>
<YR>2005</YR>
<EN>2005</EN>
<PB>Health Publication Ltd</PB>
<CY>France</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abrams-2013" MODIFIED="2015-09-14 13:35:33 +0100" MODIFIED_BY="[Empty name]" NAME="Abrams 2013" TYPE="BOOK_SECTION">
<AU>Milsom I, Altman D, Cartwright R, Lapitan MC, Nelson R, Sillén U, et al</AU>
<TI>Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI) (Comitttee 1)</TI>
<SO>Incontinence: 5th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence; 2012 Feb 23-25; Paris</SO>
<YR>2013</YR>
<PG>15-107</PG>
<ED>Abrams P, Cardozo L, Khoury S and Wein A</ED>
<PB>International Consultation on Urological Diseases (ICUD)</PB>
<CY>Belgium</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Agur-2008" MODIFIED="2015-09-14 13:36:51 +0100" MODIFIED_BY="[Empty name]" NAME="Agur 2008" TYPE="JOURNAL_ARTICLE">
<AU>Agur WI, Steggles P, Waterfield M, Freeman RM</AU>
<TI>The long-term effectiveness of antenatal pelvic floor muscle training: eight-year follow up of a randomised controlled trial</TI>
<SO>British journal of obstetrics and gynaecology</SO>
<YR>2008</YR>
<VL>115</VL>
<NO>8</NO>
<PG>985-990</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Avery-2004" MODIFIED="2015-09-14 13:37:12 +0100" MODIFIED_BY="[Empty name]" NAME="Avery 2004" TYPE="JOURNAL_ARTICLE">
<AU>Avery K, Donovan J, Peters T, Shaw C, Gotoh M, Abrams P</AU>
<TI>ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>4</NO>
<PG>322-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baumgart-2015" MODIFIED="2015-11-19 12:38:19 +0000" MODIFIED_BY="[Empty name]" NAME="Baumgart 2015" TYPE="JOURNAL_ARTICLE">
<AU>Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H</AU>
<TI>Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population based perspective</TI>
<SO>Alzheimer&#8217;s &amp; Dementia</SO>
<YR>2015</YR>
<VL>11</VL>
<PG>718-726</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2006a" MODIFIED="2015-08-18 18:58:33 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Brown JS, Wing R, Barrett-Connor E, et al
</AU>
<TI>Lifestyle intervention is associated with lower prevalence of urinary incontinence</TI>
<SO>Diabetes Care</SO>
<YR>2006</YR>
<VL>29</VL>
<PG>385-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cartwright-2007" MODIFIED="2015-09-14 13:37:20 +0100" MODIFIED_BY="[Empty name]" NAME="Cartwright 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cartwright R, Srikrishna S, Cardozo L, Gonzalez J</AU>
<TI>Does Diet Coke cause overactive bladder? A 4-way crossover trial, investigating the effect of carbonated soft drinks on overactive bladder symptoms in normal volunteers (Abstract 19)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>626-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chowdhury-2012" MODIFIED="2015-11-19 12:36:03 +0000" MODIFIED_BY="[Empty name]" NAME="Chowdhury 2012" TYPE="JOURNAL_ARTICLE">
<AU>Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S, Ward H, Johnson L, Crowe F, Hu FB, Franco OH</AU>
<TI>Association between fish consumption, long-chain omega 3 fatty acids and risk of cerebrovascular disease: a systematic review and meta-analysis</TI>
<SO>BMJ (Clinical Research ed)</SO>
<YR>2012</YR>
<VL>345</VL>
<PG>e6698</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creighton-1990" MODIFIED="2010-01-25 16:38:20 +0000" MODIFIED_BY="[Empty name]" NAME="Creighton 1990" NOTES="&lt;p&gt;{316}&lt;/p&gt;" NOTES_MODIFIED="2010-01-25 16:38:20 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Creighton SM, Stanton SL</AU>
<TI>Caffeine: does it affect your bladder?</TI>
<SO>British Journal of Urology</SO>
<YR>1990</YR>
<VL>66</VL>
<NO>6</NO>
<PG>613-4</PG>
<IDENTIFIERS MODIFIED="2010-01-25 16:37:46 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Dallosso-2003" MODIFIED="2015-09-14 13:37:31 +0100" MODIFIED_BY="[Empty name]" NAME="Dallosso 2003" TYPE="JOURNAL_ARTICLE">
<AU>Dallosso HM, McGrother CW, Matthews RJ, Donaldson MMK, and the Leicestershire MRC Incontinence Study Team</AU>
<TI>The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women</TI>
<SO>BJU International</SO>
<YR>2003</YR>
<VL>92</VL>
<PG>69-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dallosso-2004a" MODIFIED="2015-09-14 13:37:41 +0100" MODIFIED_BY="[Empty name]" NAME="Dallosso 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Dallosso HM, Matthew R, McGrother CM, Donaldson MMK and the Leicestershire MRC Incontinence Study Team</AU>
<TI>Diet as a risk factor for the development of stress urinary incontinence: a longitudinal study in women</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2004a</YR>
<VL>58</VL>
<NO>6</NO>
<PG>920-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dallosso-2004b" MODIFIED="2015-09-14 13:37:46 +0100" MODIFIED_BY="[Empty name]" NAME="Dallosso 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Dallosso HM, Matthews RJ, McGrother CW, Donaldson MMK, Shaw C and the Leicestershire MRC Incontinence Study Team</AU>
<TI>The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men</TI>
<SO>Public Health Nutrition</SO>
<YR>2004b</YR>
<VL>7</VL>
<NO>7</NO>
<PG>885-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dallosso-2004c" MODIFIED="2015-09-14 13:37:56 +0100" MODIFIED_BY="[Empty name]" NAME="Dallosso 2004c" TYPE="JOURNAL_ARTICLE">
<AU>Dallosso HM, McGrother CM, Matthew R, Donaldson MMK and the Leicestershire MRC Incontinence Study Team</AU>
<TI>Nutrient composition of the diet and the development of overactive bladder: a longitudinal study in women</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>3</NO>
<PG>204-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Danforth-2007" MODIFIED="2015-09-14 13:39:01 +0100" MODIFIED_BY="[Empty name]" NAME="Danforth 2007" TYPE="JOURNAL_ARTICLE">
<AU>Danforth KN, Shah AD, Townsend MK, Lifford KL, Curhan GC, Resnick NM, et al</AU>
<TI>Physical activity and urinary incontinence among healthy, older women</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>109</VL>
<PG>721-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dasgupta-2006" MODIFIED="2015-08-18 19:02:13 +0100" MODIFIED_BY="[Empty name]" NAME="Dasgupta 2006" TYPE="JOURNAL_ARTICLE">
<AU>Dasgupta J, Elliott RA, Doshani A, Tincello DG
</AU>
<TI>Enhancement of rat bladder contraction by artificial sweeteners via increased extracellular Ca2+ influx</TI>
<SO>Toxicology and Applied Pharmacology</SO>
<YR>2006</YR>
<VL>217</VL>
<NO>2</NO>
<PG>216-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dumoulin-2010" MODIFIED="2010-06-08 10:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Dumoulin 2010" TYPE="COCHRANE_REVIEW">
<AU>Dumoulin C, Hay-Smith J</AU>
<TI>Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005654.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD005654"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2014-11-05 16:16:40 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fader-2007" MODIFIED="2010-06-08 10:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Fader 2007" TYPE="COCHRANE_REVIEW">
<AU>Fader M, Cottenden AM, Getliffe K</AU>
<TI>Absorbent products for light urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001406.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD001406"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fader-2008" MODIFIED="2010-06-08 10:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Fader 2008" TYPE="COCHRANE_REVIEW">
<AU>Fader M, Cottenden AM, Getliffe K</AU>
<TI>Absorbent products for moderate-heavy urinary and/or faecal incontinence in women and men</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD007408"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD007408"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Folstein-1975" MODIFIED="2015-10-14 14:21:35 +0100" MODIFIED_BY="[Empty name]" NAME="Folstein 1975" TYPE="JOURNAL_ARTICLE">
<AU>Folstein MF, Folstein SE, McHugh PR</AU>
<TI>"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1975</YR>
<VL>12</VL>
<NO>3</NO>
<PG>189-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glazener-2005" MODIFIED="2015-09-14 15:53:08 +0100" MODIFIED_BY="[Empty name]" NAME="Glazener 2005" TYPE="JOURNAL_ARTICLE">
<AU>Glazener CMA, Herbison GP, MacArthur C, Grant A, Wilson DP</AU>
<TI>Randomised controlled trial of conservative management of postnatal urinary and faecal incontinence: six year follow up</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>330</VL>
<NO>7487</NO>
<PG>337-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2015-09-14 13:41:56 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, et al</AU>
<TI>What is "quality of evidence" and why is it important to clinicians?</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7651</NO>
<PG>995-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hannestad-2004" MODIFIED="2015-09-14 13:42:02 +0100" MODIFIED_BY="[Empty name]" NAME="Hannestad 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hannestad YS, Rortveit G, Daltveit AK, Hunskaar S</AU>
<TI>Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study</TI>
<SO>BJOG: An International Journal of Obstetrics and Gynaecology</SO>
<YR>2004</YR>
<VL>110</VL>
<NO>3</NO>
<PG>247-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-He-2006" MODIFIED="2015-11-19 12:37:20 +0000" MODIFIED_BY="[Empty name]" NAME="He 2006" TYPE="JOURNAL_ARTICLE">
<AU>He FJ, Nowson CA, MacGregor GA</AU>
<TI>Fruit and vegetable consumption and stroke: meta-analysis of cohort studies</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9507</NO>
<PG>320-326</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herbison-2002" MODIFIED="2010-06-08 10:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Herbison 2002" TYPE="COCHRANE_REVIEW">
<AU>Herbison GP, Dean N</AU>
<TI>Weighted vaginal cones for urinary incontinence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002114"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD002114"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-09-14 13:42:09 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunskaar-2008" MODIFIED="2013-06-11 09:37:36 +0100" MODIFIED_BY="[Empty name]" NAME="Hunskaar 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hunskaar S</AU>
<TI>A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>8</NO>
<PG>749-57</PG>
<IDENTIFIERS MODIFIED="2010-01-25 16:52:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-James-1988" MODIFIED="2015-10-14 14:21:23 +0100" MODIFIED_BY="[Empty name]" NAME="James 1988" TYPE="JOURNAL_ARTICLE">
<AU>James JE, Paull I, Cameron-Traub E, Miners JO, Lelo A, Birkett DJ</AU>
<TI>Biochemical validation of self-reported caffeine consumption during caffeine fading</TI>
<SO>Journal of Behavioral Medicine</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>1</NO>
<PG>15-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kiff-1984" MODIFIED="2010-01-25 16:52:51 +0000" MODIFIED_BY="[Empty name]" NAME="Kiff 1984" NOTES="&lt;p&gt;{9968}&lt;/p&gt;" NOTES_MODIFIED="2010-01-25 16:52:51 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kiff ES, Barnes PR, Swash M</AU>
<TI>Evidence of pudendal neuropathy in patients with perineal descent and chronic straining at stool</TI>
<SO>Gut</SO>
<YR>1984</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1279-82</PG>
<IDENTIFIERS MODIFIED="2010-01-25 16:52:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lipp-2011" MODIFIED="2014-01-30 18:38:19 +0000" MODIFIED_BY="[Empty name]" NAME="Lipp 2011" TYPE="COCHRANE_REVIEW">
<AU>Lipp A, Shaw C, Glavind K</AU>
<TI>Mechanical devices for urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2014-01-30 18:38:19 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-30 18:37:42 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001756.pub5"/>
<IDENTIFIER MODIFIED="2014-01-30 18:38:19 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CD001756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maserejian-2010" MODIFIED="2013-06-20 16:13:43 +0100" MODIFIED_BY="[Empty name]" NAME="Maserejian 2010" TYPE="JOURNAL_ARTICLE">
<AU>Maserejian NN, Giovannucci EL, McVary KT, McGrother C, McKinlay JB</AU>
<TI>Dietary macronutrient and energy intake and urinary incontinence in women</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2010</YR>
<VL>171</VL>
<NO>10</NO>
<PG>1116-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mattiasson-1998" MODIFIED="2015-09-14 13:42:19 +0100" MODIFIED_BY="[Empty name]" NAME="Mattiasson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mattiasson A, Djurhuus JC, Fonda D, Lose G, Nordling J, Stöhrer M</AU>
<TI>Standardization of outcome studies in patients with lower urinary tract dysfunction: a report on general principles from the Standardisation Committee of the International Continence Society</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>3</NO>
<PG>249-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGrother-2004" MODIFIED="2015-09-14 13:42:25 +0100" MODIFIED_BY="[Empty name]" NAME="McGrother 2004" TYPE="JOURNAL_ARTICLE">
<AU>McGrother CW, Donaldson MMK, Shaw C, Matthews RJ, Hayward TA, Dallosso HM, et al</AU>
<TI>Storage symptoms of the bladder: prevalence, incidence and need for services in the UK</TI>
<SO>BJU International</SO>
<YR>2004</YR>
<VL>93</VL>
<NO>6</NO>
<PG>763-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGrother-2007" MODIFIED="2015-08-18 19:05:36 +0100" MODIFIED_BY="[Empty name]" NAME="McGrother 2007" TYPE="BOOK_SECTION">
<AU>McGrother C, Donaldson M, Wagg A, Matharu G, Williams K, Watson J, et al</AU>
<TI>Continence</TI>
<SO>Health Care Needs Assessment: the epidemiologically based needs assessment reviews</SO>
<YR>2007</YR>
<PG>69-175</PG>
<EN>3rd</EN>
<ED>Stevens ARJ, Mant J, Simpson S</ED>
<PB>Radcliffe Medical Press Ltd</PB>
<CY>Abingdon</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGrother-2012" MODIFIED="2015-09-14 13:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="McGrother 2012" TYPE="JOURNAL_ARTICLE">
<AU>McGrother CW, Donaldson MMK, Thompson J, Wagg A, Tincello DG, Manktelow BN</AU>
<TI>Etiology of overactive bladder: a diet and lifestyle model for diabetes and obesity in older women</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2012</YR>
<VL>31</VL>
<PG>487-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moller-2000" MODIFIED="2015-09-14 13:42:43 +0100" MODIFIED_BY="[Empty name]" NAME="Moller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Moller L, Lose G, Jorgensen T</AU>
<TI>Risk factors for lower urinary tract symptoms in women 40-60 years of age</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>96</VL>
<PG>446</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moon-1997" MODIFIED="2010-01-25 16:59:41 +0000" MODIFIED_BY="[Empty name]" NAME="Moon 1997" NOTES="&lt;p&gt;{9971}&lt;/p&gt;" NOTES_MODIFIED="2010-01-25 16:59:41 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Moon TD, Hagen L, Heisey DM</AU>
<TI>Urinary symptomatology in younger men</TI>
<SO>Urology</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>5</NO>
<PG>700-3</PG>
<IDENTIFIERS MODIFIED="2010-01-25 16:59:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2013" MODIFIED="2015-09-14 13:43:32 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2013" TYPE="BOOK_SECTION">
<AU>Moore K, Dumoulin C, Bradley C, Burgio K, Chambers T, Hagen S, et al</AU>
<TI>Adult conservative management (Chapter 12)</TI>
<SO>Incontinence: 5th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence2012 Feb 23-25; Paris</SO>
<YR>2013</YR>
<PG>1101-227</PG>
<ED>Abrams P, Cardozo L, Khoury S, Wein A</ED>
<PB>International Consultation on Urological Diseases (ICUD)</PB>
<CY>Belgium</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nabi-2006" MODIFIED="2010-06-08 10:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Nabi 2006" TYPE="COCHRANE_REVIEW">
<AU>Nabi G, Cody JD, Ellis G, Hay-Smith J, Herbison GP</AU>
<TI>Anticholinergic drugs versus placebo for overactive bladder syndrome in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003781.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD003781"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nygaard-2006" MODIFIED="2015-09-14 13:43:41 +0100" MODIFIED_BY="[Empty name]" NAME="Nygaard 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nygaard I, Girts T, Fultz NH, Kinchen K, Pohl G, Sternfeld B</AU>
<TI>Is urinary incontinence a barrier to exercise in women?</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>2</NO>
<PG>307-314</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ogah-2009" MODIFIED="2015-09-03 17:15:03 +0100" MODIFIED_BY="[Empty name]" NAME="Ogah 2009" TYPE="COCHRANE_REVIEW">
<AU>Ogah J, Cody JD, Rogerson L</AU>
<TI>Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006375.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD006375"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ortega-2012" MODIFIED="2015-11-19 12:39:40 +0000" MODIFIED_BY="[Empty name]" NAME="Ortega 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ortega RM, Rodriguez-Rodriguez E, Lopez-Sobaler AM</AU>
<TI>Effects of omega 3 fatty acids supplementation in behavior and non-neurodegenerative neuro-psychiatric disorders</TI>
<SO>British Journal of Nutrition</SO>
<YR>2012</YR>
<VL>107</VL>
<PG>S261-S270</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-Manager-2012" MODIFIED="2015-09-14 13:44:08 +0100" MODIFIED_BY="[Empty name]" NAME="Reference Manager 2012" TYPE="COMPUTER_PROGRAM">
<TI>Reference Manager Professional Edition Version 12</TI>
<SO>New York: Thomson Reuters</SO>
<YR>2012</YR>
<PB>Thomson Reuters</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-09-14 13:44:17 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011a" MODIFIED="2015-09-14 13:44:33 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011a" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and &#8216;Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>Available from www.cochrane-handbook.org.</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011b" MODIFIED="2015-09-14 13:44:40 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011b" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skerrett-2010" MODIFIED="2015-11-19 12:41:25 +0000" MODIFIED_BY="[Empty name]" NAME="Skerrett 2010" TYPE="JOURNAL_ARTICLE">
<AU>Skerrett PJ, Willett WC</AU>
<TI>Essentials of healthy eating: a guide</TI>
<SO>Journal of Midwifery &amp; Women's Health</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>6</NO>
<PG>492-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Subak-2002" MODIFIED="2010-01-25 17:05:36 +0000" MODIFIED_BY="[Empty name]" NAME="Subak 2002" TYPE="JOURNAL_ARTICLE">
<AU>Subak LL, Johnson C, Whitcomb E, et al</AU>
<TI>Does weight loss improve incontinence in moderately obese women?</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>1</NO>
<PG>40-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Subak-2005a" MODIFIED="2015-09-14 13:47:10 +0100" MODIFIED_BY="[Empty name]" NAME="Subak 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS</AU>
<TI>Weight Loss: a novel and effective treatment for urinary incontinence</TI>
<SO>Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<PG>190-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Subak-2009a" MODIFIED="2015-09-14 13:47:30 +0100" MODIFIED_BY="[Empty name]" NAME="Subak 2009a" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19846133&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - J Urol. 182(6 Suppl):S2-7, 2009 Dec&lt;br&gt;JC - kc7, 0376374&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2015-09-14 13:47:30 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Subak LL, Richter HE, Hunskaar S</AU>
<TI>Obesity and urinary incontinence: epidemiology and clinical research update</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>182</VL>
<NO>6 Suppl</NO>
<PG>S2-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT39545"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Subak-2009b" MODIFIED="2015-09-14 13:47:40 +0100" MODIFIED_BY="[Empty name]" NAME="Subak 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al; PRIDE Investigators</AU>
<TI>Weight loss to treat urinary incontinence in overweight and obese women</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>5</NO>
<PG>481-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tampakoudis-1995" MODIFIED="2015-09-14 15:52:38 +0100" MODIFIED_BY="[Empty name]" NAME="Tampakoudis 1995" TYPE="JOURNAL_ARTICLE">
<AU>Tampakoudis P, Tantanassis T, Grimbizis G, Papaletsos M, Mantalenakis S</AU>
<TI>Cigarette smoking and urinary incontinence in women? A new calculative method of estimating the exposure to smoke</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>1995</YR>
<VL>63</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Townsend-2008" MODIFIED="2015-09-14 13:49:39 +0100" MODIFIED_BY="[Empty name]" NAME="Townsend 2008" TYPE="JOURNAL_ARTICLE">
<AU>Townsend MK, Curhan GC, Resnick NM, Grodstein F</AU>
<TI>Body mass index, waist circumference, and incident urinary incontinence in older women</TI>
<SO>Obesity</SO>
<YR>2008</YR>
<VL>16</VL>
<PG>881- 6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-2004" MODIFIED="2015-09-14 13:49:46 +0100" MODIFIED_BY="[Empty name]" NAME="Turner 2004" TYPE="JOURNAL_ARTICLE">
<AU>Turner DA, Shaw C, McGrother CW, Dallosso HM, Cooper NJ</AU>
<TI>The cost of clinically xignificant urinary storage symptoms for community dwelling adults in the UK</TI>
<SO>BJU International</SO>
<YR>2004</YR>
<VL>93</VL>
<NO>9</NO>
<PG>1246-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wallace-2004" MODIFIED="2010-06-08 10:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Wallace 2004" TYPE="COCHRANE_REVIEW">
<AU>Wallace SA, Roe B, Williams K, Palmer M</AU>
<TI>Bladder training for urinary incontinence in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001308.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD001308"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ware-1993" MODIFIED="2013-05-30 16:54:30 +0100" MODIFIED_BY="[Empty name]" NAME="Ware 1993" TYPE="BOOK">
<AU>Ware JE, Snow KK, Kosinski M, Gandek B</AU>
<SO>SF-36® Health Survey Manual and Interpretation Guide</SO>
<YR>1993</YR>
<PB>New England Medical Center, The Health Institute</PB>
<CY>Boston, MA</CY>
<IDENTIFIERS MODIFIED="2013-05-30 16:54:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-30 16:54:30 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wing-2010" MODIFIED="2015-09-03 17:16:24 +0100" MODIFIED_BY="[Empty name]" NAME="Wing 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wing RR, Creasman JM, West DS, Richter HE, Myers D, Burgio KL, et al</AU>
<TI>Improving urinary incontinence in overweight and obese women through modest weight loss</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>2 Pt 1</NO>
<PG>284-92</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-06-20 16:13:47 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES MODIFIED="2014-01-30 13:44:04 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-11-20 12:59:42 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-11-20 12:51:55 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-11-20 12:49:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-2006b">
<CHAR_METHODS MODIFIED="2015-09-14 13:02:21 +0100" MODIFIED_BY="[Empty name]">
<P>Design: A sub-study of the Diabetes Prevention Program (DPP), an RCT with overweight non-diabetic individuals, randomly allocated to the intensive lifestyle weight loss programme (Group I), metformin (Group II) or placebo (Group III). For the purpose of this sub-study, men were excluded from analysis<BR/>Study centre: 27 centres in the USA</P>
<P>Recruitment period: 1996-1999</P>
<P>Power calculation: performed for the original DPP trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>Number of (female) participants randomized: total = 2191<BR/>Number of (female) participants followed up: total = 1957; Group I = 660; Group II = 636; Group III = 661<BR/>Withdrawals/dropouts/lost to follow-up: total = 234 (11%) women with missing UI data were excluded from analysis</P>
<P>Gender: female<BR/>Mean age, years (SD): Group I: 49.3 (10.6); Group II: 49.9 (9.6); Group III: 49.5 (9.7)</P>
<P>BMI mean (SD): Group I: 34.7 (6.9); Group II: 34.8 (6.9); Group III: 35.1 (7.0)</P>
<P>Ethnicity:</P>
<P>Group I: white = 343; African American = 138; Hispanic = 103; Native American = 51; Asian = 25</P>
<P>Group II: white = 333; African American = 148; Hispanic = 97; Native American = 45; Asian = 13</P>
<P>Group III: white = 355; African American = 144; Hispanic = 94; Native American = 51; Asian = 17</P>
<P>Education: not stated</P>
<P>Employment status: not stated</P>
<P>Severity of symptoms: not stated<BR/>Prior incontinence surgery: not stated</P>
<P>Inclusion criteria: age at least 25 years, BMI &#8805; 24 kg/m², a fasting plasma glucose level 95&#8211;125 mg/dl, and a 2-h post challenge glucose level 140&#8211;199 mg/dl<BR/>Exclusion criteria: people taking medications that could affect glucose tolerance or who had serious medical illness</P>
<P>Diagnostic groups: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-20 12:49:21 +0000" MODIFIED_BY="[Empty name]">
<P>Group I: intensive lifestyle intervention. The goals were at least 7% weight loss and at least 150 minutes of moderate-intensity physical activity per week. A 16-lesson curriculum covering diet, exercise, and behaviour modification, taught by case managers during the first 24 weeks after enrolment, was "flexible, culturally sensitive, and individualized". Subsequent individual sessions (usually monthly) and group sessions with the case managers were also provided to reinforce the behavioural changes<BR/>Treatment duration: 24 weeks with monthly follow-up thereafter</P>
<P>Length of follow-up: average 2.8 (range 1.8-4.6) years</P>
<P>Training provided by: case managers, with training in nutrition, exercise or behaviour modification, on a one-to-one basis<BR/>
</P>
<P>Group II: metformin 850 mg twice daily with standard lifestyle intervention<BR/>
</P>
<P>Group III: placebo twice daily with standard lifestyle intervention</P>
<P>The standard lifestyle intervention included written information and an individual meeting (20-30 minutes) that emphasized a healthy diet, reduced weight, increased activity levels and smoking cessation, at baseline and annually</P>
<P>Co-interventions: not stated</P>
<P>Compliance: Mean change in weight, kg (SD): Group I = -3.4 (8.2); Group II = -1.5 (7.6); Group III = +0.5 (6.7); P value &lt; 0.001</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:03:24 +0100" MODIFIED_BY="[Empty name]">
<P>Weekly prevalence of UI by type (stress, urge or any UI) based on participant's report at the end-of-trial visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>The primary aim of the DPP trial was to evaluate whether an intensive lifestyle intervention with improved diet and increased physical activity or metformin therapy among overweight pre-diabetic men and women would prevent or delay the onset of type 2 diabetes. Not all participants had UI at baseline. The objective of the analysis included in this review was to assess whether these interventions were associated with a lower prevalence of incontinence in women, because weight loss may decrease incontinence, whereas increased physical activity may worsen incontinence, and incontinence may also be a barrier to exercise</P>
<P>Funding: The DPP trial was supported by the following: The Diabetes Prevention Program, National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Child Health and Human Development, the National Institute on Aging, the Office of Research on Minority Health and Health Disparities, the Office of Women&#8217;s Health, the Indian Health Service, the Centers for Disease Control and Prevention, the General Clinical Research Program, the National Center for Research Resources, the American Diabetes Association, Bristol-Myers Squibb, Lipha Pharmaceuticals, and Parke-Davis. LifeScan, Health O Meter, Hoechst Marion Roussel, Merck-Medco Managed Care, Merck, Nike Sports Marketing, and Slim Fast Foods. Quaker Oats donated materials, equipment, or medicines for concomitant conditions. McKesson ioServices, Matthews Media Group, and the Henry M Jackson Foundation provided support services under subcontract with the Co-ordinating Center</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-11-20 12:49:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bryant-2002">
<CHAR_METHODS MODIFIED="2015-09-14 13:04:25 +0100" MODIFIED_BY="[Empty name]">
<P>Design: quasi-RCT. Participants were randomized by health record numbers and allocated to caffeine reduction education (Group I) or control (Group II)<BR/>Study centre: 2 nurse-led continence clinics, Sydney, Australia</P>
<P>Recruitment period: not stated</P>
<P>Power calculation: performed<BR/>Funding: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-11-20 12:49:38 +0000" MODIFIED_BY="[Empty name]">
<P>Number of participants randomized: total = 95; Group I = 48; Group II = 47<BR/>Number of participants followed up: total = 74; Group I = 36; Group II = 38<BR/>Withdrawals/dropouts/lost to follow-up: total = 21 (22%); Group I = 12; Group II = 9. Reasons: failure to return to follow-up (n = 14); anxiety or family problem (n = 4); hospital admission (n = 2); intercurrent illness (n =1)</P>
<P>Gender (number and % female): Group I = 45 (94%); Group II = 41 (87%)<BR/>Mean age, years (SD): Group I = 56 (18); Group II = 58 (16)</P>
<P>Mean body weight, kg (SD): Group I = 69 (17); Group II = 68 (20)</P>
<P>Ethnicity: not stated</P>
<P>Education: not stated</P>
<P>Employment status: not stated</P>
<P>Severity of symptoms: mean number of leakage episodes per 24 hours (SD): Group I = 2.8 (3.2); Group II = 3.1 (3.9)<BR/>Prior incontinence surgery: not stated</P>
<P>Inclusion criteria: adults with symptoms of urgency, frequency and/or urge incontinence, and who routinely ingested caffeine at levels of 100 mg or more every 24 hours<BR/>Exclusion criteria: significant cognitive impairment, pregnancy or symptoms of urinary tract infection</P>
<P>Diagnostic groups: 83% of the sample had urge UI, while 17% reported no UI at baseline (only frequency and urgency)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-20 12:49:42 +0000" MODIFIED_BY="[Empty name]">
<P>Group I: educational intervention (with bladder training) to reduce caffeine intake to &lt; 100 mg a day. The intervention consisted of a thorough review (with participants) of their caffeine intake history, urinary symptoms and time/volume/caffeine charts for 3 randomly selected 24-hour periods, followed by a planned caffeine reduction intervention using a caffeine fading method (<LINK REF="REF-James-1988" TYPE="REFERENCE">James 1988</LINK>). This method decreases caffeine intake by one drink each day until the desired maximum intake of 100 mg caffeine a day is reached and the caffeinated drinks have been replaced by other fluids<BR/>Treatment duration: participants were seen weekly for 4 weeks<BR/>Length of follow-up: no follow-up after 4-week programme</P>
<P>Training provided by: not stated<BR/>
</P>
<P>Group II: continued usual daily caffeine intake of &gt; 100 mg every 24 hours. Also received bladder training</P>
<P>Co-interventions: not stated<BR/>
</P>
<P>Compliance: mean caffeine intake reduction per 24 hours, (SD):</P>
<P>Group I: 58%; Group II: 11%; P value &lt; 0.0001</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-14 16:44:52 +0100" MODIFIED_BY="[Empty name]">
<P>Number of incontinent episodes in 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-31 11:37:53 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-11-20 12:50:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dowd-1996">
<CHAR_METHODS MODIFIED="2015-09-14 13:06:31 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT. Participants were assigned randomly to increased fluid intake (Group I), decreased fluid intake (Group II) or maintained fluid intake (Group III)<BR/>Study centre: USA</P>
<P>Recruitment period: not stated</P>
<P>Power calculation: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-11-20 12:49:55 +0000" MODIFIED_BY="[Empty name]">
<P>Number of participants randomized: total = 58; Group I = 20; Group II = 18; Group III = 20<BR/>Number of participants followed up: total = 32; Group I = 14; Group II = 10; Group III = 8<BR/>Withdrawals/dropouts/lost to follow-up: total = 26 (45%); Group I = 6; Group II = 8; Group III = 12. Reason: diaries were not sufficiently completed</P>
<P>Gender: female<BR/>Mean age, years (range): 70.25 (52-89)</P>
<P>BMI: 19/32 participants with data had normal or below normal weight; 8/32 participants were obese</P>
<P>Ethnicity: not stated</P>
<P>Education: not stated</P>
<P>Employment status: not stated</P>
<P>Severity of symptoms (mean daily UI episodes per day): 0.6 (n = 32)<BR/>Prior incontinence surgery: not stated</P>
<P>Inclusion criteria: women over 50 years of age who had had UI for 6 months or more, were independent in self-care, scored over 20 on the Mini-Mental State Examination (<LINK REF="REF-Folstein-1975" TYPE="REFERENCE">Folstein 1975</LINK>) and were English speaking<BR/>Exclusion criteria: not stated</P>
<P>Diagnostic groups: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-20 12:50:18 +0000" MODIFIED_BY="[Empty name]">
<P>The first week served as the baseline, after which participants were assigned to 1 of the 3 groups. Participants were instructed in the detailed recording of intake using the same measuring cups and glasses for the duration of the study and were instructed to keep intake and output diaries for 5 weeks</P>
<P>Group I: increased fluid intake by 500 ml, total intake not to exceed 2400 ml per day<BR/>
</P>
<P>Group II: decreased intake by 300 ml, total intake not to be less than 1000 ml per day</P>
<P>Group III: maintained fluid intake at baseline level</P>
<P>Treatment duration: 5 weeks (randomisation in second week)<BR/>Length of follow-up: a 3-month telephone follow-up (n = 29) was undertaken for the entire cohort; no data were available for each randomized group</P>
<P>Treatment provided by: registered nurses who were given in-service training on UI and oriented to the study procedures. They provided new data-collection sheets and responded to questions on a weekly basis</P>
<P>Co-interventions: not stated<BR/>
</P>
<P>Compliance (mean daily fluid intake): Group I = fluid intake was increased until week 3 when they returned closer to the baseline level; Group II = intake was less than baseline through the first 4 weeks but increased in week 5; Group III = increased intake by approximately 170 ml in week 5; this suggests generally low compliance across the groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-14 16:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>Number of incontinent episodes in 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:06:41 +0100" MODIFIED_BY="[Empty name]">
<P>The secondary aim of the study was to assess whether there was any relationship between caffeine intake and incontinence episodes</P>
<P>Funding: Kidney Foundation of Summit County in Akron, Ohio, USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-11-20 12:50:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hashim-2008">
<CHAR_METHODS MODIFIED="2015-09-14 13:09:32 +0100" MODIFIED_BY="[Empty name]">
<P>Design: prospective 2-group cross-over trial. After a 4-day screening period (baseline), there were 4 phases of 4-day fluid manipulation and 2-day washout over the period of 4 weeks. Participants were randomly assigned to 1 of the 2 groups and asked either to increase or decrease their fluid intake first, from baseline<BR/>Study centre: Bristol Urological Institute, Southmead Hospital, Bristol, UK</P>
<P>Recruitment period: not stated</P>
<P>Power calculation: performed<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-11-20 12:50:32 +0000" MODIFIED_BY="[Empty name]">
<P>Number of participants randomized: 67 were contacted, 40 were recruited and 24 were randomized<BR/>Number of participants followed up: 24<BR/>Withdrawals/dropouts/lost to follow-up: none</P>
<P>Gender: male = 11; female = 13<BR/>Age (years): mean 62.7, median (range) 62.5 (42, 80)</P>
<P>BMI: not stated</P>
<P>Ethnicity: not stated</P>
<P>Education: not stated</P>
<P>Employment status: not stated</P>
<P>Severity of symptoms: not stated</P>
<P>Prior incontinence surgery: not stated</P>
<P>Inclusion criteria: adult men and women (&#8805;18 years old) with symptoms of OAB.  Enrolled after a 4-day screening period (to establish baseline values) using frequency/volume charts (FVC), completed daily, if they had a mean of 8 or more voids and 1 or more urgency and/or urgency incontinence episodes in 24 hours. Participants were identified from a database that included those who were contacted and/or participated in previous trials. They were initially screened by telephone to see if they would agree to take part in the trial and were eligible for it</P>
<P>Exclusion criteria: participants were excluded from any part of the study if their increase/decrease resulted in them drinking &gt; 3 L or &lt; 1 L of fluid, as drinking 3 L would be excessive and drinking &lt; 1 L would cause symptoms of dehydration, e.g. headaches and constipation. People were also excluded if they were pregnant or breast-feeding; had haematuria, bacteriuria, pyuria, proteinuria, glucosuria or ketosuria on urine dipstick testing; had a residual volume of &gt; 150 mL, as assessed by a bladder scan; had uncontrolled hypertension, suspicion or evidence of clinically relevant cardiac failure, renal disease or hepatic disease; were diagnosed with or suspected of having diabetes insipidus/primary polydipsia or diabetes mellitus; had neurogenic dysfunction of the lower urinary tract; were known alcohol or drug abusers; were scheduled to be admitted to hospital for inpatient surgery during the trial; had any history of clinically relevant psychiatric disorders within the last 24 months preceding enrolment in the trial; had a history of not complying with medical regimens or were not compliant with protocol requirements or unable to keep a diary or perform the required volume measurements on their own; had significant pelvic organ prolapse (Stage III or IV) or had significant stress UI.</P>
<P>Diagnostic groups: OAB = 24 (100%). Only 7 (29%) participants had 1 or more urge UI episode at baseline<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-20 12:50:50 +0000" MODIFIED_BY="[Empty name]">
<P>4-day screening period with FVC to establish baseline drinking habits, prior to randomisation to Group I or II</P>
<P> </P>
<P>Group I:</P>
<P>4 days drinking 25% less than baseline followed by 2 days normal drinking (i.e. a washout); followed by</P>
<P>4 days drinking 50% less than baseline followed by 2 days normal drinking; followed by</P>
<P>4 days drinking 25% more than baseline followed by 2 days normal drinking; followed by</P>
<P>4 days drinking 50% more than baseline</P>
<P> </P>
<P>Group II:</P>
<P>4 days drinking 25% more than baseline followed by 2 days normal drinking; followed by</P>
<P>4 days drinking 50% more than baseline followed by 2 days normal drinking; followed by</P>
<P>4 days drinking 25% less than baseline followed by 2 days normal drinking; followed by</P>
<P>4 days drinking 50% less than baseline</P>
<P> </P>
<P>Participants who drank &gt; 3 L or &lt; 1 L were excluded. Patients completed a 4-day FVC in each part of the study, and the ICIQ-OAB questionnaire at the end of each 4-day period, to assess their quality of life for that period</P>
<P>Significance was analyzed by comparing each intervention group to the overall baseline of the study group (n = 24). The number of participants differed in each period so this is presented for reference</P>
<P>Treatment duration: 4 weeks</P>
<P>Co-intervention: not stated</P>
<P>Compliance: all 24 participants participated in the period with a 25% reduction, but not all participated in the other parts of the study because they did not fulfil the criteria, i.e. their input was &lt; 1 L or &gt; 3 L when the fluid intake was manipulated. The mean fluid output was approximately 289 ml higher than the fluid intake. When participants were asked to drink 25% more than their normal fluid input they only managed to drink 17% more, and when asked to drink 50% more they managed 23% more, when comparing the respective groups with baseline. When asked to drink 50% less, participants managed to drink 32% less than the baseline. The 25% reduction was adhered to quite well</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:11:13 +0100" MODIFIED_BY="[Empty name]">
<P>Condition-specific quality of life</P>
<P>Adverse effects</P>
<P>Number of incontinent episodes in 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:11:29 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Bristol Urological Institute PA Research Fund</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-11-20 12:50:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manonai-2006">
<CHAR_METHODS MODIFIED="2015-09-14 13:12:07 +0100" MODIFIED_BY="[Empty name]">
<P>Design: cross-over trial with 2 x 12-week diet periods and 2 x 4-week washout periods before and between treatments. Participants were randomly allocated to the order in which they followed an isocaloric soy-rich diet or a control diet<BR/>Study centre: Mahidol University, Bangkok, Thailand</P>
<P>Recruitment period: not stated</P>
<P>Power calculation: not stated<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-11-20 12:50:58 +0000" MODIFIED_BY="[Empty name]">
<P>Number of participants randomized: 42<BR/>Number of participants followed up: 36<BR/>Withdrawals/dropouts/lost to follow-up = 6. Reasons: 5 withdrew from the study because of their inability to comply with the study; 1 lost to pelvic examination follow-up</P>
<P>Gender: female<BR/>Mean age, years: 52.5 (SD 5.11; range 40-59)</P>
<P>BMI: not stated</P>
<P>Ethnicity: not stated</P>
<P>Education: not stated</P>
<P>Employment status: not stated</P>
<P>Severity of symptoms: not stated<BR/>Prior incontinence surgery: not stated</P>
<P>Inclusion criteria: healthy women whose periods had ceased at least 3 months previously,who were 45-70 years of age, not using hormone therapy and did not regularly consume a vegetarian diet. All women had experienced at least one type of urinary or genital symptoms owing to urogenital atrophy<BR/>Exclusion criteria: presence or history of sex hormone-dependent malignancies; presence or history of liver or renal disorders; and pathology of urogenital tract</P>
<P>Diagnostic groups: before soy-rich diet, 61% had SUI and 19% had UUI; and before control diet 63% had SUI and 11% had UUI. Some women may have had symptoms of both SUI and UUI. Other women had frequency, urgency or other vaginal symptoms, e.g. vaginal dryness, but no UI<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-12 11:27:42 +0100" MODIFIED_BY="[Empty name]">
<P>During both study periods, participants consumed self-selected diets with low-fat and low-cholesterol foods. Subjects were advised to maintain their physical activity consistently throughout the study and were instructed to avoid all additional soy products, herbal or vitamin and mineral supplements. They were also instructed to keep an accurate 3-day food record</P>
<P>Intervention period I: isocaloriic soy-rich diet: Participants consumed 25 g soy protein in various forms containing &gt; 50 mg per day of isoflavones, which was substituted for an equivalent amount of animal protein. All soy foods for the study were provided monthly</P>
<P>Intervention period II: control diet</P>
<P>Treatment duration: 2 x 12-week diet periods with 2 x 4-week washout periods before and between treatments</P>
<P>Treatment provided by: the same nutritionist throughout the study</P>
<P>Co-intervention: not stated</P>
<P>Compliance: good compliance was shown by the significant elevation of serum levels of daidzein and genistein during the soy-rich diet period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:13:16 +0100" MODIFIED_BY="[Empty name]">
<P>Number of women with incontinent episodes</P>
<P>Incontinence symptom scores<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:13:17 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Thai Health Promotion Foundation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-14 13:14:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-2007">
<CHAR_METHODS MODIFIED="2015-09-14 13:14:17 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT with 2 groups<BR/>Study centre: University of Michigan School of Nursing, USA</P>
<P>Study period: 01 January 2007-31 December 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:14:23 +0100" MODIFIED_BY="[Empty name]">
<P>Number of participants: Group I = around 30; Group II = around 30<BR/>
</P>
<P>Gender: female<BR/>
</P>
<P>Diagnostic groups: OAB (unclear if wet or dry)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-14 13:14:26 +0100" MODIFIED_BY="[Empty name]">
<P>Group I: reduced intake of 'irritating' beverages (caffeine or non-caffeine). Participants were instructed to maintain the overall volume of fluid intake by replacing the 'irritating' beverages with water or milk</P>
<P>Group II: control (no details provided)</P>
<P>Treatment duration: unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:14:28 +0100" MODIFIED_BY="[Empty name]">
<P>The study found a significant reduction in OAB symptoms (not defined) in the intervention group. However, the author noted that findings were confounded by a significant reduction in overall fluid intake in the intervention group from baseline (by an average of 8 fluid oz (around 230 ml) per 24 hours). The author also notes that caffeine reduction was not associated with the OAB symptom reduction<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:14:31 +0100" MODIFIED_BY="[Empty name]">
<P>Unpublished trial. All information was obtained from an author email to the Cochrane Incontinence Group search co-ordinator (26 January 2009)</P>
<P>Funding: Pfizer, GA6120A8 Detrol Competitive Grant</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-11-20 12:51:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Phelan-2012">
<CHAR_METHODS MODIFIED="2015-09-14 13:14:53 +0100" MODIFIED_BY="[Empty name]">
<P>Design: a sub-study of the Look AHEAD (Action for Health in Diabetes) trial, an RCT with overweight or obese individuals with type 2 diabetes, randomly allocated to intensive lifestyle weight loss intervention (Group I) or a diabetes support and education control condition (Group II). For the purpose of this sub-study, men were excluded from analysis<BR/>Study centre: 16 centres, USA</P>
<P>Recruitment period: from 2001. Planned follow-up until 2014</P>
<P>Power calculation: performed<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:15:20 +0100" MODIFIED_BY="[Empty name]">
<P>Number of (female) participants randomized in Look AHEAD trial: 3063. Of these, 69 who did not complete baseline incontinence assessment were excluded from this sub-study</P>
<P>Number of randomized participants in this sub-study: Group I = 1495; Group II = 1499<BR/>Number of participants followed up: Group I = 1385; Group II = 1354<BR/>Withdrawals/dropouts/lost to follow-up: Group I = 110; Group II = 145. Study completers were more likely to be white (P value = 0.01) and to be never smokers (P value = 0.02) than non-completers, but no other significant differences were observed</P>
<P>Gender: female<BR/>Mean age, years (SD): Group I: 57.8 (6.7); Group II: 58.1 (6.9)</P>
<P>Mean BMI (SD): Group I: 36.3 (6.2); Group II: 36.7 (6.0)</P>
<P>Ethnicity:</P>
<P>Group I: non-Hispanic white 56%, African-American 20%, Hispanic 15%, Native American/Alaskan native 6%, Other 3%;</P>
<P>Group II: non-Hispanic white 55%, African-American 20%, Hispanic 15%, Native American/Alaskan native 7%, Other 3%</P>
<P>Education: not stated</P>
<P>Employment status: not stated</P>
<P>Severity of symptoms: not stated<BR/>Prior incontinence surgery: not stated</P>
<P>Inclusion criteria: overweight and obese individuals (men and women) with type 2 diabetes, 45-76 years of age with a BMI of &#8805; 25 kg/m² (&gt; 27 kg/m² if currently taking insulin)</P>
<P>Exclusion criteria: &#8805; HbA1c 11%, blood pressure &#8805; 160/100 mmHg, triglycerides &#8805; 600 mg/dl, inadequate control of comorbid conditions, factors that may limit adherence to the intervention, and underlying disease likely to limit life span and/or affect safety of the interventions </P>
<P>Diagnositic groups: at baseline 27% of participants reported weekly (or more frequent) urinary incontinence. The reference group was 'less than weekly'. Predominant type of UI was coded based on whether a participant reported a higher frequency of stress or urgency episodes. About 13% in each group reported predominant SUI and 10% reported predominant UUI. Only 2% of women were classified as having MUI (defined as frequency of SUI = frequency of UUI)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-20 12:51:07 +0000" MODIFIED_BY="[Empty name]">
<P>Group I: intensive lifestyle intervention designed to promote an average of 7% or greater weight loss at 1 year. Participants were encouraged to consume a low calorie and low fat, portion controlled diet that included liquid meal replacements, and to achieve at least 175 minutes of physical activity weekly. The participants were seen weekly for the first 6 months and 3 times monthly for the next 6 months for a total of 44 sessions (Phase I, months 1-12)<BR/>Treatment duration: the intensive intervention occurred in the first 4 years of the study period (e.g. Phase II, months 13-48; Phase III, months 49+)</P>
<P>Length of follow-up: for the purpose of this sub-study, outcomes were assessed after 1 year of intervention</P>
<P>Training provided by: lifestyle counsellor</P>
<P>Group II: diabetes support and education: participants were invited to 3 group sessions during the year which focused on diet, physical activity or social support</P>
<P>Co-interventions: not reported</P>
<P>Compliance: Mean weight lost at 1 year, kg (SD): Group I: 7.7 (7.0); Group II: 0.7 (5.0); P value &lt; 0.0001</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:15:52 +0100" MODIFIED_BY="[Empty name]">
<P>Improvement (decrease of at least 2 episodes per week) and resolution (cure) in women who had weekly or more frequent incontinence episodes at baseline, assessed by validated self-report questions after 1 year of intervention</P>
<P>Prevalence of UI (that occurred at least weekly) assessed by validated self-report questions after 1 year of intervention</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:15:54 +0100" MODIFIED_BY="[Empty name]">
<P>The primary objective of the LOOK AHEAD trial was to assess the intervention effects on cardiovascular morbidity and mortality</P>
<P>Funding: the Department of Health and Human Services. The following organizations have committed to make major contributions to Look AHEAD: FedEx Corp; Health Management Resources; LifeScan, Inc, a Johnson and Johnson Company; Optifast ® of Nestle HealthCare Nutrition, Inc; Hoffmann-La Roche Inc; Abbott Nutrition; and Slim-Fast Brand of Unilever North America</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-11-20 12:51:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Subak-2005">
<CHAR_METHODS MODIFIED="2015-09-14 13:17:12 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT stratified by type of incontinence (either stress only and stress-predominate MUI or urge only and urge-predominate MUI), then randomly allocated to immediate (Group I) or delayed (Group II) enrolment in the weight reduction programme<BR/>Study centre: University of California, USA</P>
<P>Recruitment period: January 1999-March 2000</P>
<P>Power calculation: performed<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:17:39 +0100" MODIFIED_BY="[Empty name]">
<P>Number of participants randomized: total = 48; Group I = 24; Group II = 24<BR/>Number of participants followed up: total = 40; Group I = 19; Group II = 21<BR/>Withdrawals/dropouts/lost to follow-up: total = 8; Group I = 5 (2 loss to follow-up for unknown reasons, 1 medical exclusion, 2 missing primary outcome data); Group II = 3 (2 lost to follow-up for unknown reasons, 1 withdrew from study due to death of spouse)</P>
<P>Gender: female<BR/>Median age, years (IQR): Group I = 50.5 (46-54); Group II = 57.5 (50-62); P value = 0.006</P>
<P>Median BMI (IQR): Group I = 34 (32-40); Group II = 36 (32-38)</P>
<P>Ethnicity:</P>
<P>Group I: white = 18; other 2; Group II: white = 17; other = 3</P>
<P>Education: not stated</P>
<P>Employment status: not stated</P>
<P>Severity of symptoms (number of women with 'severe' incontinence defined as &gt; 10 episodes per week): Group I = 19; Group II = 20</P>
<P>Prior incontinence surgery (number of women): Group I = 1; Group II = 3</P>
<P>Inclusion criteria: a consecutive sample of women 18 to 80 years old with BMI between 25-45 kg/m², UI for at least 3 months and at least 4 incontinent episodes in a 7-day urinary diary. Prior incontinence therapies (including surgery) were not exclusions from study eligibility<BR/>Exclusion criteria: pregnancy, urinary tract infection, significant medical condition, pelvic cancer, neurological condition possibly associated with incontinence, interstitial cystitis or potential inability to complete the study</P>
<P>Diagnostic groups:</P>
<P>Group I: stress alone = 3; stress-predominate MUI = 9; urge alone = 3; urge-predominate MUI = 9 Group II: stress alone = 0; stress-predominate MUI = 10; urge alone = 2; urge-predominate MUI = 11<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-20 12:51:15 +0000" MODIFIED_BY="[Empty name]">
<P>Group I: a 3-month intensive group-based medical and behavioural weight loss programme. Participants were placed on a standard low calorie liquid diet (800 kcals per day or less), encouraged to increase physical activity gradually until they were exercising 60 minutes daily, and were taught standard cognitive and behavioural skills to assist in modifying eating and exercise habits. Participants met weekly in group sessions led by a nutritionist, exercise physiologist or behavioral therapist and followed a structured protocol<BR/>Treatment duration: 3 months<BR/>Length of follow-up: 3 and 6 months after completion of the 3-month programme for the entire cohort; no data were available for each randomized group</P>
<P>Training provided by: nutritionist, exercise physiologist or behavioural therapist<BR/>
</P>
<P>Group II: a waiting list control group had no intervention for 3 months and then entered the weight reduction programme<BR/>
</P>
<P>Co-interventions: participants currently using incontinence therapy were included in the study, but were asked to not change treatment during study</P>
<P>Compliance: median % weight improvement, (IQR): Group I: 16 (9-20); Group II: 0 (-2-2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:18:16 +0100" MODIFIED_BY="[Empty name]">
<P>Condition-specific quality of life</P>
<P>Adverse effects</P>
<P>Cure rates based on quantification of symptoms (defined as number of women with a 100% reduction in weekly UI episodes recorded by 7-day diary)</P>
<P>Improvement (including cure) rates based on quantification of symptoms (defined as number of women with a 75%-100% reduction in weekly UI episodes recorded by 7-day diary)</P>
<P>Number of incontinent episodes per week</P>
<P>Generic quality of life<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:18:20 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Mount Zion Health Services Inc and University of California</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-11-20 12:51:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Subak-2009">
<CHAR_METHODS MODIFIED="2015-09-14 13:19:09 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT stratified by clinical centre, then randomly allocated by 2:1 ratio to 6-month weight loss programme (Group I) or 4-session education programme (Group II)<BR/>Study centre: multiple centres in Alabama, USA (PRIDE study)</P>
<P>Recruitment period: 2004-2006</P>
<P>Power calculation: performed<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:19:25 +0100" MODIFIED_BY="[Empty name]">
<P>Number of participants randomized: total = 338; Group I = 226; Group II = 112<BR/>Number of participants with data on incontinence at 6 months: total = 304; Group I = 214; Group II = 90<BR/>Withdrawals/dropouts/lost by 6 months: total = 34; Group I = 12 (5 discontinued; 3 were unwilling to follow the program, 1 had a medical reason and 1 had schedule conflicts; 7 did not fill diary); Group II = 22 (15 discontinued; 10 were unwilling to follow the programme, 3 had family problems, 1 was disappointed by the group assignment and 1 had schedule conflicts; 7 did not fill diary)</P>
<P>Number of participants with data on incontinence at 12 months: total = 294; Group I = 207; Group II = 87</P>
<P>Number of participants with data on incontinence at 18 months: total = 287; Group I = 197; Group II = 90</P>
<P>Gender: female<BR/>Mean age, years (SD): Group I = 53 (11); Group II = 53 (10)</P>
<P>Mean BMI (SD): Group I = 36 (6); Group II = 36 (5)</P>
<P>Ethnicity:</P>
<P>Group I: white = 171; black = 47; other = 8; Group II: white = 91; black = 17; other = 4</P>
<P>Education (beyond high school): Group I = 200; Group II = 93</P>
<P>Employment status: not stated</P>
<P>Severity of symptoms: not stated<BR/>Prior incontinence surgery: none (see exclusion criteria)</P>
<P>Inclusion criteria: women at least 30 years of age, BMI of 25-50, and at baseline reported 10 or more UI episodes in a 7-day diary of voiding. Previous medical therapy for incontinence or obesity did not affect eligibility<BR/>Exclusion criteria: use of medical therapy for incontinence or weight loss within the previous month, current urinary tract infection or &#8805; 4 or more urinary tract infections in the previous year, a history of incontinence of neurologic or functional origin (due to factors not involving the lower urinary tract, such as chronic impairment of physical or cognitive functioning), previous surgery for incontinence or urethral surgery, major medical or genitourinary tract conditions, pregnancy or parturition in the previous 6 months, type 1 or type 2 diabetes mellitus requiring medical therapy that increased the risk of hypoglycemia, and uncontrolled hypertension</P>
<P>Diagnostic groups:</P>
<P>Group I: stress alone = 8; stress-predominant (at least 2/3 of the total number of episodes were stress episodes) = 36; urge alone = 33; urge-predominant (at least 2/3 of the total number of episodes were urge episodes) = 71 MUI with no predominant type = 78;</P>
<P>Group II: stress alone = 10; stress-predominant = 21; urge alone = 8; urge-predominant = 37; MUI with no predominant type = 36<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-20 12:51:24 +0000" MODIFIED_BY="[Empty name]">
<P>At randomisation, all participants were given a self-help behavioural-treatment booklet with instructions for improving bladder control (including pelvic floor muscle training). Incontinence was not discussed further with either group</P>
<P>Group I: weight loss programme designed to produce an average loss of 7% to 9% of initial body weight within the first 6 months of the program, modelled after that used in 2 large clinical trials: the Look AHEAD (Action for Health in Diabetes), and the DPP (Diabetes Prevention Program). Participants met weekly for 6 months in groups of 10-15 for 1-hour sessions that were led by experts in nutrition, exercise, and behaviour change and were based on a structured protocol. Given a standard reduced-calorie diet (1200-1500 kcal per day), with a goal of providing no more than 30% of the calories from fat. To improve adherence, the participants were provided with sample meal plans and were given vouchers for a meal-replacement product (Slim-Fast) to be used for 2 meals a day during months 1-4 and for 1 meal a day thereafter. Encouraged to increase physical activity (brisk walking or activities of similar intensity) gradually until active for at least 200 minutes each week. Behavioural skills, including self-monitoring, stimulus control, and problem-solving, were emphasized</P>
<P>Treatment duration: 6 months<BR/>Follow-up (weight loss maintenance): On completion of the 6-month programme, participants underwent a second randomisation to a motivationally focused maintenance programme or a standard skills based maintenance approach and were followed for further 12 months<BR/>
</P>
<P>Training provided by: experts in nutrition, exercise, and behaviour change</P>
<P>Group II: structured education programme (control): 4 education sessions at months 1, 2, 3, and 4. During these 1-hour group sessions, which included 10-15 women, general information was presented about weight loss, physical activity, and healthful eating habits, according to a structured protocol</P>
<P>Co-intervention: see exclusion criteria</P>
<P>Compliance (mean weight, kg (SD)):</P>
<P>Group I: baseline = 98 (17); 6 months = 90 (17); Group II: baseline = 95 (16); 6 months = 94 (17)</P>
<P>Compliance (weight % change(95% CI)):</P>
<P>Group I: 6 months = -8.0 (-9.0 to - -7.0); 12 months = -7.5 (-8.6 to - -6.4); 18 months = -5.5 (-6.7 to - -4.3); Group II: 6 months = -1.6 (-2.7 to - -0.4); 12 months = -1.7 (-3.2 to - -0.2); 18 months = -1.6 (-3.4 to - 0.7)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:19:34 +0100" MODIFIED_BY="[Empty name]">
<P>Improvement rates based on participant's report (women reported that overall leakage was better or much better)</P>
<P>Cure rates based on quantification of symptoms (defined as number of women reporting a 100% reduction in weekly UI episodes recorded by 7-day voiding diary)</P>
<P>Improvement rates based on quantification of symptoms (defined as number of women with a 70%-100% reduction in weekly UI episodes recorded by 7-day voiding diary)</P>
<P>Change in the number of incontinent episodes per week<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:19:41 +0100" MODIFIED_BY="[Empty name]">
<P>Funding:the National Institute of Diabetes and Digestive and Kidney Diseases and the Office of Research on Women&#8217;s Health</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-11-20 12:51:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swithinbank-2005">
<CHAR_METHODS MODIFIED="2015-09-14 13:20:18 +0100" MODIFIED_BY="[Empty name]">
<P>Design: cross-over trial with random allocation to the order in which participants increased or decreased decaffeinated fluids in weeks 3 or 4<BR/>Study centre: Bristol Urological Institute, Southmead Hospital, Bristol, UK</P>
<P>Recruitment period: not stated</P>
<P>Power calculation: performed<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:20:18 +0100" MODIFIED_BY="[Empty name]">
<P>Number of participants randomized: 110 women were approached to enter the study,  26 refused, the remaining 84 were included in the study (by incontinence type: USI = 48; IDO = 36)<BR/>Number of participants followed up: total = 69; USI group = 39; IDO group 30<BR/>Withdrawals/dropouts/lost to follow-up: total = 15; USI group = 9 (19%); IDO group = 6 (17%). No reasons provided</P>
<P>Gender: female<BR/>Median age, years (range): 54.8 (31-76)</P>
<P>BMI: not stated</P>
<P>Ethnicity: not stated</P>
<P>Education: not stated</P>
<P>Employment status: not stated</P>
<P>Severity of symptoms: not stated<BR/>Prior incontinence surgery: not stated</P>
<P>Inclusion criteria: women with USI or IDO: women in the IDO group had been referred for investigation of symptoms of frequency, urgency and urgency incontinence, and women with USI had been referred because of leakage secondary to coughing and exercise; the USI group was naive to surgery</P>
<P>Exclusion criteria: urinary tract infection, hepatic, cardiac or renal disease, diabetes mellitus; those on anti-depressants, anticholinergics or diuretics</P>
<P>Diagnostic groups: USI = 48; IDO = 36<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-20 12:51:36 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment duration: 4 weeks</P>
<P>Week 1: participants drank normally (baseline)</P>
<P>Week 2: all participants drank normally, but only caffeine-free fluids</P>
<P>Weeks 3 and 4: participants were randomized to either increasing caffeine-free fluids to 3 L (20 cups) per day for a week followed by a week of reducing caffeine-free fluids to 750 ml (5 cups) per day, or vice versa. Results from the weeks with increased and decreased fluids were compared. Urine osmolality was measured at weekly clinic visit to assess compliance</P>
<P>Detailed urinary diaries that included information concerning episodes of urgency and leakage were kept for each day of the 4-week study period. A reason for randomising the order of increased or decreased fluid intake was to counter the placebo effect (e.g. a bladder training effect) of keeping urinary diaries</P>
<P>Co-interventions: not stated<BR/>
</P>
<P>Compliance (mean fluid intake per day, ml; all women with USI or IDO): week 1 = 1639 ml; week 2 with caffeine-free fluids = 1630 ml; week increasing fluid = 2673 ml; week decreasing fluid: 872 ml</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:20:23 +0100" MODIFIED_BY="[Empty name]">
<P>Condition-specific quality of life</P>
<P>Adverse effects</P>
<P>Number of incontinent episodes in 24 hours<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:20:23 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-11-20 12:51:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wells-2011">
<CHAR_METHODS MODIFIED="2015-11-20 12:51:44 +0000" MODIFIED_BY="[Empty name]">
<P>Design: cross-over trial with random allocation to the order in which participants consumed caffeinated or caffeine-free fluids (feasibility study)<BR/>Study centre: single centre, UK</P>
<P>Recruitment period: not reported</P>
<P>Power calculation: not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>Number of participants randomized: total = 14<BR/>Number of participants followed up: 11<BR/>Withdrawals/dropouts/lost to follow-up: 3 withdrawals</P>
<P>Gender: female<BR/>Mean age, years (range): 52.1 (27-79)</P>
<P>BMI: not reported</P>
<P>Ethnicity: not reported</P>
<P>Education: not reported</P>
<P>Employment status: not reported</P>
<P>Severity of symptoms: not reported<BR/>Prior incontinence surgery: not reported</P>
<P>Inclusion criteria: women aged &gt; 18 years with newly diagnosed OAB, experiencing &gt; 7 voids per day and &gt; 2 episodes per night, self-rated urgency and/or UUI with or without stress incontinent symptoms, and consuming &gt; 2 caffeinated drinks per day (minimum 60 mg caffeine per 24 hours)<BR/>Exclusion criteria: stress incontinence only, smoking, taking oestrogen and/or medications containing caffeine or interfere with caffeine metabolism, postvoid residual &lt; 100 ml, history of frequent (&gt; 3/6 months) [sic] urinary tract infections, pregnant, or unable to undertake a bladder diary</P>
<P>Diagnositic groups: OAB with or without UI<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-20 12:51:49 +0000" MODIFIED_BY="[Empty name]">
<P>All participants underwent 2 x 2-week periods of caffeinated and caffeine-free fluid intake with the 2 periods separated by a 14-day washout period. Before starting their assigned period, participants took part in a run-In period of caffeine withdrawal, during which they were requested to reduce their caffeine intake by substituting one cup of caffeinated tea or coffee with decaffeinated every other day</P>
<P>Co-interventions: not reported</P>
<P>Compliance: "2 participants did not comply with caffeine substitution" based on caffeine levels from saliva samples</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:20:55 +0100" MODIFIED_BY="[Empty name]">
<P>ICIQ-OAB; ICIQ-OABqol</P>
<P>Number of incontinent episodes (3-day bladder diary)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:20:55 +0100" MODIFIED_BY="[Empty name]">
<P>Available as abstract only</P>
<P>Funding: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviations</B>
</P>
<P>BMI: body mass index<BR/>DPP: Diabetes Prevention Program<BR/>FVC: frequency volume charts<BR/>HbA1c: glycated haemoglobin<BR/>ICIQ-OAB: Internatioanal Consultation on Incontinence Questionnaire Overactive Bladder<BR/>ICIA-OABqol:Internatioanal Consultation on Incontinence Questionnaire Overactive Bladder Symptoms Quality of Life<BR/>IDO: idiopathic detrusor overactivity<BR/>MUI: mixed urinary incontinence<BR/>OAB: overactive bladder<BR/>oz: (fluid) ounce<BR/>RCT: randomized controlled trial<BR/>SD: standard deviation<BR/>SUI: stress urinary incontinence<BR/>UI: urinary incontinence<BR/>USI: urodynamic stress incontinence<BR/>UUI: urgency urinary incontinence<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-11-20 12:52:15 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:22:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BE_x002d_DRI">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:22:12 +0100" MODIFIED_BY="[Empty name]">
<P>Anticholinergic medications plus behavioural training versus anticholinergic medications alone. Behavioural training included specific fluid management as well as pelvic floor muscle control and exercises, urge suppression, and delayed voiding. Study conducted by the Urinary Incontinence Treatment Network (UITN). Complex interventions for which we could not separate the effect of lifestyle interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:22:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bird-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:22:19 +0100" MODIFIED_BY="[Empty name]">
<P>Not a relevant population. Healthy volunteers (N = 80). Caffeine tablet versus placebo. Outcome: perceived change in LUTS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:22:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:22:25 +0100" MODIFIED_BY="[Empty name]">
<P>Self-management plus standard care versus standard care. Self-management included lifestyle (fluid, caffeine, alcohol), bladder training and toileting. Complex intervention meant we could not separate the effect of lifestyle interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:22:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dougherty-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:22:25 +0100" MODIFIED_BY="[Empty name]">
<P>BMC versus control. BMC = lifestyle change, if needed; if lifestyle not needed, bladder training (BT); if BT not effective, PFMT + biofeedback (BF).  Complex intervention meant we could not separate the effect of lifestyle interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:22:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dumoulin-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:22:36 +0100" MODIFIED_BY="[Empty name]">
<P>Physiotherapy versus control. Physiotherapy treatment combined 1) PFMT and other exercises with 2) dietary recommendations/changes and constipation management. We could not separate the effect of (2) from (1)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:22:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glazener-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:22:36 +0100" MODIFIED_BY="[Empty name]">
<P>Not a relevant intervention. PFMT (for all UI) plus bladder training (for urge UI) versus control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:22:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herschorn-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:22:36 +0100" MODIFIED_BY="[Empty name]">
<P>Tolterodine plus health education intervention versus tolterodine alone. N = 84. Abstract only, so no details of health education intervention available. Possibly related to <LINK REF="STD-Herschorn-2004" TYPE="STUDY">Herschorn 2004</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:22:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herschorn-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:22:45 +0100" MODIFIED_BY="[Empty name]">
<P>Health education intervention plus tolterodine versus tolterodine alone. Participants received a behavioural modification information sheet with multiple components including: 1) fluid intake regulation, 2) caffeine limitation, 3) scheduled toileting, 4) bladder stretching, 5) PFMT, and 6) urge suppression. We could not separate the effect of 1) and 2) from the rest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-11-20 12:52:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hofbauer-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-11-20 12:52:08 +0000" MODIFIED_BY="[Empty name]">
<P>Not a relevant intervention. Electrical stimulation (ES) + 'gymnastic' versus 'gymnastic' versus ES versus sham ES.  German publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>Multidimensional exercise treatment, consisting of stretching, PFMT and fitness exercises. Community-dwelling elderly Japanese women with SUI, UUI or MUI.  We could not separate the effect of non-PFMT exercise</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2011b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>Exercise treatment with or without heat and steam generating sheet (HSGS).  Exercise consisted of stretching, PFMT and fitness exercises. A 4-arm trial comparing: 1) exercise + HSGS, 2) exercise only, 3) HSGS only, and 4) education. Community-dwelling elderly Japanese women with stress, urge or mixed UI. We could not separate the effect of non-PFMT exercise</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kincade-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>Described the characteristics of women participating in 2 clinical trials and explored the relationships between demographic characteristics, caffeine and fluid intake, quality of life, and severity of urine loss. No usable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kincade-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:12 +0100" MODIFIED_BY="[Empty name]">
<P>Self-monitoring including: 1) caffeine, 2) fluid intake, 3) PFMT, 4) voiding frequency, 5) constipation. We could not separate the effect of lifestyle change</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:22 +0100" MODIFIED_BY="[Empty name]">
<P>The study did not focus on UI, but assessed the effects of Tai Chi on physical function. The only incontinence-related outcome was use of toilet, as part of a composite measure of "eating, dressing, bathing or using the toilet"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parker-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:22 +0100" MODIFIED_BY="[Empty name]">
<P>Not a relevant population. Healthy volunteers (N = 64). Caffeine tablet versus placebo. Outcome: LUTS. Abstract only.  Probably related to <LINK REF="STD-Bird-2005" TYPE="STUDY">Bird 2005</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ree-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:27 +0100" MODIFIED_BY="[Empty name]">
<P>The study did not focus on UI, but examined whether strenuous physical activity could produce pelvic floor muscle fatigue among young nulliparous women with stress UI. No outcome data on UI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schauss-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:27 +0100" MODIFIED_BY="[Empty name]">
<P>Not a relevant intervention. 'UroLogic' versus placebo. UroLogic is a nutritional supplement containing <I>Equisetum arvense</I> and <I>Crataeva murvale</I> </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tomlinson-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:35 +0100" MODIFIED_BY="[Empty name]">
<P>Complex intervention for which we could not separate the effect of lifestyle change. BMC versus control. The three phases of BMC were: 1) self-monitoring including fluid management and caffeine reduction; 2) bladder training; and 3) pelvic muscle exercise with biofeedback.  218 women were randomized into treatment or control. Analysis focused on 41 women who were randomized into the treatment and completed the first phase of BMC. No data were available for the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Hespen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:43 +0100" MODIFIED_BY="[Empty name]">
<P>Not a relevant population. RCT of the UI training programme, INCOndition, including training of pelvic floor muscles, bladder function and mobility, for women living in homes for the elderly. German with English abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-14 13:23:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wagg-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-14 13:23:43 +0100" MODIFIED_BY="[Empty name]">
<P>Lifestyle leaflet versus structured help in clinic (including BT and PFMT). Leaflet-only interventions, without a standardised (within trial) protocol, are not eligible </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviations</B>
</P>
<P>BF: biofeedback<BR/>BMC: behavioural management for continence<BR/>BT: bladder training<BR/>ES: electrical stimulation<BR/>LUTS: lower urinary tract symptoms<BR/>MUI: mixed urinary incontinence<BR/>PFMT: pelvic floor muscle training<BR/>RCT: randomized controlled trial<BR/>SUI: stress urinary incontinence<BR/>UI: urinary incontinence<BR/>UUI: urgency urinary incontinence</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-11-20 12:59:42 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-09-14 13:24:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baker-2011">
<CHAR_METHODS MODIFIED="2015-08-25 07:53:39 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-30 18:26:56 +0000" MODIFIED_BY="[Empty name]">
<P>Women with urgency incontinence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-14 13:24:16 +0100" MODIFIED_BY="[Empty name]">
<P>Mindfulness-based stress reduction technique and yoga (MBSR-yoga) versus sham yoga</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:24:16 +0100" MODIFIED_BY="[Empty name]">
<P>Change from baseline in mean number of urge incontinent episodes from pre treatment to post treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:24:16 +0100" MODIFIED_BY="[Empty name]">
<P>Estimated enrolment: 30</P>
<P>Study start date: February 2011</P>
<P>Primary completion date: May 2012 (final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-09-14 13:24:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gozukara-2014">
<CHAR_METHODS MODIFIED="2014-11-29 18:14:55 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:24:21 +0100" MODIFIED_BY="[Empty name]">
<P>Overweight/obese women with UI recorded in a 3-day diary</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-14 13:24:21 +0100" MODIFIED_BY="[Empty name]">
<P>Behavioural weight loss versus structured education programme</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-29 18:15:27 +0000" MODIFIED_BY="[Empty name]">
<P>Change in voiding diary from baseline to 6 months in voiding diary parameters; Pelvic Floor Distress Inventory and POP-Q</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:24:21 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolment: 158</P>
<P>Study start date: June 2008</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-09-14 13:24:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heesakkers-2009">
<CHAR_METHODS MODIFIED="2014-01-30 18:21:39 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:24:25 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with OAB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-14 13:24:25 +0100" MODIFIED_BY="[Empty name]">
<P>Low versus normal versus high fluid intake</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-30 18:26:10 +0000" MODIFIED_BY="[Empty name]">
<P>Urine osmolality; PPIUS (Perception of Intensity of Urgency Scale) urge-score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:24:25 +0100" MODIFIED_BY="[Empty name]">
<P>Enrollment: 0</P>
<P>Study start date: July 2009</P>
<P>Primary completion date: December 2010 (final data collection date for primary outcome measure)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-09-14 13:24:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2012">
<CHAR_METHODS MODIFIED="2014-01-30 18:16:35 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:24:30 +0100" MODIFIED_BY="[Empty name]">
<P>Women with UI or OAB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-14 13:24:30 +0100" MODIFIED_BY="[Empty name]">
<P>Yoga therapy versus control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:24:30 +0100" MODIFIED_BY="[Empty name]">
<P>Change in the number of incontinence episodes over 7 days from pre treatment to post treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-30 18:23:41 +0000" MODIFIED_BY="[Empty name]">
<P>Enrollment: 20</P>
<P>Study start date: August 2012</P>
<P>Study completion date: December 2012</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-09-14 13:24:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Markland-2013">
<CHAR_METHODS MODIFIED="2014-01-30 18:30:17 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>Older women with UI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-14 13:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>Vitamin D supplementation versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-30 18:31:16 +0000" MODIFIED_BY="[Empty name]">
<P>Change in the number of incontinent episodes on a 7-day bladder diary from the baseline evaluation to the final visit at 12-weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>Estimated enrollment: 100</P>
<P>Study start date: January 2014</P>
<P>Estimated study completion date: November 2015</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-09-14 13:24:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seckin-2011">
<CHAR_METHODS MODIFIED="2014-11-29 18:13:16 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:24:46 +0100" MODIFIED_BY="[Empty name]">
<P>Individuals with incontinence due to stress or OAB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-14 13:24:46 +0100" MODIFIED_BY="[Empty name]">
<P>Aerobic pelvic floor muscle exercise versus targeted Pilates exercise group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-29 18:13:46 +0000" MODIFIED_BY="[Empty name]">
<P>Change in SEAPI quality of life score from baseline</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-14 13:24:46 +0100" MODIFIED_BY="[Empty name]">
<P>Enrolment: 80</P>
<P>Poster only, minimal detail available</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-09-14 13:24:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wells-2014">
<CHAR_METHODS MODIFIED="2015-09-14 13:24:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-29 18:16:42 +0000" MODIFIED_BY="[Empty name]">
<P>Women with newly diagnosed OAB and history of caffeine consumption</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-14 13:24:54 +0100" MODIFIED_BY="[Empty name]">
<P>Group A: 14-day caffeinated drink period followed by a 14-day decaffeinated drink period<BR/>Group B: 14-day decaffeinated drink period followed by a 14-day caffeinated drink period (with a 14-day run-in period and 14-day wash-out period between group entry</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:24:54 +0100" MODIFIED_BY="[Empty name]">
<P>Episodes of urgency and frequency, volume per void and incontinence recorded in a 3-day diary</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-29 18:17:32 +0000" MODIFIED_BY="[Empty name]">
<P>Enrolment: 11</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviations</B>
</P>
<P>OAB: overactive bladder<BR/>POP-Q: Pelvic Organ Prolapse Quantification System<BR/>RCT: randomized controlled trial<BR/>SEAPI: stress-related leak (S), emptying ability (E), anatomy (A), protection (P), inhibition (I)<BR/>UI: urinary incontinence</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-09-14 13:25:08 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-09-14 13:25:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moholdt-2011">
<CHAR_STUDY_NAME MODIFIED="2013-07-30 11:06:48 +0100" MODIFIED_BY="[Empty name]">
<P>Exercise Training in Pregnancy (ETIP) for obese women</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-09-14 13:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>Design: randomised controlled trial with 2 parallel arms (intervention versus control)</P>
<P>Study centre: the Norwegian University of Science and Technology and the St Olav's Hospital, Trondheim University Hospital</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-14 13:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>150 previously sedentary, pregnant women with a pre-pregnancy BMI at or above 30 kg/m<SUP>²</SUP>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-14 13:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: organised exercise training 3 times per week</P>
<P>Control: standard antenatal care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-14 13:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>The main outcome measure will be weight gain from baseline to delivery</P>
<P>Secondary outcomes include incontinence</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-09-14 13:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>September 2010. Recruitment anticipated until the end of 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-09-14 17:01:33 +0100" MODIFIED_BY="[Empty name]">
<P>Trine T Moholdt, Department of Publich Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway. Email: trine.moholdt@ntnu.no</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-09-14 13:25:03 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviation</B>
</P>
<P>BMI: body mass index</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-09-14 13:21:26 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-09-14 13:21:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:04:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-2006b">
<DESCRIPTION>
<P>Quote: "Adaptive randomisation stratified by clinical centre"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:06:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bryant-2002">
<DESCRIPTION>
<P>Quote: "Patients were randomized by health record number to two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:09:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowd-1996">
<DESCRIPTION>
<P>Quote: "The women were assigned randomly"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:11:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashim-2008">
<DESCRIPTION>
<P>Quote: "randomized into one of the two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:13:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manonai-2006">
<DESCRIPTION>
<P>Quote: "The subjects were randomized into two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:14:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2007">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:16:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Phelan-2012">
<DESCRIPTION>
<P>Quote: "Partiicpants were randomly assigned within centers to the ILI [intensive lifestyle intervention] or the DSE [diabetes support and education] conditions with equal probability". "Randomisation is stratified by clinical center and blocked with random block sizes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:18:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subak-2005">
<DESCRIPTION>
<P>Quote: "The randomization codes were prepared by computer generated random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subak-2009">
<DESCRIPTION>
<P>Quote: "Randomization was performed with the use of randomly permuted blocks of three or six, stratified according to clinical center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:20:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swithinbank-2005">
<DESCRIPTION>
<P>Quote: "randomized in the order in which [participants] increased and decreased fluids"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:21:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wells-2011">
<DESCRIPTION>
<P>Quote: "&#8230; randomized &#8230; via random number generator"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 16:56:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2006b">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:06:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bryant-2002">
<DESCRIPTION>
<P>Quote: "Patients were randomized by health record number to two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 16:24:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowd-1996">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 16:47:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashim-2008">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-13 17:06:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manonai-2006">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:14:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2007">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-13 16:47:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Phelan-2012">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:18:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subak-2005">
<DESCRIPTION>
<P>Quote: "sealed, opaque envelopes numbered consecutively"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subak-2009">
<DESCRIPTION>
<P>Quote: "... random assignment [was] concealed in tamper-proof envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 17:03:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swithinbank-2005">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-13 17:06:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-2011">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-14 13:04:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brown-2006b">
<DESCRIPTION>
<P>Assignments to metformin and placebo were blinded but the lifestyle intervention was not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-14 13:06:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bryant-2002">
<DESCRIPTION>
<P>Not mentioned but unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 16:24:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dowd-1996">
<DESCRIPTION>
<P>Not mentioned but unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 16:47:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hashim-2008">
<DESCRIPTION>
<P>Not mentioned but unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-01 11:28:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manonai-2006">
<DESCRIPTION>
<P>Not mentioned but unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-14 13:14:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2007">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-14 13:16:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Phelan-2012">
<DESCRIPTION>
<P>Blinding of patient and personnel not mentioned but unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-14 13:19:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Subak-2005">
<DESCRIPTION>
<P>Quote: "Participants could not be blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Subak-2009">
<DESCRIPTION>
<P>Quote: "The participants were aware of their treatment assignment ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 17:04:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Swithinbank-2005">
<DESCRIPTION>
<P>Not mentioned but unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-13 17:06:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wells-2011">
<DESCRIPTION>
<P>Not mentioned but unlikely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-27 15:34:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2006b">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-14 13:06:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bryant-2002">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-31 16:24:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowd-1996">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-31 16:47:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashim-2008">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-14 13:13:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manonai-2006">
<DESCRIPTION>
<P>Pelvic examination and vaginal pH test were performed by the same examiner who was blinded, but these outcomes were not relevant to this review. No mention of blinded assessment for the outcomes specified in the review</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-14 13:14:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2007">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-14 13:16:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Phelan-2012">
<DESCRIPTION>
<P>Quote: "All measures were completed at baseline and 1 year by assessors who were masked to participant treatment group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-14 13:19:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subak-2005">
<DESCRIPTION>
<P>Quote: "... research investigators assessing outcomes and statistical analysts were blinded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subak-2009">
<DESCRIPTION>
<P>Quote: "... the staff members who collected the outcome data were not" aware of their treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-31 17:04:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swithinbank-2005">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-13 17:07:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-2011">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-09-14 13:21:26 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:04:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-2006b">
<DESCRIPTION>
<P>Of the 2191 women enrolled in the 3 arms of the DPP, 234 (11%) women with missing UI data were excluded from the analysis. The study stated that "women missing data on urinary incontinence did not differ in incident diabetes, mean weight change, or mean change in physical activity overall or within treatment groups compared with women with completed urinary incontinence data"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bryant-2002">
<DESCRIPTION>
<P>Data reported for 74 (78%) of 95 participants who completed the study. Reasons for withdrawal were reported but not separately for each group. The study states that caffeine levels did not differ between the completers and those who withdrew, but it is unclear if severity of incontinence differed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:09:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dowd-1996">
<DESCRIPTION>
<P>Data were presented for 32/58 (55%) of the women randomized who maintained the diaries for the entire study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-31 16:48:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hashim-2008">
<DESCRIPTION>
<P>No missing outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:13:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manonai-2006">
<DESCRIPTION>
<P>Data are presented for 36 (86%) of 42 women who completed the study. Reasons for withdrawals and drop-outs were described but their incontinence severity was unclear and it was also unclear at what time point the withdrawals/drop-out occurred</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:14:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2007">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:16:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Phelan-2012">
<DESCRIPTION>
<P>Of the 3063 women enrolled in the Look AHEAD trial, 69 (2%) women with no UI data at baseline were excluded from this sub-study. The 1-year follow-up rate was 93% (1385/1495) in the intervention group and 90% (1354/1499) for the control group.  Survey completers were more likely to be white and non-smokers. The implication for the incontinence outcome is unknown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:19:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subak-2005">
<DESCRIPTION>
<P>The analysis was "by intent to treat". The study states that the "40 women (83%) who completed the first 3 months of the trial were similar in demographic and clinical characteristics to the 8 women (17%) who did not complete the first 3 months of the trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subak-2009">
<DESCRIPTION>
<P>Quote: "Baseline variables, including age, race, parity, BMI, type of incontinence, frequency of incontinence episodes, and pad weight were not significantly associated with the retention of participants at 6 months". Also, multiple imputation methods were used for missing data</P>
<P>The study stated that "Participants who dropped out of the study had a higher number of baseline UI episodes than completers ... but dropouts in the intervention and control groups did not differ" (Wing 2010b)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:20:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swithinbank-2005">
<DESCRIPTION>
<P>Data not available for 15 (18%) of 84 participants enrolled. Reasons for this were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-09-14 13:21:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-2011">
<DESCRIPTION>
<P>14 randomized and 11 completed the follow-up (79%).  No further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-09-14 13:20:29 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:04:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2006b">
<DESCRIPTION>
<P>Insufficient information provided. The main outcome for this analysis was prevalence of incontinence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:06:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bryant-2002">
<DESCRIPTION>
<P>Insufficient information. Reported outcomes specified in the method section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:09:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dowd-1996">
<DESCRIPTION>
<P>Insufficient information provided. The only outcome reported was the number of incontinence episodes, but this was according to the study aim</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-21 17:55:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hashim-2008">
<DESCRIPTION>
<P>Insufficient information available. The study described what was measured by frequency/volume charts in the method section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manonai-2006">
<DESCRIPTION>
<P>Insufficient information available. Reported outcomes were specified in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:14:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-2007">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:16:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Phelan-2012">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:19:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Subak-2005">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Subak-2009">
<DESCRIPTION>
<P>Insufficient information available. Reported outcomes were specified in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:20:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swithinbank-2005">
<DESCRIPTION>
<P>Insufficient information available. Reported outcomes were specified in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-13 17:07:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-2011">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-09-14 13:21:26 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:04:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2006b">
<DESCRIPTION>
<P>The DPP trial was closed early after 2.9 years when lifestyle changes and metformin treatment had each reduced the incidence of diabetes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:06:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bryant-2002">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:09:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dowd-1996">
<DESCRIPTION>
<P>The study reported that adherence to the fluid manipulation was poor and made results difficult to interpret</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:11:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hashim-2008">
<DESCRIPTION>
<P>The study reported that participants had difficulty in adhering to the study protocol when they were asked either to increase or decrease fluids by 50%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:13:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manonai-2006">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:14:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Miller-2007">
<DESCRIPTION>
<P>The study author noted non-adherence to the protocol among study participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:17:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Phelan-2012">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:19:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Subak-2005">
<DESCRIPTION>
<P>Imbalance in age at baseline due to chance (P value = 0.006), the effect(s) on outcome are unknown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:19:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Subak-2009">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:20:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Swithinbank-2005">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-14 13:21:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wells-2011">
<DESCRIPTION>
<P>2 participants did not comply with caffeine substitution</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-11-20 13:00:22 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-11-20 12:59:57 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-09-14 13:25:18 +0100" MODIFIED_BY="[Empty name]">Weight loss compared to control for the treatment of urinary incontinence in adults</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Weight loss compared to control for the treatment of urinary incontinence in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with urinary incontinence<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> weight loss<BR/>
<B>Comparison: </B>control</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Weight loss</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by patient observation (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by patient observation (all UI types)</B>
<BR/>Follow-up: 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>544 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>762 per 1000</B>
<BR/>(621 to 931)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.4 </B>
<BR/>(1.14 to 1.71)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>304<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Condition-specific quality of life</B>
<BR/>Incontinence Impact Questionnaire. Scale from: 0 to 400. Better quality of life indicated by lower values.<BR/>Follow-up: 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The median condition-specific quality of life in the control groups was<BR/>
<B>89 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The median condition-specific quality of life in the intervention groups was<BR/>
<B>52 lower</B>
<BR/>(95% CI not estimable)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects</B>
<BR/>Follow-up: 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>The study reported that the intervention had 'few side effects'.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by symptom quantification (all UI types)</B>
<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>315 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>350 per 1000</B>
<BR/>(287 to 431)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.11 </B>
<BR/>(0.91 to 1.37)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>738<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by symptom quantification (all UI type)</B>
<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>325 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>393 per 1000</B>
<BR/>(332 to 468)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.21 </B>
<BR/>(1.02 to 1.44)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1032<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Prevalence of weekly UI (all UI type)</B>
<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>286 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>252 per 1000</B>
<BR/>(223 to 286)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.88 </B>
<BR/>(0.78 to 1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2739<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>UI:</B> urinary incontinence</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias: We downgraded the evidence by one level because blinding of participants and personnel was unlikely.<BR/>
<SUP>2</SUP> Indirectness: We downgraded the evidence by one level because of short follow-up &lt; 12 months<BR/>
<SUP>3</SUP> Risk of bias: We downgraded the evidence by one level because the authors did not report or provide a description of an allocation concealment method in one study (<LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>).<BR/>
<SUP>4</SUP> Missing outcome data in 7%-10% of the participants in one study (<LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>).<BR/>
<SUP>-</SUP> Indirectness: We downgraded the evidence by one level because data include a sub-study of a trial (<LINK REF="STD-Phelan-2012" TYPE="STUDY">Phelan 2012</LINK>) for diabetes that included continent as well as incontinent patients; only 27% had weekly urinary incontinence at baseline.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-09-14 13:27:06 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-09-14 13:26:50 +0100" MODIFIED_BY="[Empty name]">Soy-rich diet compared to control for the treatment of urinary incontinence in adults</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Soy-rich diet compared to control for the treatment of urinary incontinence in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with urinary incontinence<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> soy-rich diet<BR/>
<B>Comparison: </B>control</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Soy rich diet</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by patient observation (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by patient observation (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Condition-specific quality of life</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by symptom quantification (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by symptom quantification (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Incontinent episodes per week (all UI types) </B>- not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>UI:</B> urinary incontinence</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2015-11-20 13:00:08 +0000" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2015-09-14 13:27:13 +0100" MODIFIED_BY="[Empty name]">Decreasing fluids compared to increasing fluids for the treatment of urinary incontinence in adults</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Decreasing fluids compared to increasing fluids for the treatment of urinary incontinence in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with urinary incontinence<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> decreasing fluids<BR/>
<B>Comparison: </B>increasing fluids</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Increasing fluids</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Decreasing fluids</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by patient observation (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by patient observation (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Condition-specific quality of life</B>
<BR/>Follow-up: 1 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>69<BR/>(1 study<SUP>1</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,4,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Quality of life improved when fluid intake was decreased but the impact of incontinence on daily life did not differ significantly before or after the treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects</B>
<BR/>Follow-up: 1 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>93<BR/>(2 studies<SUP>1</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,5,6,7,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Reported adverse effects include constipation, thirst, headache and concentrated urine with decreasing fluids</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by symptom quantification (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by symptom quantification (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Incontinent episodes per week (all UI types)</B>
<BR/>Follow-up: 1-4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>125<BR/>(3 studies<SUP>9</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,5,6,8,10,11</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Decreasing fluid intake significantly reduced incontinent episodes in one study, no difference was found in another study and the results were inconclusive in the other study</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>UI:</B> urinary incontinence</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Randomised cross-over trial<BR/>
<SUP>2</SUP> Risk of bias: We downgraded the evidence by one level because blinding of participants, personnel and outcome assessors was probably not done and could introduce bias.<BR/>
<SUP>3</SUP> Risk of bias: We downgraded the evidence by one level because the authors did not report or provide a description of an allocation concealment method.<BR/>
<SUP>4</SUP> Missing outcome data in 18% of participants.<BR/>
<SUP>5</SUP> Indirectness: We downgraded the evidence by two levels because of short follow-up &lt; 12 months in all studies and because study participants included both continent and incontinent patients in one study (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>)<BR/>
<SUP>6</SUP> Imprecision: We downgraded the evidence by one level because confidence intervals for relative effect were not estimable.<BR/>
<SUP>7</SUP> Missing outcome data in 18% of participants in one study (<LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>), whereas the other study had no missing outcome data (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>).<BR/>
<SUP>8</SUP> Inconsistency: We downgraded the evidence by one level because becuse of heterogenous interventions.<BR/>
<SUP>9</SUP> One RCT compared increasing versus decreasing versus maintaining fluid intake (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>) and two randomized cross-over trials comparing increasing versus decreasing fluid intake (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>; <LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>).<BR/>
<SUP>10</SUP> Missing outcome data in 45% of participants in the RCT (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>), 18% of participants in a cross-over trial (<LINK REF="STD-Swithinbank-2005" TYPE="STUDY">Swithinbank 2005</LINK>), whereas the other cross-over trial had no missing outcome data (<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>).<BR/>
<SUP>11</SUP> Low adherence to the protocol was reported in two studies (<LINK REF="STD-Dowd-1996" TYPE="STUDY">Dowd 1996</LINK>;<LINK REF="STD-Hashim-2008" TYPE="STUDY">Hashim 2008</LINK>).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2015-11-20 13:00:15 +0000" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2015-09-14 13:27:54 +0100" MODIFIED_BY="[Empty name]">Caffeine reduction compared to control for the treatment of urinary incontinence in adults</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Caffeine reduction compared to control for the treatment of urinary incontinence in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with urinary incontinence<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> caffeine reduction<BR/>
<B>Comparison: </B>control</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Caffeine reduction</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by patient observation (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by patient observation (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Condition-specific quality of life</B>
<BR/>ICIQ Overactive Bladder Symptoms Quality of Life. Scale from: 25 to 160. Better quality of life indicated by lower values.<BR/>Follow-up: 2 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean condition-specific quality of life in the control groups was<BR/>
<B>68.36 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean condition-specific quality of life in the intervention groups was<BR/>
<B>14.45 lower</B>
<BR/>(95% CI not estimable)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>11<BR/>(1 study<SUP>1</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,4,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by symptom quantification (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by symptom quantification (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Incontinent episodes per day (all UI types)</B>
<BR/>Follow-up: 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean number of incontinent episodes per day (all UI types) in the control groups was<BR/>
<B>1.4 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean number of incontinent episodes per day (all UI types) in the intervention groups was<BR/>
<B>0.2 lower</B>
<BR/>(1.02 lower to 0.62 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>74<BR/>(1 study<SUP>7</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,4,5,6,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Randomised cross-over trial; feasibility study.<BR/>
<SUP>2</SUP> Risk of bias: We downgraded the evidence by one level because blinding of participants, personnel and outcome assessors was probably not done.<BR/>
<SUP>3</SUP> Risk of bias: We downgraded the evidence by one level because the authors did not report or provide a description of an allocation concealment method.<BR/>
<SUP>4</SUP> Missing outcome data in &gt; 20% of participants.<BR/>
<SUP>5</SUP> Indirectness: We downgraded the evidence by two levels because of short follow-up &lt; 12 months and because study participants included both continent and incontinent patients.<BR/>
<SUP>6</SUP> Imprecision: We downgraded the evidence by one level because confidence intervals for relative effect were not estimable.<BR/>
<SUP>7</SUP> A quasi-randomised controlled trial based on health record numbers.<BR/>
<SUP>8</SUP> Risk of bias: We downgraded the evidence by one level because allocation concealment was inadequate (quasi-randomisation based on health record numbers).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2015-11-20 13:00:22 +0000" MODIFIED_BY="[Empty name]" NO="5" READONLY="YES">
<TITLE MODIFIED="2015-09-14 13:28:34 +0100" MODIFIED_BY="[Empty name]">Lifestyle weight loss compared to metformin weight loss for the treatment of urinary incontinence in adults</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Lifestyle weight loss compared to metformin weight loss for the treatment of urinary incontinence in adults</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> adults with urinary incontinence<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> lifestyle weight loss<BR/>
<B>Comparison: </B>metformin weight loss</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Metformin weight loss</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Lifestyle weight loss</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by patient observation (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by patient observation (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Condition-specific quality of life</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Cure rates by symptom quantification (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement rates by symptom quantification (all UI types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Prevalence of weekly UI (all UI types)</B>
<BR/>Follow-up: mean 2.8 years</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>482 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>381 per 1000</B>
<BR/>(337 to 434)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.79 </B>
<BR/>(0.7 to 0.9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1294<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias: We downgraded the evidence by one level because blinding of participants, personnel and outcome assessors was not mentioned and may introduce bias.<BR/>
<SUP>2</SUP> Risk of bias: We downgraded the evidence by one level because the authors did not report or provide a description of an allocation concealment method.<BR/>
<SUP>3</SUP> Missing outcome data in 11% of participants.
<BR/>
<SUP>4</SUP> Indirectness: We downgraded the evidence by one level because data come from a sub-study of a trial (Brown 2006) for diabetes that included continent as well as incontinent patients.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-06-19 12:45:22 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-11-20 13:04:13 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-10-12 11:55:29 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Weight loss versus no active intervention</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="163" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-09-14 13:51:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="279.02" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="214" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>Improvement rates based on women's perception (all types UI)</NAME>
<GROUP_LABEL_1>Weight loss</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weight loss</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="163" EVENTS_2="49" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-06 14:01:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="214" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="1.71440001097809" CI_START="1.1416378529417714" EFFECT_SIZE="1.3990082014114056" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="49" LOG_CI_END="0.2341121608147591" LOG_CI_START="0.0575283601163972" LOG_EFFECT_SIZE="0.14582026046557817" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.10372619863412859" STUDY_ID="STD-Subak-2009" TOTAL_1="214" TOTAL_2="90" VAR="0.0107591242830867" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-001.02" MODIFIED="2015-09-14 13:51:58 +0100" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Improvement rates based on women's perception (all types UI)</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Weight loss<BR/>(
number<BR/>improved)</P>
</TH>
<TH>
<P>Weight loss<BR/>(t
otal N)</P>
</TH>
<TH>
<P>Weight loss<BR/>(%)</P>
</TH>
<TH>
<P>Control<BR/>(
number<BR/>improved)</P>
</TH>
<TH>
<P>Control<BR/>(t
otal N)</P>
</TH>
<TH>
<P>Control<BR/>(%)</P>
</TH>
<TH>
<P>Reported 
P value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-06-14 16:58:31 +0100" MODIFIED_BY="[Empty name]" ORDER="2" STUDY_ID="STD-Subak-2009">
<TR>
<TD>
<P>At 12 months (N = 298)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>0.2</P>
</TD>
</TR>
<TR>
<TD>
<P>At 18 months (N = 291)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>0.02</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-001.03" MODIFIED="2015-10-12 11:52:19 +0100" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Quality of life and symptom scores</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Weight loss (total N)</P>
</TH>
<TH>
<P>Weight loss, median (IQR)<BR/>
</P>
</TH>
<TH>
<P>Control (total N)</P>
</TH>
<TH>
<P>Control, median (IQR)</P>
</TH>
<TH>
<P>Reported P value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-10-12 11:52:19 +0100" MODIFIED_BY="[Empty name]" ORDER="3" STUDY_ID="STD-Subak-2005">
<TR>
<TD>
<P>3 months</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>Incontinence Impact Questionnaire (score range 0-400 with lower score indicating better quality of life)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>37 (11 to 86)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>89 (56 to 136)</P>
</TD>
<TD>
<P>0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Urogenital Distress Inventory (score range 0-300 with lower scores indicating less distress)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>104 (67 to 122)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>195 (156 to 228)</P>
</TD>
<TD>
<P>&lt;0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 physical component (higher scores indicate better quality of life)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>55 (49 to 58)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>47 (41 to 50)</P>
</TD>
<TD>
<P>0.003</P>
</TD>
</TR>
<TR>
<TD>
<P>SF-36 mental component (higher scores indicate better quality of life)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>48 (46 to 49)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>51 (48 to 54)</P>
</TD>
<TD>
<P>0.09</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="150" EVENTS_2="118" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-09-14 13:52:10 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="198.66" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="609" TOTAL_2="473" WEIGHT="0.0" Z="0.0">
<NAME>Cure rates based on quantification of symptoms (all types UI)</NAME>
<GROUP_LABEL_1>Weight loss</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weight loss</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="140.03244580468458" CI_START="0.42340187418205144" EFFECT_SIZE="7.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1462286742592993" LOG_CI_START="-0.3732472239143358" LOG_EFFECT_SIZE="0.8864907251724818" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="1.479952614194029" STUDY_ID="STD-Subak-2005" TOTAL_1="19" TOTAL_2="21" VAR="2.1902597402597404" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="4" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="214" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="4.621337053673603" CI_START="0.5382107439192496" EFFECT_SIZE="1.5771028037383177" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.6647676446088033" LOG_CI_START="-0.2690476369730975" LOG_EFFECT_SIZE="0.19786000381785288" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.5485277188614025" STUDY_ID="STD-Subak-2009" TOTAL_1="214" TOTAL_2="90" VAR="0.30088265835929384" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="132" EVENTS_2="114" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="376" TOTAL_2="362" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="1.3682406437736634" CI_START="0.9082745051107617" EFFECT_SIZE="1.1147816349384099" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="114" LOG_CI_END="0.13616248705655817" LOG_CI_START="-0.04178287610679432" LOG_EFFECT_SIZE="0.047189805474881934" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.104525987165907" STUDY_ID="STD-Phelan-2012" TOTAL_1="376" TOTAL_2="362" VAR="0.010925681993007353" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-001.05" MODIFIED="2015-10-12 11:52:53 +0100" MODIFIED_BY="[Empty name]" NO="5" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Cure rates based on quantification of symptoms (by type of UI)</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Weight loss (number<BR/>cured)</P>
</TH>
<TH>
<P>Weight loss<BR/>(total N)</P>
</TH>
<TH>
<P>Weight loss (%)</P>
</TH>
<TH>
<P>Control (number<BR/>cured)</P>
</TH>
<TH>
<P>Control (total N)</P>
</TH>
<TH>
<P>Control (%)</P>
</TH>
<TH>
<P>Reported P value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-07-28 23:33:03 +0100" MODIFIED_BY="[Empty name]" ORDER="7" STUDY_ID="STD-Subak-2009">
<TR>
<TD>
<P>Stress UI at 6 months</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0.004</P>
</TD>
</TR>
<TR>
<TD>
<P>Urgency UI at 6 months</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>0.02</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="9.168398133606615" CI_END="1.5001561799314218" CI_START="1.1345203142656184" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.304590993646402" ESTIMABLE="YES" EVENTS_1="420" EVENTS_2="202" I2="56.3718771620741" I2_Q="57.41338348773439" ID="CMP-001.06" LOG_CI_END="0.17613647542335936" LOG_CI_START="0.05481227659334489" LOG_EFFECT_SIZE="0.11547437600835216" METHOD="MH" MODIFIED="2015-09-14 13:52:22 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.05702551521108201" P_Q="0.07049398320172029" P_Z="1.907795789734327E-4" Q="7.04446665570615" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1013" TOTAL_2="650" WEIGHT="400.0" Z="3.7309229369931005">
<NAME>Improvement rates based on quantification of symptoms (all types UI)</NAME>
<GROUP_LABEL_1>Weight loss</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weight loss</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="270.7763193227633" CI_START="1.005442428203923" DF="0" EFFECT_SIZE="16.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="2.432610680555397" LOG_CI_START="0.002357207872415619" LOG_EFFECT_SIZE="1.2174839442139063" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.049557224019745945" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="21" WEIGHT="100.0" Z="1.9637660920863989">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="270.7763193227633" CI_START="1.005442428203923" EFFECT_SIZE="16.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.432610680555397" LOG_CI_START="0.002357207872415619" LOG_EFFECT_SIZE="1.2174839442139063" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="1.4275429198026894" STUDY_ID="STD-Subak-2005" TOTAL_1="19" TOTAL_2="21" VAR="2.037878787878788" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.811950784469286" CI_START="1.217741508576428" DF="0" EFFECT_SIZE="1.8504672897196262" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="20" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.4490077152736544" LOG_CI_START="0.0855551098789885" LOG_EFFECT_SIZE="0.2672814125763215" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.003942859893810099" STUDIES="1" TAU2="0.0" TOTAL_1="214" TOTAL_2="90" WEIGHT="100.0" Z="2.882697411497326">
<NAME>At 6 months</NAME>
<DICH_DATA CI_END="2.811950784469286" CI_START="1.217741508576428" EFFECT_SIZE="1.8504672897196262" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="20" LOG_CI_END="0.4490077152736544" LOG_CI_START="0.0855551098789885" LOG_EFFECT_SIZE="0.2672814125763215" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.2134938595282393" STUDY_ID="STD-Subak-2009" TOTAL_1="214" TOTAL_2="90" VAR="0.045579628056263574" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.814040173971815" CI_END="1.435426780929816" CI_START="1.01850911538621" DF="1" EFFECT_SIZE="1.2091299602799122" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="146" I2="44.87442922443584" ID="CMP-001.06.03" LOG_CI_END="0.15698104465618293" LOG_CI_START="0.007964920173901576" LOG_EFFECT_SIZE="0.08247298241504224" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.17802448621388545" P_Z="0.030045930990898403" STUDIES="2" TAU2="0.0" TOTAL_1="583" TOTAL_2="449" WEIGHT="100.0" Z="2.1694843533567822">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="1.3704172720904315" CI_START="0.9228355266003179" EFFECT_SIZE="1.1245753620597174" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="119" LOG_CI_END="0.1368528236339679" LOG_CI_START="-0.03487569469983001" LOG_EFFECT_SIZE="0.050988564467068946" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.10087418173914837" STUDY_ID="STD-Phelan-2012" TOTAL_1="376" TOTAL_2="362" VAR="0.010175600541542736" WEIGHT="76.12950852858586"/>
<DICH_DATA CI_END="2.0909944931938473" CI_START="1.0458384572111776" EFFECT_SIZE="1.478797638217928" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="27" LOG_CI_END="0.3203528890689037" LOG_CI_START="0.019464607514218645" LOG_EFFECT_SIZE="0.1699087482915612" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.17674326600623674" STUDY_ID="STD-Subak-2009" TOTAL_1="207" TOTAL_2="87" VAR="0.031238182078551363" WEIGHT="23.870491471414145"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5503183105285276" CI_START="0.8602198764064284" DF="0" EFFECT_SIZE="1.1548223350253808" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="36" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="0.1904208764369795" LOG_CI_START="-0.06539052677390284" LOG_EFFECT_SIZE="0.06251517483153832" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3380870994858056" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="90" WEIGHT="100.0" Z="0.9579517536677785">
<NAME>At 18 months</NAME>
<DICH_DATA CI_END="1.5503183105285276" CI_START="0.8602198764064284" EFFECT_SIZE="1.1548223350253808" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="36" LOG_CI_END="0.1904208764369795" LOG_CI_START="-0.06539052677390284" LOG_EFFECT_SIZE="0.06251517483153832" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.15026488453294057" STUDY_ID="STD-Subak-2009" TOTAL_1="197" TOTAL_2="90" VAR="0.022579535523697958" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="8" ID="CMP-001.07" MODIFIED="2015-10-12 11:53:13 +0100" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Improvement rates based on quantification of symptoms (by type of UI)</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Weight loss<BR/>(number<BR/>cured)</P>
</TH>
<TH>
<P>Weight loss<BR/>(total)</P>
</TH>
<TH>
<P>Weight loss<BR/>(%)</P>
</TH>
<TH>
<P>Control<BR/>(number<BR/>cured)</P>
</TH>
<TH>
<P>Control<BR/>(total)</P>
</TH>
<TH>
<P>Control<BR/>(%)</P>
</TH>
<TH>
<P>Reported P value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-07-28 23:33:16 +0100" MODIFIED_BY="[Empty name]" ORDER="13" STUDY_ID="STD-Subak-2009">
<TR>
<TD>
<P>Stress UI at 6 months</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Urgency UI at 6 months</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>0.04</P>
</TD>
</TR>
<TR>
<TD>
<P>Stress UI at 6 months</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>51</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Urgency UI at 6 months</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>0.04</P>
</TD>
</TR>
<TR>
<TD>
<P>Stress UI at 18 months</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>0.92</P>
</TD>
</TR>
<TR>
<TD>
<P>Urgency UI at 18 months</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>0.03</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="602" EVENTS_2="689" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-09-14 13:52:32 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.65" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2044" TOTAL_2="2014" WEIGHT="0.0" Z="0.0">
<NAME>Prevalence of weekly urinary incontinence after intervention (all types UI)</NAME>
<GROUP_LABEL_1>Weight loss</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weight loss</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="350" EVENTS_2="387" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-14 21:24:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1385" TOTAL_2="1354" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<DICH_DATA CI_END="1.0005288702734196" CI_START="0.7813080803382102" EFFECT_SIZE="0.8841500387130476" ESTIMABLE="YES" EVENTS_1="350" EVENTS_2="387" LOG_CI_END="2.2962472589385465E-4" LOG_CI_START="-0.10717768416584914" LOG_EFFECT_SIZE="-0.05347402971997764" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.06309158491776355" STUDY_ID="STD-Phelan-2012" TOTAL_1="1385" TOTAL_2="1354" VAR="0.00398054808743537" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="252" EVENTS_2="302" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-14 21:25:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="659" TOTAL_2="660" WEIGHT="0.0" Z="0.0">
<NAME>At 2.8 years</NAME>
<DICH_DATA CI_END="0.9495623664171218" CI_START="0.7354967253451883" EFFECT_SIZE="0.8357033032188044" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="302" LOG_CI_END="-0.02247650591240829" LOG_CI_START="-0.13341925654308714" LOG_EFFECT_SIZE="-0.0779478812277477" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.06516832089593333" STUDY_ID="STD-Brown-2006b" TOTAL_1="659" TOTAL_2="660" VAR="0.00424691004839534" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="9" ID="CMP-001.09" MODIFIED="2015-10-12 11:53:42 +0100" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Prevalence of weekly urinary incontinence after intervention (by type of UI)</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Weight loss (number<BR/>with UI)</P>
</TH>
<TH>
<P>Weight loss (total N)</P>
</TH>
<TH>
<P>Weight loss (%)</P>
</TH>
<TH>
<P>Control (number<BR/>with UI)</P>
</TH>
<TH>
<P>Control (total N)</P>
</TH>
<TH>
<P>Control (%)</P>
</TH>
<TH>
<P>Reported P value</P>
</TH>
<TH>
<P>Reported adjusted odds ratio (95% CI)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-10-12 11:53:36 +0100" MODIFIED_BY="[Empty name]" ORDER="16" STUDY_ID="STD-Brown-2006b">
<TR>
<TD>
<P>SUI at 2.8 years</P>
</TD>
<TD>
<P>206</P>
</TD>
<TD>
<P>659</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>242</P>
</TD>
<TD>
<P>660</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>0.04</P>
</TD>
<TD>
<P>0.80 (0.64 to 1.01)</P>
</TD>
</TR>
<TR>
<TD>
<P>UUI at 2.8 years</P>
</TD>
<TD>
<P>156</P>
</TD>
<TD>
<P>659</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>169</P>
</TD>
<TD>
<P>660</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>0.41</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-10-12 11:53:42 +0100" MODIFIED_BY="[Empty name]" ORDER="17" STUDY_ID="STD-Phelan-2012">
<TR>
<TD>
<P>SUI at 1 year</P>
</TD>
<TD>
<P>145</P>
</TD>
<TD>
<P>1385</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>173</P>
</TD>
<TD>
<P>1354</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>0.07</P>
</TD>
<TD>
<P>0.73 (0.55 to 0.96)</P>
</TD>
</TR>
<TR>
<TD>
<P>UUI at 1 year</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>0.93 (0.70 to 1.23)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2015-08-26 08:35:56 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="618" TOTAL_2="267" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Incontinent episodes per week (% change from baseline; all UI types)</NAME>
<GROUP_LABEL_1>Weight loss</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weight loss</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.01" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="214" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>At 6 months</NAME>
<CONT_DATA CI_END="-4.409575574580881" CI_START="-33.590424425419116" EFFECT_SIZE="-19.0" ESTIMABLE="YES" MEAN_1="-47.0" MEAN_2="-28.0" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="31" SD_1="51.9496" SD_2="62.0685" SE="7.444230884090996" STUDY_ID="STD-Subak-2009" TOTAL_1="214" TOTAL_2="90" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.02" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="207" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>At 12 months</NAME>
<CONT_DATA CI_END="0.37729634130703715" CI_START="-24.377296341307037" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="-57.0" MEAN_2="-45.0" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="32" SD_1="43.7854" SD_2="51.612" SE="6.315063153679135" STUDY_ID="STD-Subak-2009" TOTAL_1="207" TOTAL_2="87" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.03" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="90" WEIGHT="0.0" Z="0.0">
<NAME>At 18 months</NAME>
<CONT_DATA CI_END="4.044971733652636" CI_START="-18.044971733652638" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="-62.0" MEAN_2="-55.0" MODIFIED="2014-06-06 13:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="35.5848" SD_2="47.745" SE="5.635293209861999" STUDY_ID="STD-Subak-2009" TOTAL_1="197" TOTAL_2="90" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="6" ID="CMP-001.11" MODIFIED="2015-10-12 11:55:29 +0100" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="9" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Incontinence episodes per week (% change from baseline; by type of UI)</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Weight loss (total N)</P>
</TH>
<TH>
<P>Weight loss<BR/>(% change from baseline)</P>
</TH>
<TH>
<P>Control (total N)</P>
</TH>
<TH>
<P>Control (% change from baseline)</P>
</TH>
<TH>
<P>Reported P value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-10-12 11:55:14 +0100" MODIFIED_BY="[Empty name]" ORDER="21" STUDY_ID="STD-Subak-2005">
<TR>
<TD>
<P>All UI at 3 months, median (IQR)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>-60 (-89 to -30)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>-15 (-25 to 9)</P>
</TD>
<TD>
<P>0.0005</P>
</TD>
</TR>
<TR>
<TD>
<P>Stress UI at 3 months, median (IQR)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>-92 (-100 to -66)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>5 (-63 to 33)</P>
</TD>
<TD>
<P>0.003</P>
</TD>
</TR>
<TR>
<TD>
<P>Urgency UI at 3 months, median (IQR)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>-70 (-100 to -16)</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>-11 (-67 to 69)</P>
</TD>
<TD>
<P>0.03</P>
</TD>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2015-10-12 11:55:29 +0100" MODIFIED_BY="[Empty name]" ORDER="22" STUDY_ID="STD-Subak-2009">
<TR>
<TD>
<P>All UI at 6 months, mean (95% CI)</P>
</TD>
<TD>
<P>214</P>
</TD>
<TD>
<P>-47 (-54 to -40)</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>-28 (-41 to -13)</P>
</TD>
<TD>
<P>0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>Stress UI at 6 months, mean (95% CI)</P>
</TD>
<TD>
<P>214</P>
</TD>
<TD>
<P>-58 (-67 to -46)</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>-33 (-50 to -9)</P>
</TD>
<TD>
<P>0.02</P>
</TD>
</TR>
<TR>
<TD>
<P>Urgency UI at 6 months, mean (95% CI)</P>
</TD>
<TD>
<P>214</P>
</TD>
<TD>
<P>-42 (-51 to -32)</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>-26 (-44 to -3)</P>
</TD>
<TD>
<P>0.14</P>
</TD>
</TR>
<TR>
<TD>
<P>All UI at 12 months, mean (95% CI)</P>
</TD>
<TD>
<P>207</P>
</TD>
<TD>
<P>-57 (-63 to -50)</P>
</TD>
<TD>
<P>87</P>
</TD>
<TD>
<P>-45 (-56 to -32)</P>
</TD>
<TD>
<P>0.08</P>
</TD>
</TR>
<TR>
<TD>
<P>Stress UI at 12 months, mean (95% CI)</P>
</TD>
<TD>
<P>207</P>
</TD>
<TD>
<P>-66 (-71 to -59)</P>
</TD>
<TD>
<P>87</P>
</TD>
<TD>
<P>-45 (-59 to -27)</P>
</TD>
<TD>
<P>&lt;0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>Urgency UI at 12 months, mean (95% CI)</P>
</TD>
<TD>
<P>207</P>
</TD>
<TD>
<P>-50 (-59 to -39)</P>
</TD>
<TD>
<P>87</P>
</TD>
<TD>
<P>-48 (-63 to -29)</P>
</TD>
<TD>
<P>0.87</P>
</TD>
</TR>
<TR>
<TD>
<P>All UI at 18 months, mean (95% CI)</P>
</TD>
<TD>
<P>197</P>
</TD>
<TD>
<P>-62 (-67 to -55)</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>-55 (-65 to -43)</P>
</TD>
<TD>
<P>0.3</P>
</TD>
</TR>
<TR>
<TD>
<P>Stress UI at 18 months, mean (95% CI)</P>
</TD>
<TD>
<P>197</P>
</TD>
<TD>
<P>-69 (-76 to -61)</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>-62 (-73 to -48)</P>
</TD>
<TD>
<P>0.32</P>
</TD>
</TR>
<TR>
<TD>
<P>Urgency UI at 18 months, mean (95% CI)</P>
</TD>
<TD>
<P>197</P>
</TD>
<TD>
<P>-56 (-64 to -46)</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>-49 (-64 to -28)</P>
</TD>
<TD>
<P>0.46</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-09-14 13:52:54 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Soy-rich diet versus control</NAME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.01" MODIFIED="2015-09-14 13:52:44 +0100" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of women with UI episodes: soy-rich diet versus control</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Soy-rich diet (n/N)
</P>
</TH>
<TH>
<P>Soy-rich diet (%)
</P>
</TH>
<TH>
<P>

Control diet (n/N)
</P>
</TH>
<TH>
<P>Control diet (%)
</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-06-29 22:41:27 +0100" MODIFIED_BY="[Empty name]" ORDER="23" STUDY_ID="STD-Manonai-2006">
<TR>
<TD>
<P>SUI episodes: before (baseline)</P>
</TD>
<TD>
<P>22/36</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>23/36</P>
</TD>
<TD>
<P>63</P>
</TD>
</TR>
<TR>
<TD>
<P>SUI episodes: after</P>
</TD>
<TD>
<P>22/36</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>18/36</P>
</TD>
<TD>
<P>51</P>
</TD>
</TR>
<TR>
<TD>
<P>UUI episodes: before (baseline)</P>
</TD>
<TD>
<P>7/36</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>4/36</P>
</TD>
<TD>
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>UUI episodes: after</P>
</TD>
<TD>
<P>6/36</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>8/36</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-002.02" MODIFIED="2015-09-14 13:52:54 +0100" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mean UI symptom scores (SD; 0 = none, 1 = mild, 2 = moderate, 3 = severe): soy-rich diet versus control</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Soy-rich diet (n = 36)</P>
</TH>
<TH>
<P>Soy-rich diet (n = 36)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-09-04 10:57:28 +0100" MODIFIED_BY="[Empty name]" ORDER="24" STUDY_ID="STD-Manonai-2006">
<TR>
<TD>
<P>SUI episodes: before (baseline)</P>
</TD>
<TD>
<P>0.67 (0.68)</P>
</TD>
<TD>
<P>0.75 (0.65)</P>
</TD>
</TR>
<TR>
<TD>
<P>SUI episodes: after</P>
</TD>
<TD>
<P>0.72 (0.66)</P>
</TD>
<TD>
<P>0.72 (0.74)</P>
</TD>
</TR>
<TR>
<TD>
<P>Reported 
P value</P>
</TD>
<TD>
<P>&gt; 0.05</P>
</TD>
<TD>
<P>&gt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>UUI episodes: before (baseline)</P>
</TD>
<TD>
<P>0.17 (0.38)</P>
</TD>
<TD>
<P>0.14 (0.35)</P>
</TD>
</TR>
<TR>
<TD>
<P>UUI episodes: after</P>
</TD>
<TD>
<P>0.19 (0.47)</P>
</TD>
<TD>
<P>0.25 (0.50)</P>
</TD>
</TR>
<TR>
<TD>
<P>Reported 
P value</P>
</TD>
<TD>
<P>&gt; 0.05</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-11-20 13:04:13 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Increase in fluid intake versus decrease in fluid intake</NAME>
<OTHER_OUTCOME COLS="5" ID="CMP-003.01" MODIFIED="2015-10-12 11:55:56 +0100" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Median number of daily UI episodes (IQR)</NAME>
<TR>
<TH>
<P>Type of UI</P>
</TH>
<TH>
<P>Baseline</P>
</TH>
<TH>
<P>Caffeine-free baseline</P>
</TH>
<TH>
<P>Caffeine-free<BR/>and increasing fluids</P>
</TH>
<TH>
<P>Caffeine-free<BR/>and decreasing fluids</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-10-12 11:55:56 +0100" MODIFIED_BY="[Empty name]" ORDER="25" STUDY_ID="STD-Swithinbank-2005">
<TR>
<TD>
<P>Urodynamic stress incontinence (SUI), n = 39</P>
</TD>
<TD>
<P>1.6 (0.6 to 2.8)</P>
</TD>
<TD>
<P>0.8 (0.1 to 1.9)</P>
</TD>
<TD>
<P>0.7 (0.3 to 3)</P>
</TD>
<TD>
<P>0.5 (0.2 to 2.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>Idiopathic detrusor overactivity (IDO), n = 30</P>
</TD>
<TD>
<P>0.9 (0.4 to 2)</P>
</TD>
<TD>
<P>0.6 (0.2 to 1.8)</P>
</TD>
<TD>
<P>1.1 (0.2 to 3)</P>
</TD>
<TD>
<P>0.5 (0.2 to 1.2)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.02" MODIFIED="2015-11-20 13:04:13 +0000" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Median number of daily UI episodes (range)</NAME>
<TR>
<TH>
<P>Randomised group</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Median (range)</P>
</TH>
<TH>
<P>Reported P value<BR/>compared with baseline</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-10-12 11:56:22 +0100" MODIFIED_BY="[Empty name]" ORDER="26" STUDY_ID="STD-Hashim-2008">
<TR>
<TD>
<P>Baseline</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>0 (0, 4.8)</P>
</TD>
<TD/>
</TR>
<TR>
<TD>
<P>25% less fluid</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>0 (0, 5.5)</P>
</TD>
<TD>
<P>1.0</P>
</TD>
</TR>
<TR>
<TD>
<P>50% less fluid</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0 (0, 4.5)</P>
</TD>
<TD>
<P>0.69</P>
</TD>
</TR>
<TR>
<TD>
<P>25% more fluid</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>0 (0, 10.3)</P>
</TD>
<TD>
<P>1.00</P>
</TD>
</TR>
<TR>
<TD>
<P>50% more fluid</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>0 (0, 12.8)</P>
</TD>
<TD>
<P>0.69</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-003.03" MODIFIED="2015-10-12 11:48:53 +0100" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mean number of daily UI episodes (any UI)</NAME>
<TR>
<TH>
<P>Time period</P>
</TH>
<TH>
<P>Maintain fluid<BR/>(N = 14)</P>
</TH>
<TH>
<P>Increase fluid (N = 10)</P>
</TH>
<TH>
<P>Decrease fluid (N = 8)</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-06-06 16:06:28 +0100" MODIFIED_BY="[Empty name]" ORDER="27" STUDY_ID="STD-Dowd-1996">
<TR>
<TD>
<P>Week 1 (baseline)</P>
</TD>
<TD>
<P>0.48</P>
</TD>
<TD>
<P>0.6</P>
</TD>
<TD>
<P>0.54</P>
</TD>
</TR>
<TR>
<TD>
<P>Week 2</P>
</TD>
<TD>
<P>0.71</P>
</TD>
<TD>
<P>0.61</P>
</TD>
<TD>
<P>0.26</P>
</TD>
</TR>
<TR>
<TD>
<P>Week 3</P>
</TD>
<TD>
<P>0.81</P>
</TD>
<TD>
<P>0.67</P>
</TD>
<TD>
<P>0.17</P>
</TD>
</TR>
<TR>
<TD>
<P>Week 4</P>
</TD>
<TD>
<P>0.57</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>0.14</P>
</TD>
</TR>
<TR>
<TD>
<P>Week 5</P>
</TD>
<TD>
<P>0.48</P>
</TD>
<TD>
<P>0.55</P>
</TD>
<TD>
<P>0.07</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-10-12 11:57:05 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Caffeine reduction versus control</NAME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.01" MODIFIED="2015-10-12 11:57:05 +0100" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mean quality of life scores</NAME>
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Caffeine substitution</P>
</TH>
<TH>
<P>Caffeine exposure</P>
</TH>
<TH>
<P>Reported<BR/>P value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2015-10-12 11:57:05 +0100" MODIFIED_BY="[Empty name]" ORDER="28" STUDY_ID="STD-Wells-2011">
<TR>
<TD>
<P>ICIQ Overactive Bladder (ICIQ-OAB) total score (N = 11);</P>
<P>0-16 overall score with greater values indicating increased symptom severity</P>
</TD>
<TD>
<P>4.64</P>
</TD>
<TD>
<P>6.55</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>ICIQ Overactive Bladder Symptoms Quality of Life (ICIQ-OABqol) score (N = 11); 25-160 overall score with greater values indicating increased impact on quality of life</P>
</TD>
<TD/>
<TD/>
<TD/>
</TR>
<TR>
<TD>
<P>1) How regularly bladder symptoms interfered with the ability to get a good night's rest</P>
</TD>
<TD>
<P>2.64</P>
</TD>
<TD>
<P>4.09</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>2) How often bladder symptoms caused anxiety or worry</P>
</TD>
<TD>
<P>1.73</P>
</TD>
<TD>
<P>2.64</P>
</TD>
<TD>
<P>&lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>3) How much bladder symptoms interfered with everyday life overall</P>
</TD>
<TD>
<P>3.73</P>
</TD>
<TD>
<P>5.64</P>
</TD>
<TD>
<P>&lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>4) Total scores for the ICIQ-OABqol</P>
</TD>
<TD>
<P>53.91</P>
</TD>
<TD>
<P>68.36</P>
</TD>
<TD>
<P>0.065</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2015-10-12 11:50:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="38" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean number of UI episodes per 24 hours (SD)</NAME>
<GROUP_LABEL_1>Reduced caffeine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours reduced caffeine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6230224823053122" CI_START="-1.0230224823053122" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.4" MODIFIED="2014-06-06 15:48:05 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="1.9" SD_2="1.7" SE="0.4199171458237031" STUDY_ID="STD-Bryant-2002" TOTAL_1="36" TOTAL_2="38" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-09-14 13:55:08 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Lifestyle weight loss versus metformin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="614" EVENTS_2="740" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-09-14 13:55:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1977" TOTAL_2="1905" WEIGHT="0.0" Z="0.0">
<NAME>Prevalence of weekly UI after intervention</NAME>
<GROUP_LABEL_1>Lifestyle weight loss</GROUP_LABEL_1>
<GROUP_LABEL_2>Metformin weight loss</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lifestyle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metformin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="252" EVENTS_2="306" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-14 18:46:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="659" TOTAL_2="635" WEIGHT="0.0" Z="0.0">
<NAME>All UI types at 2.8 years</NAME>
<DICH_DATA CI_END="0.9002485336956079" CI_START="0.6994753710415326" EFFECT_SIZE="0.7935374453271445" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="306" LOG_CI_END="-0.045637577325102395" LOG_CI_START="-0.15522757267903775" LOG_EFFECT_SIZE="-0.10043257500207008" MODIFIED="2014-06-06 16:10:00 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.0643737057501276" STUDY_ID="STD-Brown-2006b" TOTAL_1="659" TOTAL_2="635" VAR="0.004143973992004012" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="206" EVENTS_2="252" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-14 20:47:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="659" TOTAL_2="635" WEIGHT="0.0" Z="0.0">
<NAME>Stress UI at 2.8 years</NAME>
<DICH_DATA CI_END="0.9136718975125339" CI_START="0.6790780820269426" EFFECT_SIZE="0.7876893802538719" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="252" LOG_CI_END="-0.03920973280184277" LOG_CI_START="-0.16808028662700703" LOG_EFFECT_SIZE="-0.10364500971442488" MODIFIED="2014-06-06 16:17:47 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.07569920123643113" STUDY_ID="STD-Brown-2006b" TOTAL_1="659" TOTAL_2="635" VAR="0.005730369067833696" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="156" EVENTS_2="182" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-07-28 23:35:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="659" TOTAL_2="635" WEIGHT="0.0" Z="0.0">
<NAME>Urgency UI at 2.8 years</NAME>
<DICH_DATA CI_END="0.9927685980927022" CI_START="0.6871238299369534" EFFECT_SIZE="0.8259267288098852" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="182" LOG_CI_END="-0.003151968304998004" LOG_CI_START="-0.1629649895602967" LOG_EFFECT_SIZE="-0.08305847893264737" MODIFIED="2014-06-06 16:17:59 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.09387495977257619" STUDY_ID="STD-Brown-2006b" TOTAL_1="659" TOTAL_2="635" VAR="0.008812508072302798" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-09-14 15:54:41 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-09-14 15:54:41 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA study flow diagram
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAhQAAASXCAYAAAC5juapAACAAElEQVR42uydD2Re1//Hf8zMTE2Z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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-09-14 13:21:27 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAdKUlEQVR42u1da3Ab13U+fOwLgEjskqxFqfGYopp2Rv2ROpViyaJi
g1YStUmcZJqZjOO8PFPZidNkOsk0iTvjOv0RW07k1PXYSWTPKH6lzdjjqZ2HZUuCY0PKg+qo02mU
ZhxSUuSIoCtyl5RILoAFwd7XvvDgAwQgQD6fHsDee849dxcf7r272G8PAAJRN7SBjgcBUSdY7XgM
EPUD0guB9EIgvRAIpBcC6YVAeiEQSC/EZUMnHoLawsJDELhSj/RqsfmgmaabhfLFizg5InDthUB6
IRBILwTSC4H0ahmYDXdE1IleCQI5ki5bdbn2bWOF2HpsmR5WcEyUt140kEZ1H72SyeSENNhU+7ad
9Krc2GT/vjpHd0+LtvM2jnaNmByNM3mAPk1WyNc5EVdl8jISUeglXCcqRx1aqMgHbVVKMXNbUtQU
rZNiDrVU9QQfGsg/M6JETeag2KROpU2KMmCtxomRE+Otdu+Rba+dRLcq+pBgf2g5t3LjPmP3gC0r
GostUx/w2nLUYd8xokT8PrC4GmsJoFeTVbJfKVlWe0GaH0QeNWLttUkCuBTNRefI+8J4jLwk1DS9
tNvzfE7uoYXpo5/rH784zKy7YtnDN5G6UYfWJV4aDwwCV89kD+nMYbob4EbtrO2XAWyV0wXaqpVT
aKvw9NEurx3oGIfZaG56jowybJzpeZ6Xgxv374+x2C/T2NO8X6wt+i6u/fe866grWfVqrw8s7vlR
bj1n5iLzAMOx3OFZgGM55FG96UXXXvlpgMwkmNeT7bMGfcmPGlNkI3stjGXI65QxtP20oe1kHoqT
2pIldf1gkhdni5EPTDgSDGmsFWqcH+u3/TIA7TRvVWKecMYYGvLagVED7EnQrneb+piIfcaNu7CF
xM7x2KIF9s7K0kiTGa8PYzCa9/pAYRn93NrW2E5K2d4txHxLHnlUAbVSCiWSYBsXyeg1tSlf2J6k
2/SfnGMvdIu8FYXsHyFU/OOPd11g0yH5/kuOZ0lfeKG7lXSX1Hyg2HvAM5IPlXGZ2rSwwPsgnJVs
IC7tE429bjLgE/CGgGOg0xBoyRxYyO9IwtTVTtvZft4fFxb+5rio1+NgaMqXyP+3wuTFAHtNoGub
42aZk31p7r7IJfKhkpMC8oHv4pbissBxXihwnDn7ZU9wW+p5yDM65rvcChf8k8NjJPZiMO6QyWPP
BpsU3m2BbtJOD4V67ID5KXFqKb9GZ9S5Ce1W0uHHcZhqwJdh+jGyWj562O7xizKD0Evnwc0wqBab
qynjBcJ/tQ/0KMAJjVket03KfTKWHdQ8y87NaY2V2bwRexP0kAWU6sCRiN8cb4fi6KSd9VipFsf+
5SlSaLPYStr1IW3ppK1fDvapjJG0Dxps/lWox92g/Tt7U/jt6E18D35EdvkU3nbSkLF2ZrcJM7v6
A22eyKltdM2VlXNTxdbrdstsJrPlDCHP2V6FWk53r/8+Pfnvlj/rD4LT8wPkA0/GZf0SH3OzCo0x
FZf2Rz0j0Q7rxzrWh871UC62TFZS6wwe+09cH9LWdaStV+yLhGTyVewCRI9shy9CzKh9vKXIbSxA
bLcyPAOwU0Ye1XntVasF3Iovgth2tVHMjz/VU8teOx982sC1V/m1VwdozdPd8YWV2X35PzsWXn20
2ij7puZ+Xsted6e/HtjKtNV7PGgeLFZahQcOBj5joqbAm6EDN0NbuCqt16FFAN6Qg0B6IZBeCATS
C9FI4NIezxzreHqD9Lrc80ELzx8oo0Xg2guB9EIgkF4IpBcC6XWZYF7+plFY1rr0MhL0Tq1ERXnt
xrUJb5fyvZu/2A8u43P3qmS0MRtp1Dz0yo30Llm/tIZ1TfgNH5v07cvbrUJGe07H0a5p6GU6Vt77
OEyuVHU0qoNNa7J6xNWwmhFZMz01LjB5ru3rcbs1OeX6ibI+TVG4aUJX9tq2KtkBpS21T/CB56Sy
DQxF1mymx43wzphRmb5La4rt629locuVuf4W+iKsT14sW5a0FBgyymgroeF3q94TW1D/UYKBM/Tv
w8rsum/loFue7s7Db062r3sif2YgSWvuWzfXRWoGzr/x3Tl2cbid2ejSXFTLwkD63J5EQfjpFqz7
ws+hELs0277AGj7/h891xs/91Q8X4CuHIUbquD1tmuC5nx6EQmSua/co/Nsr3724v43Fm4fkn7bB
t2KRtgXRBRIrwmK9QWMRDLxx7sDdzFrEikbmLz2ThyOPO/7+rfpu1bbWJc/yd6s2fPQ6IIPsyQKd
URglH03utJQBeFEDa4dbo46xGqHGJbiF2WTH4LSvnOV+VAv7ENPvunLXKWNy+2ljiGw9JIH1kGfP
ccsWgE7THn2RxN8GGlcRaVyje/vpC1nXLhwL2LsL3FrE+mbetqmM1sFhquJ3p7G3V5ofJZQ/njZK
lKqk6ppPH9iRXErDCkXFIXmt05vflU0GpLiV5LhURmv+8cJi94UiGW3KWV5GywtErJEb8pDcybS1
Hiz8zbE+MtoVQftFMpnsOCW2qFK1zRUkbmx/6pJnJ2ogWABcE1tSxhWw3TD5Qkm4YyE5rn/dwZhP
xy4GZbT0neMqHIVvifa31+2TiLVtfiI6jNcxmui7Q1WqoJ4UW/efgs0SgLTJIcUFaZTev5EaoTVU
wyoFHbmNuhk2qcVlXE2bD+l33TnW8bS1lDBsFpPJJLjHYGcB0ggYYrrjul150FFcuy+EYrErGvB2
/gQKEUszjHEyGGt420mz0Cs/Sv4b/Yr4wn/ivUrmHMDvsrHDANHZr9LPXGELqHM9rMYHtzmT3etM
FZVNxaUPEArNPNH/XEm4qfjejC/kltijAf7jKoATtjQ3TaLcqNwilLndCtXtWvad067dvVnJCWt/
RzWb384lYr1sy3FietXzyKMmWXs1Acz+1LZatufE0muR0V7Ra6+3os7RyM7VsrkHvx5cfCG93ur0
qivwZmiU0Tbi0CIAb8hBIL0QSC8EAumFaCRwaY9njnU8vUF6NeoLu/CWOQIoo0Xg2guB9EIgkF4I
pBcC6bVimDWyQVwZ9KJJzdS+MhLXxJLqVFv+ctnyoB62kvvGpXu3Bj2tcNXLqVlSctcamiyR0eKv
2CsbvZLJCY3fvFmiIl1CVto1862y5UE9bCX37XXePTNTLhne8NGLa2izeF+sDI7BK5wcDavgjVc6
U7CaGssnm/DyuTpRlgoW3DyviaG/Zh4GU6SmNInmaSW2rhiVZZKl7immaO1VFZ6tVhGCVaFohaAv
jyMEtJCwmedIVI6MsH65PmYoX6zrx5WzHIOSRHumjQRz1yZ2/lMgRy1zFzlyUxFZjfP8timm3D0Y
as9RRTZaYZeSFK0XJAlltCtdexm+qpbnk/2hlnavNy+yfK49Uvpevs3zvIrcrTCVVn8I8B7ToXla
oWNclD+inZ3n5jsnnu8BmD2cnf4bYDle48x3NpIz+fTi+vI4nfKEe6d73wTNFLt1OjdF85DBOMxx
n6uVrPqk25bnZ+Ve9DQdOZpNKp9Wt/rlHU/TqG6O2o5x6n5E5Mh9z0s5TvWnj5J27R91fzbU3mPj
Gn8n7J6MZV/+CIB8D/JoJfQii6933O9tnWEK1md5PlkKnpY1e9p4J9/OiDyvHHlj9FkvTyvNCcvx
wli/sDlhdGWJ0xBoo7wxro+VHKZFBd+Xx1HHjBPudGTQOKoEGhUUjhnQyX3eNQajL/htCT8Jdnm6
w+tep8Q3xlS/nPfM7Tvd8nPk2kNgXc92fYj0MXfthUyovXcaIletsPuBY285APD6PyCPKiB4MzSV
ifZdzAZUpKF8sqKAakaLs7OCpzE1B6a1HcmAbjUoTKUGTt/Xv7o9aDBywwLMMs1Z2Lc0DnhK15F3
F6hPqai2OK+syHFLX0sVtYEcteLfyG43jW25JLi+j7Bz4rn2dZNcmOutxPA3xyVktBeKz7TaS8Sk
XkE4x6zDNKYb23peC1kf90xGmEF34drwunrbfDpyJz+NDPv6rZtehlqxCNpmpyOxMlpbipBytt3k
7h3FitrjxTlqGXa1yYHOHTOL2utzeyTspLk3aU5bsw2HqRWuvfSO4ssOg3BNqEDZBPoxPjn+GgYV
r7wXNpOZo/C/LE+r/+l0Dqb38O2b4CSxvnVqS0/oE9Rso+37fLHn+9I4J73AOouTcbyVIfUhL/cX
a20pVAde86SNnVQPPgCDclE567ta+r3jSl4B+WSfGvKbg1NK0I7mtP0kwKn7kUcrW3vJmVeLDE7k
lLA6dcpxH0GS3xPM89omZ8laKXqbl4z2DpYM9hX7GpEx+Jvyh4j19nXBbLXEJvoRaW6GbURvWx+o
mrpZcR/zZrA4VrcyL8YW6jNN2uqRMyWXPKbi0r2eMPsBqsltU3Jni8qL+u4i+pfrA1nXtf0XrZDf
z9T3TQXt1uny8CfIOQsu7Vey9lox9FypUHDZTLKJqh8KV70nmBsvSolkfQ+h03XewLVX+bXX6ukV
cxY7oxdKiuXcMn5S1Y8pWrbppb4Jzmzw+TV1OZo9IRkt0gtltPUD3gyNMtpGHFoE4A05CKQXAumF
QCC9EI0ELu3xzLGOpzdIryadD1p4Wsnj5IjAtRcC6YVAIL0QSC8E0qv2MC9zHPMy9QfpVRlUdBtJ
r1p0aygPlpRtaNDOijhG1O1nhfgbVpWN9kEDaVSH0SuZnJBv4+9Kqip7zUa/WFK2o0E7y+OY828s
E3/HqrLRbp/H0a4uk6MxfdQbr46wnK1OdK8ruo0z/aypKUf4151rXhM730E3iJ1QpIrcr1xta0a5
LlZXlNdSTG5rPihH+afXqym0bUNmCtrUXlntJdVfYu3Y8vs+nwJXXZs4oii2zfoj6hPxPXttLxut
bLj95PFouYjjaHsNNxvtlOhjXN0rsmWntQjPRuv2hcXbJp9EHtVl7aX72ohD4zNM+3qfe1dmYTw6
Ryz+Jf0RYatkVd0V3XY+f0Du9IeDJMS1rnliI2cfph/7Qnr63venmf/23CT/jWH25ex2YjIXzZmk
xeHtucOzpPq+A5M9AN3RQ+/cDUxdS6MdSh8x+ll/RD0Unt7e7ca++U2vn/p09uFrWLmIE1cennft
DIn3cXH8E928o/vPR672+jLnxXvzQ8ij2tOLLL7+wtdy3cV0qLePGWdFAc8jq33UVeFqYzDqaXNu
vxbGlGBj+TEqWSU2N2vMV8tyFa+6DTQuD8oMwWeup3lkDftFAPnvercQh9sl0D4GIN2Tujnj1ZG+
uLpYUU8a/MxON5Rje/3UJPgMv9NaxHFYflvRx9O8j2dYXluKe41Jx+vLTi+ejdloK6H6m6GpQiK1
O1NWY1uiwgVfzVqswC1S27o2YVEsZUVfnkpXRR5ZoWCl1cez4Oi5NrJlbixA14Vi9+PZsC6W9tHt
J7jK3JD41u9SQGkbykbbl8/vSLrxwjJa/M0xX6tstEOF0nP88Dq3PSS69aLRjU8FLwJwtW3Ihpd7
ItauxRdPA8sjG/0wU7Bqs7yaMEWanfgJ2TLsdOTDJe7FSo5PmVCqzBVxNodz3Yo+uki7vetavHAG
vHi4sq+IDj9t+yoxQA5wfNGhr/wv/Rf918x3NgQLnEcz3xljJNTukh691MbKCcEfsw8ca4Pzs5e+
kT4D45kO9ZFYIR+0Ef/yJx41+E/w7TPfvp/Y7vmfByInFkB95c8suQDR2Q693QH10gN/+/iCWxdw
F/Vii8QhDf32EdvtZz7fcfDlPC0Xca6/7VKUbdPQvI9ua+T/rzjvP8AK2mfmAn15FAKjV6atVtNK
y6LgUSqzprWX7IwVlU3llfAtPlZWeY7HOGcomRPe+JmVc4Q0R7v6HwOW/XV6/lKE24RvmLJukIV2
9ug6ZnuXwRS0sd1y10WqcZUzY1TPqgwf5XXRcH94vQDPMvt83uvnCZ6DlpSLOF9j+W25HemjE346
WER7r1XcFxIvL+EwVfO114px8M75ptplc8OlmvJhZNf4WrLRXtFrr3rTq+tjj3fMNNm32z7wxVo2
F7sQXF8gvRpJr7cc8GZolNE24tAiAG/IQSC9EEgvBALphWgkcGmPZ451PL1BerXYfNBM002FJ+Jh
NloErr0QSC8EAumFQHohkF6NhllV1WpdzGAV3n5aKzT4jokVpzDwDdVMRSORB3I1rYVddC8dECmP
zLu2ZKNcR0VZcVXRc+3xwsSi3qiDUQMsobGtIpdtyCWQq5aUX8ffJcN5dEtRXJW3cbRrni+DyB07
wnSzjsgn+z152EjxnLL2MM05C0x3G+UaV5GHFnx7cOW3fXtkm2Wu5YpXRT6Y4npeL4csqTsILLWs
whWyNB8u/37RXLVeOWsvroh2SYSRUK5bihFNaH97NXlYpzm5qZZXmsdstE001hbS090AN2pnba6t
pcrUvRM/zr6flcNVzyhbmd3VM9lDXHe79Q2Rh9azF8NIEuxfzMVpXtwcyy1bSB/93AfGj9KcuVZO
4ZnXeuSJTwN9+EBueo6nvz2cneY5kWiuWq+ciWefTYt2KX9FLN5fiq3nJ3mbc2buv0jvh2NMy9uX
Qx41D7140tj8WL9N/4dROsicMLR3nWHlIncsMIXEEL/NWDVA4x+ha+/BOS1l/dyyPK8sVb1mJTC5
Ai07ZtDfAe1JEOlvaT5crovNvx4sp7g2cNe8G4v3ly0lDI23SfPmkklbyqaolvf1PPKoAqoXolUF
qlC7g728+w66vesO2NexAAN3gVs+cA72tRfou10DAwO/Z7Kyd5N3ZwtBey4O85oh/+/rXKC+XvPE
5RxbenZ+A/aRgqnvdXa+jbk4PftefRtTlrXfC4Fyv2/8rxvrDk+IRt51suDmd6V24jTx7YP7/7Cf
9ddDps4KsmYSqC1WOuXyDsZlW9r7utmhcIXDcsdCUEHb5qtdPXu+FnMzxpbklg3kkDWZ7dtgMsa3
uwpdIi0kzVXrl5fpYVHfHPeSxUaQad7cnrkJ7VYoVv4imuA8t3NzmpBc0mDzr8IVPSx3LLCnARwk
JsccODLi5qEV9scM8ybOKnmTo5DZc3NxblmVePHnqygngdrmJ+0s58zC1M0iHy7NVeuXp7wTQM7Z
+0v61g0afzBG4bejdH2opYwfkdOIU3jbSdPRa3p+gHyIyR7ZLjrRb2e5Y+kKu1v+7KtC46rYfMAR
9rG5fjrCyevBysSOkBkuW5xbdiou7eeK2qkPKdR2hmfBldZTDazYa3lnsFxZ7zrL7F1prtsZtY93
LXpbPz33jO5WhmcAdsrIo4pTeZNJW+qdOzZ03WvD+Z61tzK1sR4y2qYbD8pg+cuqTUeveueODcHI
za69kZgUvEMV6RWkV9MtGxrJrtr8uFjE0EJ9u1yAVgKuSmsMlNE261iLQHohEEgvBNILcaUDl/Y1
BspoUUaLX9h6ArPRInDthUB6IRBILwTSC4H0umwwG+CxNj9EM9PLiSh7u3yhRnHW1w1LZrkth7sr
eOixqvwqZKON2UijVqBXl5K+D75WsXrpHLHl8JvyHuZ1VlV+AsVV53Qc7VqBXoUxw7j4EM0RK0f4
J0aVtCNMAmsLcavmgKO55XQo6VZd+4TNlLM06+0IU78KOWwirsoG1cAqcT7wDB6XqvKDvojGNbx9
GkuVa8iSlgJD2YQ8agF6dQ4ccejthPp07iX+u8LVP8tObgWwlTk3j630R/CU5JZTdIx79n0TUg/x
UbMKo0NayGGhMB6bA9iqpsWteLmfVOcH2T/EeL8uRbPTswCzEcfcDfBjTBfaCvR6458/GNXSLEes
0M8620BTCR/8HLE/uQc+r7jlFKOGZ3/OOE3I6YzCGP28T3s3wPO8uOqYcYZv57dU5wdnjAs8amaS
KXG/mbdt0rEtSK9KaLJ77c2BHS8umSPW3JBRM4EctSxXrGcvksW6LxXy4kpOdX6BbLS9+V3ZJIzc
kIfkzrA+ANPo1C4bbW2hmGDMHC2TI/a4v3Y2OuL7ggpb18ph1xPMT3P1azkps58Xt92szg/6XItu
mHyBvGybn4gO43WMFpkcMwOO2S2RV66fpeMM189KmxzVJZl8bZdX7voJ+2tgE607BZtFhr9jwVnL
HoRrUnyNd6o6P5iHt3MZbf6wTRVsmmGML5IXHLBagV7WfbH1+XPkleeIpauiG5VbYgC/Yzli7++n
Rf937Gav3PUT9h1783eRuvcqmXO8Qgpe3/Lz4sq/rs4PRjX7LHsz80T/c3SZZstxYnrV88ij1lh7
rQXLC3BFXlzz4y9I1fhVQFE2WhzKAmuvBj8hp544v7Bkdddi509ffZS+2zeVbavGrwL+/JkHgjM8
/oobSNWO2WhrPcPjIcBstA04tAjAG3IQSC8E0guBQHohGglc2uOZYx1Pb5Beb8kv7EI9G8dstAhc
eyGQXggE0guB9EIgvd4awDtQkV51gLFHZglrK2l2K0hpEUivFSA9f1fO1HuXzIFLkcRDhfRaPdZr
Q6BpGa6j1RXJz2ub6N7DLBxVZKRNRWQlDmBLipbCA4f0WgnUMfLfWI5rdgvpizyv7YtUt9HxNLN4
bPwQz0P0npdyETKNfjGWfflJPHAVgHerhpdWbNZTskzn+KxBX6iIkRY8y26oT9y3zVVDcvMYXLAD
t9q3yA2a9f1RqDl1jk0AlsnRPWvkrLk+kUgseluwzU0Ia3bH6D3l1mJXfy8eOJwcV4LsIPlvUAox
LiTZpVJa/mZDm0xVbNLcm5FZPHBIr5Vgwk5Byv4dwHFPSZt14LWIbzEHp7iUdlEapfOgahsvfBIP
XAVcQUK0WmD/pclzT1sPEtZ0Loh88Pl42/nJeZGtHQaeevIHVgfdmh2+8zunzoDe3v7E/oN+C60h
RFusa+soRKsbcGmPS3tEg4B3q9YaeTwESK+6AdcaeOaIQHohkF4IBNILgfRCIL0QCKQXAumFQHoh
VgXrMvs3VwNILwSOXgikFwJRBLzfq8nWXlcC8MHjDTi2VdJzrV/3JmgAJ0cErr0QSC8EApf2iMtx
noNL+3qcO+rsRV/5MtnzYa+rcvWX03p1sf3luL7iHvAqv9eVgiK9as4ufpDZ3xWzy/1gdLG1ctfQ
CWs1sX13C1baA6toTysGxbVXE13MqP6SgKXX7HtR02g4etV5IKtmXq3C1Sq+4Lb62PqKe6CveIeR
XvUakCz611rxmZM7N5LX1bqC51ll7JJ2qupBOR+kVz0nPLEyWeUcWYWrvubYa+1BeR9cezXH3Git
cWpb+7ysr301V+qD9GoiJlb/c3itfkiv9Q/yeFm19lQJXiVY2eENXHVarWs46Boa0FfT+XLXvcr4
WEgvRB2/aTg5IuoIpBcC6YVAeiEQSC8E0gtxRSDwoxBqXBA1gl6GXngFDFEbWDg5InDthUB6IRBI
LwTSC3FloXPplX/rnVNi35ueXsVjWqGF96ilUvy0hTcXW51dODkikF6IK55e1gprS+wsyy+9TD88
WWWDWy2xP17fK3WpmQ99rYRoyz2OoNXWqk24P3oLHvrVT46WJb5J3jfDYn9ETfAbxy2tom+SMPOt
GzqMucGDe+O+WE29PzwWhPrf7Id+1aNXuScRWHq4JrjtPtXCE1iGH3zRcH7p/t/Szvh9bc79oXFC
wZv90Fc5OeqW+FM07uolY3LJ2Kxf1vFaLxtbD7821/5YRUe+tIPNe+hr+BAAPfCQquUPl241xUps
iXVvs+zPChS2TXvoO2t7HOi3Z5lHE1iBh5Rdfn7poT617P40a1erve6ls+eo6NVcuQicFDTs6Fsl
E4e1zFWLZt0fay0XjRp+6DtXuWN65ZHVr+G8C1vqllfJaxo6ORZFC3aGvhN9avr9KdvPZj70gYcA
+N/uYu12oZV+Fi7+zbGV+l78m6O+3MWsJt0PvcKHgWjuzw1a7C4KpFcroeVu0ClPr0ILfwT5Fu77
4pX2fei8Ir4k2PcmBd6Qg0B6IZBeCATSC4H0QiC9EIilEbwwgU9gQtSPXvj8JQROjgikFwKB9EIg
vRBILwQC6YVAeiEQCMTy+H/vNxxGa7BH1gAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-09-14 13:21:27 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU0AAAKfCAIAAABljA0qAAAgfUlEQVR42u3dvW4dxxnG8QMECFKw
UKEryDWwCohUSZV7ikoWBuJSdxHkEoTILhVV6YI4lGGrcCEnne0YmyMTCGhyP2b37Hy8s78HhKFQ
zMPVnPnvOzM7O8/pRERH0EBE/QrnRDgnIpwTEc6JCOdEhHMiwjkR4ZyIcE6Ec6KJHmMnJc6p476S
8k3COUXtKJv/lnBORDinVgu7noNz6h9yI3acE84J54Rzwjk13mNAjnMiwjkR4ZwC9BhbX3FOHXeX
h3/Qc3BO/XMOdZwTzgnnFB91PQfnRIRzIsI5NThcF86HcyLCORHhnCL1GIN2nFPfs/T57xDOCeeE
cwqFup6Dc+p5Wm6KjnMiwjkR4ZyIcE5EOCcinNMOPca5UTinjrvL1B8I54RzwjnhnHBODc7P9Ryc
ExHOiQjn1P4U3eQc59Q/5FDHOeGccE7Re4z1dpwTEc6JCOcUZ9yu8+CcOuwuGgHnhPPdRgpaG+fU
FeqjnVDPxDm1Mjm/vPPMO+icOCcinFPMGYE+iXNqbui+O+RG7DinVkruvijiHOfUKOc70ohznFP/
nD+aluuTOKdWUNdzcE5EOCca7Yu2vuKceqUx30o+4Zw20ph12p/7d+GcatZGnOMc5x22e8o3j4m6
Ponzzke/jX8cVstwTubnhHMKPlLNdMjEkOfNdsJ5W5AHqpZ6C86pc85VXZzTIep5sZuIHoLzrlrf
oH2Q3IZzOgLqOMc5HWJ+Llkd50fBRiOYouO8zwGwN7QI50fhfIizFKfk4px65txqGc7pItSDPlfT
eXBO3d6YcI5zOkCPyTA/t96O8w6rYqwnSbmvTSfEOTV0b8I5zulAI/as++EI5+a6HY7e7YfDec8j
4VgFTVfBOfXPOdRxThcxE3HT6+7zc4N2nHc7Lde5BztwcE44J5xTncHIvijiHOfUXNXN8Y6dKQzO
qX/OCeeEc8J58LlurC1x+16w3CWcH6I2EuEc5wdtDe2Dc6h3NW63awjnB5qcH/kcSJ0Q52R0TTin
Sqjvfj6c2wfO+x+6B51r7HLxRgo4NwbWGse6n+Jcz27lane/8hw0jlodsM/jXAXrlpkC9yacU580
GgPjnFSwHe4gQ7aVfPNzoibuULu/CecdO5zX7NNlMg/CnQyPc5xTtz0b5zg/ylz64D07dxLrYSHH
eRMdOseS++6ce6sM57RPPT9yBbM7EOdkdLPzr8A51SliUT6FYue37+6cO8Id51R6pBpo5l+sna23
47wrzvNVsDI5DYGuGee0uuq237ODPuW27xXnPY8UAqUjqbo4p/4rGM5x3v+4XbceJL3g3Oi6WRp1
HpxTac5zVzBdBefUfz3PcYXl98PhnGLPSIOi/tQ5604783NyB1ldexunEec473xGEKhn594FfPAl
BpzXL7aBamOsMYh35nF+oJKe42wWz9VwTgcaKeT21Dlx3g+WQ9hTX3Zsh5RvEs6jDq2jH/DU7Pw8
4poCznHe6LzgyBUyyhgE5zg/4rLF0dYUcG7Ud5T7qZ6mIVSwbu9Nuc/PbnzEjnMVbAfnEHt78j0m
iDLzwnkrU/RYZyTv+LsKPPN3+i3Om4A8XAUrUM8P/gniHOfVKthg7XCsNdq/Vfm0VIPG+qJ7E85V
g+7veoHmGjintmpjpmHIYdcOC4xBcN557cqxWytWakoUzgMlNOK8/oh9/psH4Tzi2qH1dmqi/8Wq
53HHZTinDufnIM+9WoFz6v/etNcdRO4SzmmfGcEBx8A4pyY4zL2mFYvzTHvyY40UcE7bp/2NvxPi
XGecN4pNsxWsfGu0P9fAOdXpfypYH/cmnOO8cgULdBZ1+ZRo83PqYUiZe99rrDEIzmnjGDtHFwyx
0zPu6CbEXRvnhxgmhNjfHmjcFG4dBOc4v6iLt194rUrivK2hewjnkhMZPQTnqm7nraGdcY7z3sYg
dhPgHOfbu/iQ+ciXiOfJGLdTV7UxxDshM7U34jXLS6XSI4Xcp7i1vx8uN4qjrSEvlWJzHnHGW36F
D+f0s94gmWDq9hQ0iRXnRDXnGiXvpzin5WqA893nGo0XW5x33egZxu1xnxgX43ywT4bq1nMNkvUB
wZHfpcU5dT5SGAJmwuG8c3h2d969OwZ6fm5EhvPmZqQH3w+Xo+rmzqsMhDrOW+F8iHkaROPXnDuv
0vycOuR8iJk96rV2nLeC+sHPmfD0C+d0oL4YAnK5S7R9rhupMjjdST2n6qh7Ylzl41PPabkwOn05
UNKLc52plTqT+5yJQNdc5qQa43bqgfPQY5ACp+XhnIqOVAOtXRfm/Jio47zP0XUHCxZHHt3gHOfb
y0umzZ6xmtp+OOqhnufe0Z1prks4N1Ltfww8FHzmf8Cd8zinVua6OWYxWZ9y2ydDh0A96DvzIUYK
OO923O681yHU0wecU806E/qul6Nx5GHgvEPOnQw/M1LwXI3Coy7xu48ZAc57npwf8P2KKSCdSIVz
QmNb19z+HRbnRxksNE6j9Xac90/jEOQlKpzPNLVxO9VhJtA1DxmeqxXYDxdl1RPnHXKeG/VwC9ey
onDeZz33XC3iLBrnnc/Pw73InYOZiG+bRDm7EufUylz34R+8pYtzqlZngq7wuWacN1chMeOacd4b
6jOdps3+l/Xdr4e/wgoLznuDfN+padA8FsI5zpuoM7pK0NbAeXOjvhCRwEHbeciwko9z6vzGFKLz
2I+E8wMBaXTtnAmcmzd2O7oOmnuDc6rJebg324c8q5JZc29wTjVRL5AxHO79c8/Pqc5IdXCeDOG8
tZLrnInctdGqJM5xvv2yg75Lq55TD5zr3JoC5y3Oz7OGAQUqvLbr4pw6vzeFu4MEir7BOV1EY8T0
4kzmLT8pwHkr2EQ5yTgfRbmf+Re76+GcCjET6N4Ud36Oc+qT83zjhdwHzpfMP8c5LfeSxmtjxFk0
4bznkUL754pDHee0D+fDfm9iFs4qM27CeYfjdu+ExFoHcT4cVe4lEc9IxjnOcd7iZcdKR8px2c6B
pA5RL1kb25+fOweSKveSYvlqITgnnPc8TAh0GgTOcU4NcV5sgNPymkLup4w473PoPjhTMeCagnpO
vY2uw1Uwawo4N7puHcjGn9jlfv8X5zhXG9ttDeN2KlFn8tXGuCdY2A+H8/4HwIF6dsTRtf1whPPO
R9fm51S5l5SZEYS4NxHOD1F2Gr83FZj5y13COdSP9W8P8Y4dzvX1jUVM8xZYrTA/p3IodpNtgnOc
UwXOi50wGWJog3PqE/WSe/gO/o4dzrsdt2ddwca5zqZB61fdcKes5z6D6YBVF+eHGFr7IMK1s3E7
6X+dt7N1OKpJY9A7SLjWwDmpYEe5N4WYduEc52rjPrePlidKOG+iowxx9l1nqmBWJXHeedWNdW5U
vgpm7RDnOKdjjchwjvNqo2sKeqfGeUPDYHPdWFUX59REndmR87j72PPRiHPqbaSQbwpa7BXXQKmS
OO92ghd3sb1l58F6J87bgTxK/ws6eg96bs+ONQDnOKfmUN+9b+Ac563MSCO+xxJlroHz+szEgjwf
M7s7h0s1xTld2sUPyHno2dC+NQDnJo2dc044x3n/8/Mhzi50nNMhBqsh5roRZ144P8TkXHLbkHk/
3JBz57z5eW9AapNAnAdy1r0MrQ93Pz3gHQTnfXJumNDBjODhR2ncDvVl26w7wNp/lcX9FOcdzs9z
n5E8U9Caco67Hw7ninnlej76nRznWEQ5dC3HZ7f7vQnn5uc436ep1XOqgHrJO0i+c50DnRjdMko4
b2hy7oOINYvJWs/37Ri6V4d92h2k2GpFlCcmOKdLhyEhnGPNlXDeMzMhKli4pYocT9cKjJv2vTfh
vKvxZO4nxnFPcY87XPJcDecVmIF6gU8w1+0DdXrJ5mrTuHOOmX+4nXY473B+Pnjj1QAE58fp2Uc+
KcnMH+fH4nzYb19qjpFq4bXrfDeRli8Y563MciWKlWzw9ldYsszjsFd9SLn75/rwA9bIZZybXZXE
eUP9L8BBBXnG7UGf+Q/OmaDOOC85BsnqfOiZC+paKJLtMxM0dyniU8Z9T4zGuZFC586BaHz6b3fe
K9VhJmLuUu52dq4zrRtSHpaZiPMjnNOWqktBZzFZE52cJ4PznscgUXazeK5G1VAPvYE00GpFsLsz
5FoojBFXxUOMbiKuVtgPR5VHqiYy4fbw4RznrYxBvDOP86MM3Y88Ui2DTaBxO8676nxOgwg9i9l3
P5xzIDvnfGj+fbUh5jkTQZ+fG7fjvHQ16Gx+1P6dWk5Dt6j7FNypjduprZJ45DOSS44UjNvJuH17
sxy0BRBSq+dlvYvT0FHIPM4D97yHq81ZO82+96ZMm2SGDHHi+aKLHy2vtPyAAOf1Oc/aEXN0vt2j
PDM5Z53uFmiNHf8JOG+inmfCu0BMb/uc53vmj3Oqw3m+CX/oel7sE8Q5qec4Nz8/GOcFnn4VeJ+s
8efnWdv5kVXjryHh/Ci3Fe2gD+gERDgnIpwTEc6JCOdEhPOozUpUVjgvzTlnzu0441wv4Yxz0ks4
45z0P844xzlnzjjHOWfOOO+V8w8/fLi9u715e/Pss2enV6er11fXb65ffPHim++/udD5xx8/fPvt
7fv3N+/ePfvXv053d1dff3394cOLH3+81PmHDx/ubm/f3tx89uzZq9Pp9dXVm+vrL168+P6bdq85
YjvncMZ5Bc5ffvXy+efPz93u6de5O3765aebnf/zn5fv3j0/d46nX+dO8+9/b3f+6uXLz58/H7vk
0xn7Lz9t8ZojtnMmZ5yX5vxcTEZ73sOv889scD7f8kf7x8Ov889scD4X7aVLPp1/pqlrjtjO+Zxx
XpTzc4VZ7Hz3X1PVZsr5XAcWu8j911RNmHI+V/K0Sz5NVfXy1xyxnfM5V+C8ynH5U4elb/7m4pWP
/sB5rjg1jBwdWL7/7n2i83lG93Cw99e/nn7729OvfvXx6w9/OP3tb4+Hf//9b6rzeU4+NVwfHcB/
977+NUds53zO1Tgvs/Y4+itGc7Au/GY657d3t4mdb2ZUOer87be3D/vBr3/98TP9y19Of/7zxz/8
5jdJY79R57vb2zWXPD56L3zNEds5n3NbnD86t/Dp4Vsz3KZHHeyF9OJvHP3+zdubkX52r7H+d/3m
OtH5/fub0QHeP/7x0fuXv3z8/a+/TnV+e3OzivM31/WvOWI753NujvMZ3hY5T6y0mzl/Om5PuRE8
0v2jnfT+d/X6KtH5/gHMo6+///30u9999P7Tnx7/1d1dqvP9I7T0r9dX9a85Yjvnc25rfr7450el
e5HPxAF8Cufz8bfpnI/3vId60gUTnUdLwe9//9Hyj38cX8tJdH7KxfOFS65/zRHbOZ9zi+P2NjlP
v9qm6swvfvHR+J//HOkizdbzXa45Yjvncz4W5zPrf8U4Lz9vnPpqeX5++TVHbOd8zsE43/DnmW9e
zvmG+XmxdeD7r3ul77Wou96+4zVHbOd8zu3Oz4eEePB0zmd+44XPz9eutxd7rjvfS9p8fr7jNUds
53zOdTg/iOyHq3vN9sPhvCbng/3tpa7Z/nac1+T8vtqMrwn/NIz85N0nm51/etvp2fTbTtudz1V9
au39/P13n7R4zRHbOZMzzitwPky/Fz06V1zlPPX28uiMbpXz1Pvno3PyRq45YjvncMZ5Hc45cy7p
jHO9hDPOSS/hjHPS/zjjHOecOeMc55w54zwu50TyUtVzzpzVc5xz5oxznHPmjHOcc+aMc5xzxjnp
JZxxTpd+lvmyRyM6x8oejeiM8wqc58sejegcLnt0kJdKiy2e72yWiM4Rz2ZxngwttHi+s9YiOkc8
a835cJeCkS9Hdero5X1DVBd/Y76zUyM6R8welZe6M4r7XlKO89sXbyJPv5nvLPSIzhGzR+Wl5uJ8
KsZwqqiOJisubvHfHenC2SYRnSNmj8pLzcj5VGTqttjDipznyyqL6Bwxe1Reaq75+TzeG1hNGcCn
c75qfp4vezSic8TsUXmpecftM2X80a2hZc7V88UK1nj2qLzUCpxvWzZLXPxL4Tzx9mF+3k32qLzU
EpwPK9NL10aaruI8cc5vvX3oKHtUXmqJ+fkwEas6rIkxXvx1iXmp80/7PT9f+8Q4RPaovNQ6ZT/c
ddoP91B2rZVxDsZ5H/cj+9sfyi70Ms72t1e4JeXLHo3oHC57dJCXSolDj3zZoxGdY2WPRnTGebAp
BmfOOMc5Z844xzlnnJNewhnnpP9xxjnpf5xxfijOieSlquecOavnOOfMGec458wZ5zjnzBnnOOeM
c9JLOOOcLv0sI+Z4RsxLdc04r8Z5xBzPiHmprhnn1TiPeBpJxPNkXDPOq3Ee8XSxiOfDueamOc+U
mpqeppA1LzVi2mbEvFTXHIDzHCuTM7nIUz+WI3QtYtpmxLxU1xyM82EiZWketvkMxoc/swvn6XeW
iGmbEfNSXXNgzhPzUoexeKbdc5dG05oXWzxi2mbEvFTX3BXnj5BOCWZJ5HwqXHkx6Wn+N0ZM24yY
l+qacZ60Djc6X7h8fh4xbTNiXqprxvmKdpn55jbOI6ZtRsxLdc2B19s3/znf/PzC9fYQaZsR81Jd
c+zn51PPsWe4nVpvb+H5eYi0zYh5qa65dc67kf1wrtl+uONyPtjf7prtbz8C50PMHM+IeamuGec1
OR9i5nhGzEt1zTivyTlnziWdca6XcMY56SWccU76H2ec45wzZ5zjnDNnnMflnEheqnrOmbN6jnPO
nHGOc86ccY5zzpxxjnPOOCe9hDPO6dLPUl5qmWv+8MOH27vbm7c3zz57dnp1unp9df3m+sUXL775
Xl4qZeZcXmqZa3751cvnnz8fPa7hjP2nX8pLpWycO0+mzDWfi/biCUznnzlIO+O8KOfOhytzzedK
nnhy6lRVdz7cbl1/w+89rYyhmLe65GhXeanNZo+e5+RTw/XRAfz77+SlRuD8wovZcFS7vNSWs0dv
725Pay56dPQuLzUL54k1czTAcCbeMOVfV4xzeallrvnm7c3IlU3FlL06Xb+Rl1qE81WAjSYcjv5t
YoxxMc7lpZa55vtHaOmcX72Wl7or5ymv0aXnkM4AP6Tlqw1psU3pA5D53ygvtcw1jxM+e9Edt3Oj
4/Z5lhrhXF5qy9mjheu5vNSLxu0bhtZrOS+coygvtcw1l5+fy0tdx/nUpDoH54vji9zr7fJSM11z
sfV2eakbx+2Lc+C9OJ9aJpCXWuv5+Y7XXOz5ubzUo8t+uLrXbD8czmtyPtjfXuqa7W/HeU3OB3mp
pa75XNXH195/Gq5/8k5eKuXkfJCXWuqap94/H52Td9zOOK/DOWfOJZ1xrpdwxjnpJZxxTvofZ5zj
nDNnnOOcM2ecx+WcSF6qes6Zs3qOc86ccY5zzpxxjnPOnHGOc844J72EM87p0s9SXmr01ojljPMK
nMtLjd4a4ZxxXppz58lEb42Izjgvyrnz4aK3RkTnEpzvEp+Ygzp5qSnOEfNSOdfhfPT85nbqrbzU
GeeIeamcm+M8MRF1l59cZH4b5+n1XF5q9NaI6Fx03P70v8OmRNTNP5mD87Xjdnmp0VsjonN9zncs
qhuiV+dNNtxiFltcXmr01ojo3ATnT1+dvZzzec+9ON8wP5eXGr01Ijq3O27P+s2ZdpGX2sL8vOXW
iOhc+rna/B92R3rD0FpeasX19hCtEdG5PufDWEzq4mg8Zcg94/l0bC8vtYXn5yFaI6JzIc6PKfvh
em0N++EoqcXtb4/eGva303KLD/JS47dGOGecV+B8kJcavzViOeO8DuecOZd0xrlewhnnpJdwxjnp
f5xxjnPOnHGOc86ccR6XcyJ5qeo5Z87qOc45c8Y5zjlzxjnOOXPGOc4545z0Es44p0s/SzmenKeU
I5cW5xU4l+PJeUqZcmlxXppz55xwnvqrfOf24Lwo584t41z+HL52OZ85dHn+ANlVv2Lz0a6Lmw3l
eHJu5Fzd1jlfTFm9hPPcR7XL8eTcyDn5UTlPORB+NFZ1kfkNnK86v12OJ+eheO5NgHH7fFrThljV
fTlPjG37v+R4ch6K59gdiPO1A/hMnMvx5DwUz6Xtk/NVYamFOZfjyVk937meb6Bxbfry2udqcjw5
m5+vfop24bj9krzUbZzL8eRsvX0HzoelWNXFB+CrHqqv5VyOJ2fPz7uSHWCc7Yc7LueDHd2c7W8/
AueDHE/O08qUS4vzCpwPcjw5TytHLi3O63DOmXNJZ5zrJZxxTnoJZ5yT/scZ5zjnzBnnOOfMGedx
OSeSl6qec+asnuOcM2ec45wzZ5zjnDNnnOOcM85JL+GMc7r0s5Tj+VAffvhwe3d78/bm2WfPTq9O
V6+vrt9cv/jixTffS2LdxxnnFTiX4/lQL796+fzz56OHKpyx//RLSaw7OOO8NOfOOXmoc9FePCfp
/DMHaed8zjgvyrlzyx5V8sTzTaequpPnWud85sTVMusZ6Ue7DhOHQM80nRzPRefznHxquD46gH//
nSTWLc71OR/9n2U4X3tUe0qiw+K1yfF8qNu729Ma69HRuyTW2JwnhpAv/m3Kvy4l5mFtxJIcz0Xn
m7c3I///qTCxV6frN5JYtzi3y/naoJXFmNRL8lJTWjDxm3I8H+r+EVo651evJbFucQ4wP98QqJSY
W744Ak/kfNX35Xj+7JujhM9ad9zO+ZzbqueLnM8HoS7+bQucy/GsWM8Pm8QajPNt8+pVNK7lfO1g
Xo5n3fn5MZNYo3K+mH++eUl8FecHyUvtYL394EmskThPXG9Pr+er8lJHsZ8/rEeOZzvPzw+exFqZ
875lP1yKs/1wZZxxXprzwf72n8v+9jLOOC/N+SDH80lVH197/2m4/sk7Saw7OOO8AueDHM8nc/XR
989H5+Tdt3MOZ5zX4Zwz55LOONdLOOOc9BLOOCf9jzPOcc6ZM85xzpkzzuNyTiQvVT3nzFk9xzln
zjjHOWfOOMc5Z844xzlnnJNewhnndOlnmS8hNJ9zxLxUSaw4r8Z5voTQfM4R81IlseK8Guf5TlDJ
5xzxPBkn1eC8Guf5TkTL5xzxfDgnzzXKecrevbXLGItHLyfmpc5/M/2813wnnOZzjnjeqyTWRjlP
DzPbi/Nt6U7p+c2FTyzP5xzx/HZJrME4nw8wXRuouvjbL4x2W2zxfAkk+Zwj5rFIYo3B+WLVvSRQ
dS/O52cZhRPF8jlHzFeTxBpsfr4tOC09ujxlWH7hNfzsm9kSQvM5R8xLlcQaY71984T5aWTq4r9u
x9uKen7Mei4vNeP8fJdxe0pe6o6cm5/3Oj+Xl7oP50+rdOJPrkIx97jdentn6+3yUnd7fj4VhJr+
k1O3kvS81PRven5+qOfn8lKPLvvhem0N++EoqcXtb4/eGva303KLDzkTQvM5R8xLlcSK85qcDzkT
QvM5R8xLlcSK85qcc+Zc0hnneglnnJNewhnnpP9xxjnOOXPGOc45c8Z5XM6J5KWq55w5q+c458wZ
5zjnzBnnOOfMGec454xz0ks445wu/SzlpUZvDXmpJC+189aQl0oLLe48meit4TwZWmhx58NFbw3n
w10KRtC81PRf7bzX6K0hL3XP6td+Xqrz253fLi91N85D5KXKY5HHIi/1osLbcl7qBs7lq0VvDXmp
Webn7eelTrWevNQuW0Neapby3nJe6tOYJ/VcXqq81J3n57uM2+Wlmp/LS22Ic3mp1tvlpcpLnfvJ
qVuJvFTPz+WlUpYnCPbDRW8N++EoqcXtb4/eGva303KLD/JS47eGvFRa/iwHeanxW0NeKjnnhHNb
zjjXSzjjnPQSzjgn/Y8zznHOmTPOcc6ZM87jck4kL1U958xZPcc5Z844xzlnzjjHOWfOOMc5Z5yT
XsIZ53TpZxkrbfNe+fJSI7aGvFTqLW1zyJmXGrE15KXSQotHPI0k33kyEVvDeTK00OIRTxfLdz5c
xNbo/Hy49DzTR79y7eHKO65YlMlLTf93RUzbzHfea8TW6DwvdVWe6SLwxVYm8+WlbrtDRUzbzHd+
e8TW6DwvdZTzeQAenrL+9DtTOI3+bXo0apW81HTOI6Zt5stjidganeelLg5NpzgfkpNSpv42PRp1
3nztiCPl163NaYiYtpkvXy1ia/SflzqTZ/r0v4uwrf3bIS0adWqMkHgLy527FDFtM19easTWOFZe
6ihIJTkfjUadqbq7c75qsDN/z248bbNwPW+8NTrPS53POSzMedy81Ihpm+Xn5y23Rud5qSk8XEjy
tln3JZyXz0uNmLZZbL09RGv0n5c6k2e6yMnM+nziBHtbNGpreakR0zaLPT8P0RryUimpxe2Hi94a
8lIpqcXtb4/eGva303KLDwHTNoeceakRW0NeKi1/lkO0tM3/z9Uz5aVGbA15qeScE85tOeNcL+GM
c9JLOOOc9D/OOMc5Z844xzlnzjiPyzmRvFT1nDNn9RznnDnjHOecOeMc55w54xznnHFOeglnnNOl
n+WHHz7c3t3evL159tmz06vT1eur6zfXL7548c338lKPnpeao51xXoHzl1+9fP7589HjGs7Yf/ql
vNTj5qVmamecl+b8XLQXT2A6/8wGZ+fJRHfO1844L8r5uZInnpw6VdWdD9erc752bo7z+cDGtRlp
i78r/RTXtWGvo391npNPDddHB/Dvv5OXepRU03zt3Drn82mNF3K+If5ltOFWcX57d7viJPSJ0bu8
1C6d87VzMM7nT1lP/LH0e8R8SNtictvoX928vRn5xKZiyl6drt/ISz1Kqmm+dm50fj4F2NrolQ1Z
5fO5DpeP2+8foaVzfvVaXupRUk3ztXPTnKcX9hTO1w7gM3E+Tvhs+Giis7zU6M752jkw5zN5qWvH
7SU5L1zP5aXKpe2knieuw12Sl7oj5+Xn5/JS5dI2yvmQnGR64fw8/bfsxXmx9XZ5qXJpw3O+y3r7
qrzUcM/P5aXKpQ3AeQeyH67uNdsPh/OanA/2t5e6ZvvbcV6T8/uqPr72/tNw/ZN38lKPm5eaqZ1x
XoHzYfr989E5+SpneanRnXO0M87rcM6Zc0lnnOslnHFOeglnnJP+xxnnOOfMGec458wZ53E5J5KX
SkTFC4+GIMI5EeGciHBORDgnIpwTEc6JaJlzIupb/wNX34GpVmzMCwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-09-14 13:51:00 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-09-14 13:51:00 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-01-30 14:09:55 +0000" MODIFIED_BY="[Empty name]">Additional search of ClinicalTrials.gov</TITLE>
<APPENDIX_BODY MODIFIED="2015-09-14 13:51:00 +0100" MODIFIED_BY="[Empty name]">
<P>After the main searching for this review was completed, searching and assessment of 1151 records from ClinicalTrials.gov was completed (date of last search: 28 November 2013; via the Central Register of Studies (CRS) software) using the following search terms:</P>
<P>Continent OR continence OR incontinent OR incontinence OR overactive OR overactivity (in the simple search command line)</P>
<P>After screening 1151 records we identified four that were potentially eligible for this review. As this search was completed after the main search was completed (and its results had been fully incorporated into the review) these four trials were added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> so that they can be fully assessed for the next version of the review.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 reports of 2 studies were included in the quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;32 reports of 11 studies were included in the qualitative synthesis, additionally there was one report of an ongoing study (&lt;a link_type=&quot;STUDY&quot; href=&quot;Moholdt 2011&quot; protected=&quot;true&quot;&gt;Moholdt 2011&lt;/a&gt;)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;60 full-text articles were assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;338 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;338 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;338 records identified through searching the Specialised Register&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Assessment of 1151 records retrieved from ClinicalTrials.gov was completed (28 November 2013) after the main search was fully incorporated into the review - the 4 potentially relevant records are currently in &lt;a link_type=&quot;SECTION&quot; href=&quot;AWAITING_STUDIES&quot; protected=&quot;true&quot;&gt;Studies awaiting classification&lt;/a&gt;.&lt;span&gt; A further updated search of the Specialised Register was conducted on 27 October 2014, the 101 results retrieved were assessed and 3 further potentially relevant trials were added to &lt;/span&gt;&lt;a link_type=&quot;SECTION&quot; href=&quot;AWAITING_STUDIES&quot; protected=&quot;true&quot;&gt;Studies awaiting classification&lt;/a&gt;&lt;span&gt;.&lt;/span&gt;&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;278 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;27 full-text reports of 20 articles were excluded, with reasons given in the &lt;a link_type=&quot;SECTION&quot; protected=&quot;true&quot; href=&quot;CHARACTERISTICS_OF_EXCLUDED_STUDIES&quot;&gt;Characteristics of excluded studies&lt;/a&gt; table&lt;span class=&quot;deleted&quot; modified=&quot;2015-08-26 08:46:00 +0100&quot; modified_by=&quot;[Empty name]&quot;&gt;.&lt;/span&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>